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9List of abbreviations  
ACE-I Angiotensin converting enzyme inhibitors 
ARB Angiotensin II receptor blockers 
β1AR Beta1-adrenergic receptor 
β 2AR Beta2-adrenergic receptor 
β-blockers Beta-blockers 
BMI Body Mass Index 
bpm Beats per minute 
CCB Calcium channel blockers 
CVF Collagen volume fraction 
DTT Dithiothreitol 
EGTA Ethylene glycol-bis (amino-ethylether) N,N,N’,N’-tetra  
 acetic acid 
Factive Active Tension 
FibD Myofibrillar density 
Fpassive Passive Tension 
Gi G-inhibitory proteins 
Gs G-stimulatory proteins 
GRK2 G-coupled receptor kinase 2 
GRK5 G-coupled receptor kinase 5 
HF  Heart Failure 
HFNEF  Heart Failure with Normal Ejection Fraction 
HFREF Heart Failure with Reduced Ejection Fraction 
kDa Kilodalton 
Ktr Rate of force redevelopment 
LV Left ventricular 
LVEDP LV end-diastolic pressure 
LVEDVI LV end-diastolic volume index 
LVEF Left ventricular Ejection Fraction 
LVMI LV mass index 
LVPSP LV peak systolic pressure 
LVWT LV wall thickness 
M/F  Male/female 
MHC Myosin heavy chain 
MyD Myocyte diameter 
n Number of patients and myocytes 
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NADH Nicotineamide adenine dinucleotide 
NHill Measure of calcium sensitivity 
NMR Nuclear magnetic resonance 
NYHA New York heart association 
pCa50 Calcium sensitivity or Ca2+-sensitivity 
pDesmin Phosphorylated Desmin 
PKA Protein kinase A 
PLB Phospholamban 
MLC-2 Myosin light chain-2 
MyBP-C Myosin-binding protein C 
TnI Troponin I 
TnT Troponin T 
(p)MLC-2 (Phosphorylated) myosin light chain-2 
(p)MyBP-C (Phosphorylated) myosin-binding protein C 
(p)TnI (Phosphorylated) Troponin I 
(p)TnT (Phosphorylated) Troponin T 
SEM Standard error of the mean 
SERCA2a Sarcoplasmic reticulum (SR) Ca2+-ATPase 2a 
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel  
  Electrophoresis 
TM  Tropomyosin 
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Heart failure 
Heart failure is a major health care problem and one of the most frequent reasons for 
patients to be admitted to hospital. Heart failure is characterized by abnormalities of 
left ventricular (LV) function,1 structural changes,2 neurohumoral up-regulation3 and is 
accompanied with exercise intolerance,2 reduced prognosis,4 altered 
hemodynamics,5 cytokine over-expression,3,6,7 vascular and endothelial  
dysfunction.8-10 The underlying pathophysiology is not well understood and may 
depend on cause and/or phenotype of cardiac disease. Therefore, in this present 
thesis, we focussed on heart failure with different clinical phenotypes, aimed to 
characterise underlying mechanisms and to identify possible target proteins for more 
patient tailored heart failure therapy.  
 The incidence of heart failure is increasing rapidly, particularly due to the aging 
of the population around the world.11 In the Netherlands, there are 200.000 patients 
with heart failure and around 25.000 hospitalisations annually with a discharge 
diagnosis of heart failure.12 Most of these patients are managed in primary care. 
Even with the significant advances in heart failure treatment,13 the prognosis remains 
poor. Heart failure is the final common pathway to death in cardiovascular disease, 
including pressure overload (i.e. hypertension), volume overload (i.e. mitral 
regurgitation), myocardial infarction, and inherited or acquired cardiomyopathies. 
Human heart failure has many underlying causes. The major causes are: 
coronary heart disease, arterial hypertension, valvular heart disease, myocardial 
diseases (of which idiopathic dilated cardiomyopathy predominates), and diabetes 
mellitus (Table 1).14 
In order to determine the best course of therapy, physicians often assess the 
stage of heart failure according to the New York Heart Association (NYHA) functional 
classification system. This system relates symptoms to everyday activities and the 
quality of life of the patients. The severity of heart failure is classified as mild in NYHA 
I to severe in NYHA IV (Table 2).15 
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Table 1. 
 
 
Table 2. 
New York Heart Association classification system 
Class I       no symptoms with ordinary physical activity 
 
Class II      mild limitation of physical activity, symptoms with ordinary physical    
                   activity  
Class III     marked limitation activity, symptoms with less than ordinary  physical  
                   activity  
Class IV     symptoms at rest and with any physical activity 
 
 
The cardiac cycle 
The cardiac cycle is divided into two major phases, both named for events in the 
ventricles: the period of ventricular contraction and blood ejection called systole, and 
the alternating period of ventricular relaxation and blood filling, diastole Figure 1 
represents an overview of the cycle, naming the phases and the key events. During 
the first part of systole, the ventricles are contracting but all valves in the heart are 
closed, and no blood can be ejected. This period is termed isovolumetric 
ventricular contraction because the ventricular volume is constant. The ventricular 
walls are developing tension and squeezing on the blood they enclose, raising the 
ventricular pressure. Once the pressure in the ventricles exceeds that in the aorta 
and pulmonary trunk, the aortic and pulmonary valves open, and the ventricular 
ejection period of systole occurs. Blood is forced into the aorta and pulmonary trunk 
as the contracting ventricular muscle fibers shorten.  
Major causes of heart failure 
• Coronary artery disease: many manifestations 
• Hypertension: often associated with LV hypertrophy and preserved ejection  
            fraction 
• Valvular disease 
• Infectious myocarditis (e.g. viral, protozoal, bacterial) 
• Toxins (e.g. anthracyclines, cyclophosphamide, alcohol, cocaine, cobalt,  
             lead) 
• Tachycardia-related cardiomyopathy 
• Endocrine disorders (e.g. sarcoidosis, amyloidosis) 
• Hypertrophic cardiomyopathy 
• Collagen vascular dystrophies 
• Peripartum cardiomyopathy 
• Nutritional deficiencies  
• Idiopathic 
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 During diastole, the ventricles begin to relax, and the aortic and pulmonary 
valves close. AS ventricular volume is not changing, this period is called 
isovolumetric ventricular relaxation. Next, the atrioventricular valves open, and 
ventricular filling occurs as blood flows in from the atria. Atrial contraction occurs at 
the end of diastole, after most of the ventricular filling has taken place.  
 
 
 
Figure 1. Cardiac cycle: (a) systolic and (b) diastolic phase. The phases of the cycle are 
identical in both halves of the heart. The direction in which the pressure difference favors flow 
in denoted by the arrow. Adapted from Widmaier, Raff and Strang. Vander’s. Human 
Physiology; 2006; 11th Edition). 
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Systolic versus diastolic dysfunction 
About half of all patients have systolic dysfunction. This group is referred to as 
systolic heart failure (SHF) or heart failure with reduced ejection fraction (HFREF) 
(Fig 2). The other half of the patients has normal systolic function (i.e. normal or 
preserved ejection fraction), but has diastolic dysfunction evident from increased LV 
end-diastolic pressure. This group is referred to as diastolic heart failure (DHF) or 
heart failure with normal ejection fraction (HFNEF).16  
 
 
Figure 2. The two major clinical heart failure phenotypes: Systolic heart failure (heart failure 
with reduced ejection fraction, HFREF) and diastolic heart failure (heart failure with normal 
ejection fraction, HFNEF). 
 
Heart failure due to systolic dysfunction typically culminates in a progressively dilated 
heart with reduced LVEF lower than 40%, which is caused by impaired cardiac pump 
function. Patients with reduced ejection fraction have an increase of LV end-diastolic 
and end-systolic volumes (i.e. ventricular dilation), an increase in LV wall stress, 
cardiomyocyte hypertrophy and interstitial fibrosis.17 In systolic dysfunction 
contractility is depressed as evidenced by a downwardly displaced end-systolic 
pressure-volume relation. There is diminished capacity to eject blood during the 
systolic phase (Figure 3). 
 
 
The enlarged ventricles fill with blood, 
but are less capable of ejecting blood 
during the systolic phase. 
Systolic heart failure Diastolic heart failure 
Left Atrium 
Right Ventricle 
Blood flows into the heart 
Right  
Atrium 
n=8
The stiff ventricles limit filling 
during the diastolic phase 
Left Ventricle
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Figure 3. LV pressure-volume loops in systolic and diastolic dysfunction. Adapted from 
Crawford, Dimarco and Paulus: Cardiology; 2004; Second Edition. 
 
LV diastolic dysfunction is present when there is evidence of increase passive 
stiffness and/or impaired relaxation of the ventricle. Patients with diastolic heart 
failure are clinically characterized by preserved or normal LVEF (> 50%), decreased 
LV end-systolic and end-diastolic volumes and increased LV end-diastolic pressure 
(> 16 mmHg). In diastolic HF the LV chamber size is usually normal. Diastolic 
dysfunction causes an upward shift in the diastolic pressure-volume relation, resulting 
in an increase in LV diastolic pressure without corresponding increase in diastolic 
volume (Fig 3). A number of cardiomyopathic processes can impair the ability of the 
left ventricle to fill at normal diastolic pressures. These include chronic high blood 
pressure, hypertrophic cardiomyopathy, aortic stenosis, diabetes mellitus, coronary 
artery disease, restrictive cardiomyopathy (a rare condition in which the heart muscle 
is infiltrated, and made stiff, by abnormal cells, protein, or scar tissue). The most 
common cause of restrictive cardiomyopathy is amyloidosis, a disease in which 
protein-like substance is deposited within the body's tissues. Other causes include 
sarcoidosis and hemochromatosis and aging.18 
LEFT VENTRICULAR PRESSURE-VOLUME LOOPS IN SYSTOLIC 
DYSFUNCTION AND DIASTOLIC DYSFUNCTION 
Diastolic 
dysfunction 
Normal Systolic 
dysfunction 
Left ventricular     
   volume
Left ventricular     
    volume 
Left ventricular    
   volume 
Left
Ventricular
pressure
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Cellular mechanisms involved in heart failure 
Clinical and experimental studies have indicated that the two key components of 
heart failure progression are structural and functional adaptations of cardiac 
myocytes. Initially, these changes are compensatory in light of increased cardiac 
demand. However, with time they fail to correct the unfavorable changes in 
cardiomyocyte performance.16,19 
 
Contractile remodelling  
The mechanisms underlying the progressive deterioration from LV pump dysfunction 
towards overt heart failure are still unclear, however, a primary event that may lead to 
heart failure is a decrease in the number of cardiomyocytes. This results from an 
imbalance between signaling pathways that promote cell survival and those that 
promote cell death (through apoptosis or necrosis).20 Apart from loss of 
cardiomyocytes, the intrinsic cardiomyocyte function changes, due to alterations in 
proteins involved in calcium handling and myofilament contractility. 
Alterations in Ca2+ handling have been reported in cardiac disease, and may 
contribute to the progression of LV pump dysfunction. Ca2+ is the central regulator of 
excitation-contraction coupling, which drives cyclical muscle contraction (Fig 4).  
 
Figure 4. Ca2+ handling in myocytes in the heart adapted from Donald M. Bers. Cardiac 
excitation-contraction coupling. Nature 2002; 415:198-205. Abbreviations: Ca2+: Calcium; 
NCX: Na+/Ca+2 exchange; AP: Action Potential; Em: membrane potential; PLB: 
phospholamban; RYR: ryanodine receptor; ATP: Adenosine triphosphate; Na: sodium; K: 
potassium.  
Mitochondria 
A typical ventricular action potential, Ca2+ transient
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The contraction occurs from release of calcium ions from the sarcoplasmic reticulum 
(SR), the major intracellular calcium store in the cell. Calcium enters the cell via the 
opening of L-type calcium channels during the depolarization phase of the action 
potential. Subsequently, Ca2+ is released from the SR through the ryanodine channel 
(also known as the ryanodine receptor; RyR) and this is followed by re-uptake of Ca2+ 
into the sarcoplasmic reticulum by a Ca2+ uptake pump (SERCA2a) and removal of 
Ca2+ from the cell by the Na+/Ca2+ exchanger and the sarcolemmal Ca2+ pump (Fig 
4). The activity of SERCA2a is regulated by phospholamban (PLB). In its 
unphosphorylated state, phospholamban inhibits SERCA2a activity, but upon 
phosphorylation (e.g. by protein kinase A (PKA)), this inhibition is released, thereby 
increasing Ca2+ uptake.  
In the failing heart, Ca2+ uptake into the SR is impaired and Ca2+ 
concentrations in the SR are therefore decreased. 21  
The key components thought to be involved in altered calcium handling are 1) PKA-
mediated hyperphosphorylation of the RyR, which may cause diastolic calcium leak 
and trigger arrythmias;22 2) impaired re-uptake of calcium by the SR due to reduced 
expression of the SR Ca2+ATPase (SERCA2a) and up-regulation of 
phospholamban.23 Moreover, decreased phosphorylation of PLB may limit SERCA2a 
function.24 
Contraction of cardiac muscle results from the molecular interaction of two 
myofilament proteins myosin in the thick myofilament and actin in the thin 
myofilament. 
 
Structural remodelling 
Increasing the size of cardiomyocytes referred to as physiological hypertrophy, which 
occurs to meet increased metabolic demands differs from pathological hypertrophy 
that occurs in response to myocardial stress signals and injury.25 Initially hypertrophy 
is an adaptive response to an increased load resulting in improved cardiac pump 
function and decreased wall stress. However, during the progression of cardiac 
disease, cellular hypertrophy is detrimental. 
Alterations in the structure of the extracellular matrix occur during 
development and progression of heart failure. This process is governed by the 
production of collagen by cardiac fibroblasts and the degradation of the extracellular 
matrix by matrix metalloproteinases (MMPs). Activation of MMPs is a key feature of 
the remodelling ventricle, particularly in the setting of post-myocardial infarction and 
LV dilatation. 
Introduction 
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β-Adrenergic receptor signalling  
Apart from changes in cellular function at rest, alterations have been reported in the 
signaling pathway involved in cardiomyocyte function during exercise and increased 
cardiac stress. Activation of the sympathetic nervous system increases cardiac pump 
function via β-adrenergic receptor stimulation (Fig 5). The cardiac β-adrenergic 
receptor signal transduction pathway mediates the powerful effects of neuronally 
released and circulating catecholamines on the heart. The overall action of β-
adrenergic receptor stimulation on the heart includes an increase in force of cardiac 
contraction (inotropism), an increase in rate of cardiac relaxation (lusitropism), an 
increase in heart rate (chronotropism), and an increase in impulse conduction 
(dromotropism).26 The classic theory of biochemical and molecular events leading to 
these biological responses involves binding of catecholamines to the β-adrenergic 
receptors as well as triggering the interaction of guanine nucleotide-binding proteins 
(G-proteins) with adenylyl cyclases (ACs) to synthesize the second messenger cyclic 
AMP (cAMP) from ATP. It should be noted that β1-adrenergic receptors (β1ARs) 
activate only G-stimulatory (Gs) proteins, while β2ARs stimulate both Gs and Gi 
(inhibitory) proteins. β1ARs have been implicated as being pathological in heart 
failure, whereas β2ARs have generally been perceived to be cardioprotective.27,28 
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Figure 5. Activation of β-adrenergic signalling pathway in the heart. Abbreviations: β1ARs:β1-
adrenergic receptors; β2ARs:β2-adrenergic receptors; Gs: G-stimulatory; Gi:G-inhibitory; 
GRK:G-coupled receptor kinase; Ca2+:calcium; cAMP:cyclic AMP; MLC: myosin light chain; 
RyR: ryanodine receptor; PLB:Phospholamban; SERCA2a: SR Ca2+ATPase. 
 
The increase in intracellular cAMP level activates cAMP-dependent PKA, which then 
phosphorylates target proteins such as cardiac L-type Ca2+-channels, 
phospholamban, troponin I and myosin binding protein C, leading to various 
physiological responses.29 Physiologic and molecular analyses indicate that the β-
adrenergic signaling cascade is an important regulator of myocardial function, and 
several lines of investigation support alterations in β-adrenergic receptor signal 
transduction mechanisms as primary determinants of heart failure.19 The regulation of 
β-adrenergic signalling requires a synchronised and subtle balance among different 
processes involving receptor activation, desensitisation, and resensitisation. 
Desensitization refers to the reduction of receptor signalling because of 
persistent attendance of agonist stimulation. Many of these events involve regulation 
of activity of G protein-coupled receptors such as βAR, while others occur down 
stream of the receptors. By using β2AR as a model, three events namely, uncoupling, 
internalisation, and down regulation were found to be involved in the process of 
desensitisation at the receptor level.30   
Uncoupling of receptors from G-proteins results from receptor 
phosphorylation, which rapidly desensitises the receptor. Phosphorylation can occur 
by the actions of three classes of kinases, namely, PKA and protein kinase C (PKC) 
and G-coupled receptor kinases (GRKs). PKA and PKC phosphorylate and directly 
uncouple β2-AR from Gs-protein. GRK phosphorylation of receptors does not directly 
inhibit receptor G-protein interaction, but the GRK-mediated phosphorylation of 
receptors rather serves as a binding site for certain cytosolic proteins, members of 
the arrestin family.31,32 Binding of arrestin protein sterically blocks β2AR mediated G-
protein activation. 
Internalisation occurs once the receptor has been phosphorylated and 
uncoupled from the signalling pathway. The receptor will be removed and 
translocates from the plasma membrane to an intracellular endosomal 
compartment.33-36 
Down regulation occurs after desensitisation and internalisation and 
represents a decrease in the total number of receptors after prolonged agonist 
stimulation that may result from degradation of the receptors by lysosomes. The 
internalised receptor may be dephosphorylated by protein phosphatase, PP2a, which 
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thereby prevents degradation by lysosomes and leads to recycling back to the 
plasma membranes as fully functional receptors.  
 
Treatment of heart failure 
Therapy of heart failure has undergone several large shifts, moving from a focus on 
hemodynamics only, to a focus on the targeting of a specific disease mechanism. 
Early diagnosis and treatment can help people with heart failure to live longer. The 
aim of treatment is to relieve symptoms, to prevent progression to more severe 
cardiac dysfunction or to prolong survival. Diuretics and digoxin are often indicated 
for these patients because they reduce symptoms in the chronic phase, and reduce 
hospitalisations, but do not reduce deaths.37 Treatment of LV diastolic dysfunction 
has two major objectives. First to eliminate or reduce the factors that cause diastolic 
dysfunction (e.g. fibrosis), and second to reverse the consequences of diastolic 
dysfunction (e.g. improve ventricular relaxation).38 Beta-adrenergic stimulators (such 
as isoproterenol, forskolin or norepinephrine) and calcium channel blockers are used 
to improve ventricular relaxation, while diuretics, ACE inhibitors, and angiotesin II 
receptor blocking agents are used for the treatment of hypertension and heart 
failure.39,40 The mechanism underlying mortality benefit is likely complex, however, it 
has been shown that these agents can attenuate or even reverse structural 
remodelling of the heart. In addition, β-blockers and Ca2+ channel blockers are used 
to treat and prevent myocardial ischemia, control hypertension and promote 
regression of hypertrophy.41,42 Multiple trials have demonstrated evidence of 
attenuated or reversed remodelling with β-blocker treatment in heart failure.43-46  
Beta-blockers are one of the few classes of drugs that have been shown to 
improve cardiac function and reduce morbidity and mortality rates in patients with 
congestive heart failure.48-54 Because β-blockers are known to depress cardiac 
function in healthy hearts, it seems rather counter-intuitive to use this class of drugs 
for the treatment of heart failure. Recent data, however, showed the molecular 
mechanism by which β-blockers might improve cardiac contractility in patients with 
congestive heart failure (CHF).55 β-blockers reduce the chronic hyperactivity of the 
sympathetic nervous system. Lowered plasma levels of circulating catecholamines 
are associated with reduced intracellular cAMP levels, and thus reversal of PKA 
hyperphosphorylation of RyR, which might in part explain the improved cardiac 
function observed in heart failure patients treated with β-blockers.55,56 Moreover, β-
blockers might improve the energy balance in failing hearts. Finally, β-blockers 
reverse failure-specific alterations in cardiac gene expression, which might be 
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involved in progression of the disease.57 However, knowledge about the effects of β-
blockers on myofilament function is lacking. Moreover, most studies have been 
performed in patients with systolic dysfunction.  
 
Aim of this thesis 
The main objective of this thesis is to investigate diverse alterations in heart failure 
with different underlying cause and phenotype, and effects of β-blocker therapy. The 
different patient groups studied are summarized in the schematic diagram given in 
Fig 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Schematic outline of this thesis.  
 
The questions addressed in this thesis are important to obtain insight into the cellular 
pathomechanisms underlying progressive deterioration of LV pump function in 
human heart failure, and the differences between all phenotypes. This information is 
important to develop novel targeted therapeutic interventions for the treatment of 
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heart failure. 
 
The outline of this thesis is as follows: 
In Chapter 2 a review is given of the alterations that have been found in 
sarcomeric proteins in failing myocardium. Previous studies in human failing 
myocardium indicate that sarcomeric dysfunction mainly results from altered protein 
phosphorylation, caused by neurohumoral-induced alterations in the kinase-
phosphatase balance inside the cardiomyocytes. Modulation of phosphorylation of 
the sarcomeric proteins, by kinases and phosphatases, could represent a target for 
novel therapy in heart failure. 
 
In Chapter 3 alterations in the adrenergic receptor cascade, which coincide with 
diverse changes in cellular function and structure in failing human myocardium with 
different underlying cause, are described. A comparison was made between LV 
tissue samples from patients with ischemic and idiopathic cardiomyopathy. Donor 
hearts samples served as non-failing controls.  
 
In Chapter 4 functional and structural myofilament changes, which occur in Fabry 
disease cardiomyopathy, are discussed. Fabry disease is an X-linked lysosomal 
storage disorder caused by the deficiency of the enzyme α-galactosidase A, resulting 
in progressive intracellular glycosphingolipid deposition in multiple organ systems, 
including the heart. In this study, we investigated cardiomyocyte function in LV 
endomyocardial biopsies from Fabry patients, and from patients with mitral stenosis 
and normal LV function. Cardiomyocyte cross-sectional area, glycosphingolipid 
vacuole area, myofibrillolysis, and extent of fibrosis were also determined. These 
data were correlated with results of tissue Doppler imaging i.e. myocardial long axis 
shortening and lengthening velocities.  
 
In Chapter 5 it is shown that LV myocardial structure and function differ in heart 
failure with normal and reduced LV ejection fraction. This difference could underlie 
the unequal outcome of trials with β-blockers in both phenotypes. To investigate if β-
blockers have distinct myocardial effects in different phenotypes, myocardial 
structure, cardiomyocyte function and myocardial protein composition were 
compared in the two patient groups treated without or with β-blockers.  
In Chapter 6 the role of fibrosis, advanced glycation endproducts (AGEs), and 
cardiomyocyte resting tension in diastolic stiffness in diabetic heart failure patients 
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with normal or reduced LVEF was studied, since diastolic LV stiffness is an important 
contributor to heart failure in patients with diabetes mellitus.  
 
In Chapter 7 the specificity of antibodies directed against human β-adrenergic 
receptors was studied.  
 
In Chapter 8 a review is given of altered PKA-mediated myofilament protein 
phosphorylation in different animal and human studies, and the roles of troponin I, 
myosin binding protein C and titin in regulating myofilament dysfunction in cardiac 
function are discussed.  
 
In Chapter 9 a summary and conclusion of the major findings of the studies 
presented in this thesis is given followed by future perspectives.  
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Abstract 
Sarcomeric dysfunction plays a central role in reduced cardiac pump function in heart 
failure. This review focuses on the alterations in sarcomeric proteins in diseased 
myocardium that range from altered isoform expression to post-translational protein 
changes such as proteolysis and phosphorylation. Recent studies in animal models 
of heart failure and human failing myocardium converge and indicate that sarcomeric 
dysfunction, including altered maximum force development, Ca2+-sensitivity and 
increased passive stiffness, largely originates from altered protein phosphorylation, 
caused by neurohumoral-induced alterations in the kinase-phosphatase balance 
inside the cardiomyocytes. Novel therapies, which specifically target phosphorylation 
sites within sarcomeric proteins or the kinases and phosphatases involved, might 
improve cardiac function in heart failure. 
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Sarcomeric dysfunction 
The failing heart is characterized by reduced contractility (systolic dysfunction) and/or 
impaired filling (diastolic dysfunction). A number of factors, including changes in 
cardiac structure (dilation and hypertrophy), apoptotic and necrotic cell death, 
maladaptive remodeling of the extracellular matrix, abnormal energy metabolism, 
impaired calcium handling and neurohumoral disturbances have been implicated in 
the initiation and progression of heart failure.1-4 Recent studies revealed that 
alterations in sarcomeric function play a prominent role in reduced cardiac pump 
function. 
Sarcomeric function is determined by the expression levels of multiple 
isoforms and by post-translational modifications of sarcomeric proteins. During 
muscle contraction a molecular interaction takes place between the thin (actin) and 
thick (myosin) filament of the sarcomeres, which is triggered by a rise in the 
intracellular calcium and is driven by the energy from ATP hydrolysis.5 The 
tropomyosin-troponin complex inhibits the actin-myosin interaction at low intracellular 
free calcium (Fig 1A). This inhibition is released when intracellular free calcium 
increases and binds to troponin C (Fig 1B). Alterations in sarcomeric protein 
composition under pathological conditions will influence contractile performance of 
the heart. Within the first part of this review we discuss the functional role of 
individual sarcomeric protein isoforms and of post-translational protein modifications 
such as proteolysis and phosphorylation. In the second part we highlight the major 
changes in sarcomeric function reported in failing myocardium and discuss the most 
likely underlying protein modifications. 
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Figure 1. Schematic representation of the cardiac sarcomere during diastole (A) and systole 
(B). A. The thin filament is composed of actin, tropomyosin, and the troponin complex 
(composed of troponin T, cTnT; troponin C, cTnC; and troponin I, cTnI). The thick filament is 
composed of myosin, an asymmetric dimer composed of a globular head portion (S1), a 
hinged stalk region (S2) and a rod section. The S1 portion of myosin contains both the ATP 
hydrolysis domain and the actin-binding domain. Each myosin head is associated with a pair 
of myosin light chains, which consists of an essential light chain (MLC-1) and a regulatory 
light chain (MLC-2). MyBP-C, myosin binding protein C. B. Calcium binding to cTnC induces a 
conformational rearrangement in the troponin-tropomyosin complex. Movement of 
tropomyosin exposes a myosin-binding site on actin allowing cross-bridge formation to take 
place. This results in force development and/or shortening of the sarcomere (Modified from de 
Tombe, J Biomech 2003;36:721-730, with permission). 
 
A 
B 
Ca2+
MLC-1 
MLC-2cTnIcTnC 
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Isoform composition and sarcomeric dysfunction 
Myosin heavy chains 
The thick filament is composed of myosin, which consists of two myosin heavy chains 
(MHC), and two pairs of myosin light chains (MLC) (Fig 1). One of the major isoform 
changes which has been observed in hypertrophied and failing ventricular 
myocardium is the shift from the fast α-MHC to the slow β-MHC.6-8 The magnitude of 
the MHC shift largely depends on the amount of endogenous α-MHC present in 
ventricular tissue, which is species-dependent, being largest in small rodents and 
smallest in human.6-11 Hence, the functional significance of the shift in MHC 
composition in diseased human ventricles is still a matter of debate.8,10,12 
The MHCs carry the site for ATP hydrolysis and are important determinants of 
the rate of energy consumption and the speed of contraction of the sarcomeres, 
which are closely related.13 In vitro studies have shown that the α-MHC isoform has a 
higher ATPase activity14 and a higher actin filament sliding velocity compared to the 
β-MHC isoform.15 From experiments in permeabilized cardiac preparations from small 
mammals and humans it followed that the β-MHC is 3-5 times more 
economical,11,16,17 but is associated with reduced power output18 and shortening 
velocity17,18 compared to the α-MHC isoform. Consequently, in rats a shift from α- to 
β-MHC coincided with significant reductions in ATPase activity,7,19 tension cost19 and 
power output.18 Evidence that a shift in MHC may be of pathophysiological relevance 
for human sarcomeric dysfunction was already provided in 1962 by Alpert and 
Gordon who reported reduced myofibrillar ATPase activity in human congestive heart 
failure.20 However, subsequent human studies failed to unequivocally link this 
observation with a MHC isoform shift in failing ventricular myocardium. Firstly, no 
differences were found in functional properties of myosin isolated from non-failing 
and failing hearts,10,21,22 indicating that protein alterations other than a change in 
myosin composition are responsible for the reduction in myofilament ATPase 
activity.20,23 Moreover, various expression levels of α-MHC (ranging from 0 to 30%) 
have been reported in the ventricles of different individuals.8,10,12,24 This may be due to 
age-dependent changes in MHC composition and heterogeneous expression of MHC 
isoforms within the ventricular wall.25,26 Both in human25 and rat26 ventricular tissue, a 
regional difference in MHC expression has been observed, characterized by a higher 
expression of the fast α-MHC in the subepicardial than in the subendocardial layer, 
consistent with the shorter action potential and contraction duration in the subepi- as 
compared to the subendocardium. Thus, in human ventricular myocardium the 
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change in MHC isoform composition during heart failure will be variable and this may 
have obscured significant effects on sarcomeric function. However, recent studies 
have shown that even a small shift will have a significant impact on cardiomyocyte 
contractility.11,27 In contrast to ventricular human tissue, human atria contain ~80% of 
α-MHC.12,24 In atrial fibrillation the β-MHC expression increased almost two-fold, 
which coincided with a reduction in kinetics of force redevelopment.28 
Overall, the shift towards the slow and more economical β-MHC isoform 
occurs in human diseased atria and to a lesser extent in diseased human ventricular 
myocardium. The MHC shift may be beneficial under pathological conditions, since 
less energy is required to maintain cardiac pump function at rest, though at the 
expense of reduced speed of contraction and power output. 
 
Myosin light chains 
Apart from the shift in MHC, changes may occur in the expression pattern of myosin 
light chains within the heart. In particular, isoform changes have been reported for 
myosin light chain 1 (MLC-1, or essential MLC), both in atrial and ventricular tissue. 
MLC-1 not only interacts with MHC, but also binds to actin with its N-terminus. It 
exists in two forms, a ventricular (VLC-1) and an atrial (ALC-1) form.29 The latter is 
expressed in the entire heart muscle during fetal and early life and is subsequently 
replaced by the ventricular form. In the ventricles of patients with hypertrophic 
obstructive cardiomyopathy relatively high amounts of ALC-1 were found, which 
correlated with the maximal rate of force development.30 Apart from its positive effect 
on dynamics of contraction, replacement of VLC-1 by ALC-1 increased isometric 
force development of ventricular preparations at maximal and submaximal 
activation.29 Morano et al. hypothesized that MLC-1 tethers MHC to actin and thereby 
restrains cross-bridge cycling and reduces force generation.31 As actin-binding affinity 
of ALC-1 is less than of VLC-1, improved cardiac function in ventricular tissue 
expressing ALC-1 may be explained by weakening of the interaction between actin 
and MLC-1. However, although up-regulation of ALC-1 may represent a 
compensatory mechanism to improve cardiac function, it is not a consistent protein 
alteration in ischemic and idiopathic cardiomyopathy, as large individual differences 
exist.29,30,32  
Alternatively, addition of the N-terminal region of MLC-1 may be used to 
promote sarcomeric function. Cardiac function may be enhanced by disruption of the 
actin-MLC-1 interaction by additional expression of N-terminal MLC-1 fragments, 
which competitively bind to actin.29,31 Another explanation for MLC-1 induced 
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increase in function was given by Rarick et al.33 who reported increased myofibrillar 
MgATPase activity at submaximal [Ca2+] upon addition of an N-terminal VLC-1 
fragment. These authors suggested that the MLC-1 N-terminal peptide directly affects 
protein interactions and exerts an inotropic effect via cooperative mechanisms, which 
activate the entire thin filament. Hence, the N-terminus of MLC-1 seems to exert a 
beneficial effect on sarcomeric function as increased systolic force generation and 
rates of contraction and relaxation were observed in hearts from transgenic rats 
harboring minigenes encoding the N-terminal domain of MLC-1.34 Thus, although 
endogenous heterogeneous expression of MLCs may be of minor relevance in failing 
human myocardium, up-regulation of the MLC-1 N-terminal fragment might provide a 
therapeutic tool to enhance cardiac performance. 
 
Troponin T 
Anderson et al.35 have proposed that re-expression of fetal troponin T (cTnT) may 
also contribute to the  reduced ATPase activity in human heart failure. A significant 
inverse negative relationship was found between (re-)expression of fetal cTnT and 
myofibrillar ATPase activity in human ventricular tissue from normal and end-stage 
failing hearts. However, this observation has not been confirmed by others, and 
similar to the expression of α-MHC, the expression levels of fetal cTnT is variable 
among individuals.36-38 While Anderson et al.35 observed re-expression of fetal cTnT 
in all end-stage failing human hearts, Solaro et al.36 only observed this fetal cTnT 
isoform in one out of ten failing heart samples. Similarly, we have observed fetal 
cTnT in only one out of 24 patients with end-stage heart failure.38 Mesnard-Rouiller et 
al.37 found expression of fetal cTnT in half of the failing ventricles and suggested that 
re-expression of fetal cTnT isoforms is not a common characteristic of heart failure 
and most likely depends on other factors such as intensity and duration of the 
elevation of wall stress. 
The consequences of fetal cTnT on sarcomeric contraction were studied upon 
exchange of endogenous cTnT with fetal cTnT in rat cardiomyocytes.39 No 
differences were found in myofilament force development at maximal and 
submaximal Ca2+ concentrations at a sarcomere length of 2.2 µm between 
cardiomyocytes exchanged with troponin complex containing adult or fetal cTnT.39 
Akella at al.40 observed a decrease in Ca2+-responsiveness at low (1.9 µm), but not at 
high (2.4 µm) sarcomere length in skinned cardiac trabeculae from diabetic rats 
which coincided with alterations in cTnT composition. More recently, it was shown by 
Gomes et al.41 that fetal cTnT modulates Ca2+-sensitivity in the presence of fetal 
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(skeletal) TnI. Hence, the effect of fetal cTnT on sarcomeric function seems to be 
dependent on sarcomere length and protein background in the heart. 
In conclusion, most isoform changes might be an intrinsic part of the so-called “fetal” 
(hypertrophic) program yet their expression appears to be highly variable within 
human ventricular tissue. Minor shifts in MHC and MLC composition do not explain 
sarcomeric dysfunction in heart failure, but are of compensatory nature. 
 
Proteolysis and sarcomeric dysfunction 
Troponin I 
There is ample evidence that proteolytic activity is enhanced after an acute ischemic 
insult. Degradation products of several sarcomeric proteins42-47 have been observed, 
which may subsequently induce sarcomeric dysfunction. One of the main proteins 
thought to be responsible for impaired cardiac function upon ischemia/reperfusion is 
cardiac troponin I (cTnI) (Fig 1).42-45 In rodents, McDonough et al.44 showed that with 
moderate ischemia/reperfusion, cTnI is cleaved at its C-terminus, which results in a 
truncated cTnI product (cTnI1-193, in human cTnI1-192). More recently, it was postulated 
that degradation of cTnI might also impair cardiomyocyte function and contribute to 
reduced pump function in heart failure.48 Myocardial infarction in pigs induced a 
reduction in the maximal force generating capacity of single permeabilized 
cardiomyocytes isolated from remodeled non-infarcted left ventricular tissue, in which 
minor degradation of cTnI (4%) was observed.49 In addition, independent of ischemia, 
cTnI degradation has been demonstrated in human myocardium from coronary artery 
disease patients with different degrees of heart failure.45,50,51 To investigate if 
truncated cTnI may contribute to depressed cardiac pump function in human 
ischemic cardiomyopathy and heart failure, we recently investigated the direct 
functional effects of cTnI1-192 in human cardiomyocytes. Force measurements were 
performed in non-failing human cardiomyocytes permeabilized with Triton-X 100 and 
exchanged with troponin complex containing either full length (cTnIFL) or truncated 
cTnI.52 Surprisingly, truncated cTnI did not significantly alter maximal force 
development (Fig  
2A). Likewise, passive force was not different between cells containing cTnIFL and 
cTnI1-192. However, myofilament Ca2+-sensivity was significantly higher in cTnI1-192 
exchanged preparations compared to cTnIFL cells (Fig 2B).  
This implicates that in humans truncation of cTnI may limit relaxation of the heart 
muscle, while systolic function would benefit from the increase in Ca2+-
responsiveness of the myofilaments. 
     Sarcomeric Dysfunction 
39
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Isometric force was measured in single permeabilized human cardiomyocytes upon 
activation in solutions containing maximal (pCa 4.5) and submaximal Ca2+ concentrations 
(pCa 5 to 6) and in relaxing solution (pCa 9) to determine maximal (Fmax) and passive (Fpas) 
force development  (A) and Ca2+-sensitivity of force development (B). Force at submaximal 
activation was normalized to the force obtained during maximal activation. A. The maximal 
force generating capacity (Fmax) and Fpas did not differ between cardiomyocytes containing 
truncated cTnI (cTn1-192) or full-length cTnI (cTnFL). B. Ca2+-sensitivity increased in cTn1-192 
cardiomyocytes compared to cTnFL exchanged cells (From Narolska et al. Circ Res 
2006;99:1012-1020: Figures printed with permission). 
 
Role of protein phosphorylation in sarcomeric dysfunction 
Protein kinase A-mediated phosphorylation 
Not only truncation of cTnI, but also its phosphorylation status is a prominent 
determinant of sarcomeric function, both in health and disease. Upon β-adrenergic 
stimulation, protein kinase A (PKA)-mediated cTnI phosphorylation at serines 23/24 
is associated with a decrease in myofilament Ca2+-sensitivity32,53,54 and contributes to 
an acceleration of cardiac relaxation.55,56 Since β-adrenergic signaling is reduced in 
heart failure due to down-regulation and desensitization of β-adrenoceptors,57-59 PKA-
mediated cTnI phosphorylation might be less pronounced in failing myocardium. In 
agreement with reduced β-adrenergic signaling, reduced phosphorylation levels of 
cTnI have been reported in failing human myocardium compared to non-failing donor 
hearts.60-62 More specifically, phosphorylation at PKA sites 23/24 was significantly 
reduced in end-stage failing compared to donor human myocardium.61,62 At the 
functional level, reduced PKA-mediated cTnI phosphorylation would result in an 
increase in Ca2+-sensitivity of the myofilaments, as was observed in single 
BA 
Factive Fpassive
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permeabilized human cardiomyocytes isolated from end-stage failing hearts.32,54,61,63  
In comparison to cells from non-failing donor myocardium, Ca2+-sensitivity 
was significantly higher in cardiomyocytes from patients with idiopathic or ischemic 
cardiomyopathy (Fig 3A). This sarcomeric defect was normalized upon treatment of 
cardiomyocytes with the catalytic subunit of PKA (Fig 3B), as the reduction in pCa50 
was larger in cardiomyocytes from failing compared to donor hearts.32 Recently, 
Messer et al.62 have shown that altered cTnI phosphorylation most likely underlies 
the increased Ca2+-responsiveness as isolated thin filaments from failing human 
hearts displayed higher Ca2+-responsiveness compared to filaments from donor 
myocardium in an in vitro motility assay. One should be careful when using non-
failing donor myocardium as “normal”, because of the high blood catecholamine 
levels at the time of tissue procurement. The high level of cTnI phosphorylation and 
relatively small effect of PKA on myofilament Ca2+-responsiveness might reflect over-
stimulation of the β-adrenergic pathway in donors and thereby augment the 
difference between healthy and failing samples. However, a similar increase in 
myofilament Ca2+-responsiveness has been observed in several animal models of 
heart failure.49,64-66 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. A. Ca2+-sensitivity was significantly higher in cardiomyocytes isolated from end-
stage failing (n=10) compared to donor (n=6) hearts. B. Incubation of cells with the catalytic 
subunit of PKA reduced pCa50 (∆pCa50: 0.20±0.01 and 0.03±0.01 in failing and donor cells, 
respectively) and abolished the difference between both groups (Modified from van der 
Velden et al. Cardiovasc Res 2003;57:37-47, with permission). 
 
To minimize variable receptor stimulation at the time of biopsy procurement, 
we recently conducted a series of experiments on single cardiomyocytes from pigs 
with a myocardial infarction or sham-operated animals isolated from transmural 
A B
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needle biopsies, which were instantly frozen in liquid nitrogen. Biopsies were taken 
from remote left ventricular tissue 3 weeks after myocardial infarction induced by 
ligation of the left circumflex coronary artery or from sham-operated animals. 
Consistent with previous observations (Fig 4),49 Ca2+-responsiveness was 
significantly higher in cells from infarct compared to sham animals, while the shift 
upon PKA was smaller in sham than in post-infarct remodeled myocardium 
(unpublished data). These data clearly show that alterations in β-adrenergic signaling 
and the concomitant reduction in PKA-mediated cTnI phosphorylation impair 
sarcomeric function. The increased Ca2+-sensitivity of the myofilaments might 
contribute to diastolic dysfunction via impaired relaxation of failing myocardium. 
 
Protein kinase C and D 
Apart from the β-adrenergic pathway, other signaling routes might be involved in the 
alterations in phosphorylation and function of sarcomeric proteins in heart failure. 
Noteworthy, overall phosphorylation status of cTnI, determined on ProQ Diamond 
stained gels,67 did not significantly differ between sham-operated and MI pigs 
(unpublished data), while the shift in Ca2+-sensitivity upon PKA treatment was larger 
in infarct compared to sham animals (Fig 4B). This implies that, whereas PKA-
mediated cTnI phosphorylation is down-regulated in infarct animals, cTnI 
phosphorylation by other kinases should be increased. One of the most likely 
candidates is protein kinase C (PKC). Its activity and expression levels are increased 
in heart failure66,68-71 and both cTnI and cTnT contain specific PKC phosphorylatable 
sites (i.e. serine 43/45 and threonine 144 in cTnI and serine 201 and threonine 
197/206/287 in cTnT).72-74 In addition to PKC, an increase in protein kinase D (PKD) 
has been reported in heart failure.75 PKD can be activated upon phosphorylation by 
PKC, and thus may act down-stream of PKC, or it also may be directly activated 
upon receptor stimulation by e.g. endothelin 1.76 It has been shown that PKD is able 
to reduce myofilament Ca2+-sensitivity via phosphorylation of PKA-sites (serine 
23/24) in cTnI.77 Consequently, the regulatory window of PKC and PKD in sarcomeric 
function might be widened in diseased myocardium. 
  
 
 
 
 
 
Chapter 2 
42
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Isometric force measurements were performed in single Triton-permeabilized 
cardiomyocytes isolated from remote left ventricular tissue from pigs three weeks after 
myocardial infarction (MI). Maximal force development (Fmax) was significantly lower in MI 
compared to sham-operated animals (A). Similar to the observations in human heart failure, 
Ca2+-sensitivity was significantly higher (A) and the PKA-mediated reduction in Ca2+-
sensitivity was larger (B) in cells from MI compared to sham animals (Modified from van der 
Velden et al. Circ Res 2004;95:e85-e95, with permission). 
 
The functional consequences of PKC-mediated protein phosphorylation have 
been investigated in rodent models and indicated a central role for cTnI and cTnT in 
reducing maximal myofilament force development.73,74,78 Apart from its effect on 
maximal force, PKC has been shown to reduce myofilament Ca2+-sensivity in rodent 
and human myocardium.61,71,73,74,78 The possible involvement of PKC-mediated 
protein phosphorylation in sarcomeric function in failing myocardium was shown 
recently in rat models of end-stage heart failure resulting from chronic pressure 
overload (aortic banding) and myocardial infarction.71 In both models increased 
expression and activation of PKCα were observed in the late, but not in the early 
phase of heart failure. Maximal force generating capacity and Ca2+-sensivity of 
permeabilized cardiomyocytes were significantly reduced in end-stage failing animals 
compared to age-matched controls,71,79 and both parameters increased upon 
treatment with protein phosphatase 1 (PP-1). In contrast, PKCα did not significantly 
alter cardiomyocyte function of failing cardiomyocytes, while it reduced both maximal 
force and its Ca2+-sensitivity in cells from the control group. In a previous study, the 
same group performed experiments where in failing cardiomyocytes the endogenous 
Tn-complex was exchanged by unphosphorylated troponin complex, while control 
A B
Sham MI 
     Sarcomeric Dysfunction 
43
 
cells were exchanged with troponin complex extracted from failing hearts.79 Upon 
exchange, Ca2+-sensitivity of failing cardiomyocytes was restored towards the value 
observed in controls, while failing troponin complex induced a significant reduction in 
Ca2+-sensitivity in control cells. However, troponin exchange did not affect maximal 
tension, indicating that PKC-mediated phosphorylation of troponin is not involved in 
the reduced force generating capacity. Overall, the data confirm that altered 
myofilament Ca2+-sensitivity can be attributed to altered troponin phosphorylation, 
while changes in maximal force generating capacity most likely rely on the permissive 
action of other sarcomeric proteins. 
 Whether PKC- and PKD-mediated phosphorylation and a concurrent 
reduction in Ca2+-responsiveness is detrimental for cardiac function or represents an 
alternative mechanism to preserve positive lusitropy during exercise 
andcompensates for reduced PKA-mediated cardiac relaxation requires further 
investigation. 
 
Sarcomeric dysfunction in heart failure 
Increased versus decreased Ca2+-sensitivity 
Opposite to the increased myofilament Ca2+-sensitivity observed in human end-stage 
failing myocardium (Fig 2)32,54,61,63 and in several animal models of cardiac disease 
(Fig 3)49,64-66, a decrease in myofilament Ca2+-sensivity was reported in rodent models 
of heart failure resulting from chronic pressure overload (aortic banding) and 
myocardial infarction.71,79 One possible explanation for these contrasting observations 
might be the level of neurohumoral stimulation present at the time of tissue 
procurement. An intricate balance exists between kinase and phosphatase activities 
within the cardiomyocyte as was shown recently by Braz et al.68 They reported that 
both PKA and PKC may alter phosphorylation status of proteins indirectly via 
phosphorylation of protein phosphatase inhibitor-1 (I-1). Opposite to PKA, which 
suppresses PP-1 activity,80 PKC enhances PP-1 activity via phosphorylation of I-1. 
This illustrates the delicate balance between kinases and phosphatases within a cell. 
An increase in PKC and a decrease in PKA-mediated phosphorylation of I-1 would 
enhance PP-1 activity81 and thereby induce hypophosphorylation of sarcomeric 
proteins. 
Apart from differences in neurohumoral status when tissue is retrieved from 
the heart, diverse alterations in the signaling pathways known to alter sarcomeric 
protein phosphorylation upon neurohumoral stimulation most likely underlie diverse 
functional properties of the sarcomeres. Already in 1991 Bristow et al.82 have shown 
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different alterations in the β-adrenergic pathway in hearts with ischemic heart disease 
(ISHD) and idiopathic cardiomyopathy (IDCM). Analysis of sarcomeric protein 
phosphorylation on ProQ Diamond stained gradient gels (Fig 5A)67 revealed 
significant differences between left ventricular myocardial tissue from end-stage 
failing patients with IDCM and ISHD (Fig 5B). Phosphorylation of cTnI was 
significantly higher in non-failing donor compared to end-stage failing myocardium. In 
addition, myosin binding protein C, which is phosphorylated upon β-adrenergic 
stimulation is lower in failing compared to donor hearts.67,83 Noteworthy, MLC-2 
phosphorylation was significantly higher in ISHD compared to donor and IDCM 
myocardium, and statistical analysis revealed significant different phosphorylation of 
cTnI between ISHD and IDCM samples. In line with a higher level of cTnI 
phosphorylation in ISHD samples, myofilament Ca2+-sensitivity was significantly 
lower in ISHD compared to IDCM myocardium.32,54 These data provide evidence that 
diverse alterations in sarcomeric protein composition and function in failing hearts are 
related to underlying cause or phenotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. A. Human heart samples (D, donor and IDCM, idiopathic dilated cardiomyopathy; 
20 µg/lane) separated on 4-15% gradient gels. Phosphorylation of myosin binding protein C 
(MyBP-C), desmin, troponin T (cTnT), troponin I (cTnI) and myosin light chain 2 (MLC-2) was 
determined with Pro-Q Diamond stain. B. Bar graph to illustrate differences in sarcomeric 
protein phosphorylation between human donor hearts and failing myocardium (ISHD, 
ischemic heart failure). *P<0.05 in one-way ANOVA. n = number of hearts. 
 
Reduction in maximal force generating capacity 
Reduced maximal force has been observed in diverse models of cardiomyopathy (Fig 
cTnI -
Tropomyosin - 
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4A).49,65,79,84 In rat with pressure-overload and infarction-induced cardiomyopathy, the 
reduction in Fmax amounted to 35% and 42%, respectively.79 As reduced Fmax was 
only partly reversed by PP-1 (15%),71 and as described above, may not directly 
involve the troponin complex,79 alternative signaling routes and other sarcomeric 
proteins may be of relevance. Moreover, depressed cardiomyocyte force 
development was also observed in enzymatically isolated preparations from failing rat 
hearts,84 in which the isolation procedure most likely reduced phosphorylation status 
of most sarcomeric proteins. Therefore, part of the reduction in maximal force might 
at least in part be related to altered isoform composition and/or proteolysis of 
sarcomeric proteins. A recent study in transgenic mice by Vahebi et al.85 in which p38 
MAPK (mitogen activated protein kinase) was constitutively active in the heart 
revealed a possible role for tropomyosin dephosphorylation in the depression of 
maximal force of the sarcomeres. Activation of p38 MAPK, as occurs in pressure 
overload-induced hypertrophy, has been shown to exert a negative effect on 
cardiomyocyte contractility without altering Ca2+-handling.86 The study in transgenic 
mice85 indicated that apart from its role in remodeling and apoptosis, activated p38 
MAPK leads to sarcomeric dysfunction, possibly via activation of phosphatases and a 
subsequent dephosphorylation of tropomyosin. The level of tropomyosin 
phosphorylation appears to be species-dependent, being relatively high in mice85 and 
lower in human myocardium (Fig 5A). However, similar to isoform changes in MHC, 
small changes in phosphorylation may exert a significant effect on sarcomeric 
function. Therefore, the (patho)physiological role of tropomyosin phosphorylation for 
sarcomeric function requires further investigation. 
In conclusion, depressed force development cannot be explained by a single protein 
alteration, though seems to be the result of complex interactions between various 
sarcomeric proteins. 
 
Increased cardiomyocyte stiffening 
Subtle, though functionally important changes in protein phosphorylation, induced by 
kinases and phosphatases other than PKA, may have been obscured in failing 
human myocardium in comparison to donor hearts. Separation of patients with heart 
failure into subgroups, based on severity, cause or phenotype, represents a powerful 
approach to reveal the causes and functional implications of alterations in sarcomeric 
function in human heart failure. Comparison of patients with diastolic (DHF) and 
systolic heart failure (SHF) revealed an increased passive force development in 
cardiomyocytes from DHF compared to SHF patients (Fig 6).87 A significant positive 
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correlation was present between in vivo left ventricular end-diastolic pressure 
(LVEDP) and Fpassive,88 indicating that cardiomyocyte stiffening contributes to high 
filling pressures in DHF. Increased cardiomyocyte passive force was corrected to 
values observed in hearts with preserved ejection fraction and normal LVEDP88 upon 
incubation with PKA (Fig 6), indicative for hypophosphorylation of sarcomeric 
proteins. The hypophosphorylated sarcomeric protein, possibly titin,89,90 could be a 
specific myocardial target for drug therapy to lower LVEDP in DHF. 
 
 
 
 
 
 
 
 
Figure 6. Cardiomyocyte stiffening in human heart failure. Cardiomyocyte passive force 
(Fpassive) was significantly higher in DHF than in SHF (*P<0.05). PKA treatment reduced Fpas in 
SHF and DHF (#P<0.05 in paired t-test) (From van Heerebeek et al. Circulation 
2006;113:1966-1973, with permission). 
 
Future perspectives 
The question if depressed cardiomyocyte contractility is involved in heart failure has 
been positively answered. Overall, there seems to be general consensus that 
sarcomeric dysfunction in heart failure results from altered protein phosphorylation, 
which is the result of complex changes in kinase and phosphatase expression and 
activity. The balance between kinases and phosphatases in the cardiomyocyte are 
humoral and heart rate-dependent and as a consequence the activities of kinases 
and phosphatases vary in time. Apart from temporal changes, spatial changes occur, 
as complex interactions have been shown between kinases and phosphatases 
regulating calcium homeostasis within cardiomyocytes.91,92 Such complex signaling 
may also apply to the myofilaments. Moreover, within the complex pattern of 
sarcomeric protein phosphorylation each protein and its phosphorylation status 
influences the behaviour of other sarcomeric proteins.93,94 As sarcomeric function 
most likely reflects differences in phosphorylation status and depend on the 
neurohumoral status and heart rate at the time of tissue procurement, investigation of 
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the functional properties of the sarcomeres should be performed in cardiac tissue, 
which is obtained under standardized conditions. The use of catheter biopsies has 
proven to be a major leap forward in unraveling sarcomeric dysfunction in human 
myocardium.87,88 Linkage of in vivo hemodynamic data with cardiomyocyte force 
measurements revealed that stiffening of the sarcomeres contributes to impaired 
filling of the heart in DHF patients.88 To obtain insight in dynamic signaling cardiac 
samples could be retrieved upon receptor stimulation.67 This approach allows 
determination of the direct relation between functional, structural and protein 
characteristics at the cellular level with in vivo hemodynamics measured at the time 
of tissue harvesting. 
  The sarcomeric proteome will be even more complex than described in the 
present review, since other signaling routes, apart from the β-adrenergic pathway, 
may be triggered under pathological conditions and affect sarcomeric 
function.68,75,76,86,95,96 Only recently, Yuan et al.97 discovered novel phosphorylation 
sites within the N-terminus of MyBP-C, which were differentially phosphorylated upon 
stunning in canine and rat myocardium. Apart from phosphorylation, post-
translational modifications resulting from oxidative stress might impair sarcomeric 
function. Moreover, mutant sarcomeric proteins as found in inherited 
cardiomyopathies98,99 further complicate analysis of causality between protein  
alterations and function of the sarcomere. Over the past years knowledge on mutated 
sarcomeric proteins present in cardiomyopathies increased swiftly. However the 
exact consequences of these mutations on cardiomyocyte function in human cardiac 
tissue are still unclear and knowledge concerning additional (mal)adaptive changes in 
sarcomeric proteins is scarce. Hence, it remains to be elucidated if and to what 
extent altered sarcomeric protein expression and/or posttranslational changes impair 
sarcomeric function in inherited cardiomyopathies. 
The combination of sarcomeric force measurements with proteomic analysis 
(i.e. functional proteomics) will reveal (novel) post-translational modifications involved 
in cardiomyocyte dysfunction in heart failure. The use of transgenic animal models 
and protein exchange experiments in cardiac preparations are required to define the 
specific role of post-translational protein modifications and mutant sarcomeric 
proteins in cardiac function. 
 
Clinical implications 
The recently obtained data in human myocardium (Fig 5 and 6) indicate that 
divergent disturbance of receptor-signaling cascades depend on underlying cause 
Chapter 2 
48
 
and phenotype. Diverse alterations in signaling pathways might alter the 
responsiveness of patients to drug therapy and therefore the current strategy of 
treating heart failure should be re-evaluated. Large randomized, double-blind, 
placebo-controlled multicenter trials have shown that treatment of heart failure 
patients (classified according to the New York Heart Association into class II-IV) with 
neurohumoral receptor blockers, such as ACE-inhibitors and beta-blockers, reduces 
both morbidity and mortality. However, it remains to be investigated if and to what 
extent reversal of sarcomeric dysfunction contributes to the beneficial effects of beta-
blocker and ACE-inhibitor therapy in different patient groups.  
 Interestingly, exercise in mice with a myocardial infarction reversed 
depressed sarcomeric function to values observed in controls.65 The beneficial 
effects appeared to be the result of improved β-adrenergic signaling. Future studies 
should investigate if the combination of currently used neurohumoral blockers with 
exercise yield added benefit. 
Novel therapy may include drugs targeted to mediators down-stream of the 
adrenergic and angiotensin receptors. Cardiac performance may be improved by 
targeting a specific myofilament protein34,100 to directly modulate sarcomeric function. 
Further exploration of the complex signaling routes underlying defects in sarcomeric 
function is required in order to develop more precise, individualized therapy in heart 
failure patients. 
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Abstract 
Previous studies revealed differences in the β-adrenergic receptor (βAR) signalling 
pathway between ischemic cardiomyopathy (ISHD) and idiopathic dilated 
cardiomyopathy (IDCM) patients.  
To reveal if one or more components of the βAR pathway are responsible for altered 
cardiomyocyte function and structure in failing hearts, key components of the βAR 
signalling pathway were studied in left ventricular tissue samples from patients with 
IDCM and ISHD and compared with non-failing donor hearts. This analysis was 
combined with force measurements in single permeabilized cardiomyocytes, protein 
analysis of regulatory proteins involved in cardiomyocyte contractility and histological 
analysis. 
Total βAR density was significantly reduced in IDCM patients compared to 
non-failing hearts, while this reduction was less in ISHD myocardium. Expression of 
the G-protein coupled receptor kinase, GRK5, was significantly higher in ISHD than 
in IDCM, while the expression of GRK2 and the stimulatory G-protein (Gs) was 
similarly reduced in both failing groups compared to donor. Expression level of the 
inhibitory G-protein (Gi) was significantly higher in IDCM than in ISHD, though an 
increase was observed in both failing groups relative to donor. Expression of protein 
phosphatase 1 was significantly lower in ISHD than IDCM, consistent with 
significantly higher phosphorylation of myosin light chain 2. Phosphorylation of the 
βAR target proteins, Myosin binding protein C (MyBPC) and cTroponin I (cTnI) was 
lower in IDCM than in ISHD, which was associated with a significantly higher Ca2+-
sensitivity in IDCM compared to ISHD. Expression of phospholamban (PLB) was 
increased in both failing groups compared to donor, while SERCA2a expression was 
solely reduced in IDCM. Consequently, the PLB/SERCA2a ratio was significantly 
higher in ISHD compared to IDCM. Histological analysis revealed lower collagen 
volume fraction in ISHD compared to IDCM.  
Our data indicate that alterations in β-adrenergic signaling pathway and 
cardiomyocyte function and structure depend on underlying cause of the 
cardiomyopathy. 
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Introduction 
In patients with heart failure the sympathetic nervous system is chronically activated 
to maintain perfusion of vital organs via peripheral vasoconstriction, an increase in 
heart rate and an increase in myocardial contractility. Although aimed at maintaining 
cardiac pump function, chronic neurohumoral stimulation is detrimental for cardiac 
function and results in uncoupling and down-regulation of adrenergic receptors 
(AR).1-3 The adverse effects of neurohumoral overstimulation is illustrated by the 
negative correlation between noradrenaline plasma levels and prognosis of the 
patients,4 and by the improvement of symptoms and prolonged survival of patients 
treated with β-adrenergic receptor (βAR) blockers.5  
In human myocardium, the main βAR are the β1AR and β2AR subtypes, which 
are coupled to stimulatory (Gs, both receptors) or inhibitory (Gi, only β2AR) guanine 
nucleotide binding proteins. Agonist binding to βAR triggers interaction of Gs with 
adenylyl cyclase, which subsequently stimulates the production of the second 
messenger cyclic AMP from ATP, leading to activation of the down-stream kinase, 
protein kinase A (PKA).6 Active PKA phosphorylates several cellular target proteins 
involved in Ca2+-handling and myofilament contraction.7,8 It increases Ca2+ influx (via 
the L-type Ca2+-channel), accelerates Ca2+ reuptake into the sarcoplasmic reticulum 
(via phosphorylation of phospholamban (PLB)) and decreases myofilament Ca2+ 
sensitivity.9,10 These PKA-induced cellular changes exert a positive inotropic and 
lusitrophic effect on cardiac pump function.7,11,12 The β2ARs also couple to Gi, which 
results in the opposite effects by lowering cAMP levels.6 The βAR itself is also 
regulated by phosphorylation. Beta-adrenergic receptors are uncoupled from G-
proteins, and thereby lose their responsiveness to agonist stimulation, upon 
phosphorylation by PKA or by G-protein-coupled receptor kinases (GRK).6,13 
Increased GRK activity has been related to uncoupling and down-regulation of 
adrenergic receptors in human cardiac disease.14,15 
Diverse alterations in myocardial βAR density have been reported in ischemic 
heart disease (ISHD) and idiopathic dilated cardiomyopathy (IDCM).16,17 In IDCM 
patients β1AR has been found to be 50-70% downregulated, while β2AR remained 
unchanged.16,17 In contrast, no change in βAR density16 or a reduction of both β1AR 
and β2AR was reported in ISHD patients.17 Apart from altered βAR composition, a 
change in G-protein expression is thought to underlie depressed responsiveness to 
catecholamines in heart failure.6,18 Neumann et al.18 reported increased expression of 
Gi in patients with IDCM. Analysis of Gi in IDCM and ISHD revealed significantly 
higher Gi expression in IDCM than in ISHD.19,20 It is however, unknown whether 
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these changes at the receptor level translate into diverse functional and structural 
alterations. To assess the impact of changes in the adrenergic receptor pathway on 
cellular structure, function and protein composition, a careful comparison was made 
between myocardium from patients with IDCM and ISHD. Radioligand binding 
studies were performed to determine βAR density. Protein analysis included down-
stream components of the adrenergic signaling cascade, the phospho-proteome of 
the myofilaments, and SERCA2a and PLB expression levels. Myofilament function 
was determined in permeabilized single cardiomyocytes. Histological analysis of 
cardiomyocyte diameter, collagen volume fraction and myofibrillar density were 
performed using light and electron microscopy. 
 
Methods 
Human ventricular tissue 
Left ventricular (LV) tissue samples were obtained during heart transplantation 
surgery from end-stage heart failure patients (NYHA III-IV) with IDCM (n=13; 9 
males, 4 females; mean age 49±5 yrs) or ISHD (n=10; 7 males, 3 females; mean age 
51±2 yrs). Medication included angiotensin-converting-enzyme inhibitors, angiotensin 
II receptor antagonists, diuretics, β-blockers, digoxin and anti-arrhythmic agents. 
Tissue from 10 donor hearts (n=10; 8 males, 2 females; mean age 38±6 yrs) served 
as reference for non-failing myocardium. The tissue was collected in cardioplegic 
solution and stored in liquid nitrogen. Samples were obtained after informed consent 
and with approval of the local Ethical Committee (St Vincents' Hospital Human 
Research Ethics Committee: File number: H03/118; Title: Molecular Analysis of 
Human Heart Failure). The investigation conforms with the principles outlined in the 
Declaration of Helsinki (Cardiovascular Research 1997;35:2-4). 
 
Protein analysis 
Radioligand binding 
Tissues (∼200 mg wet weight) were thawed in ice-cold 1 mM KHCO3 solution, minced 
with scissors and then homogenized with an Ultra-Turrax (Janke & Kunkel, Staufen, 
Germany) for 10 sec at maximum speed followed by twice 20 sec at 2/3 of maximum 
speed. The homogenates were centrifuged for 15 min at 250 g and 4°C. The 
supernatant was filtered through medical gauze and centrifuged for 20 min at 50.000 
g at 4°C. The sediment was resuspended in binding buffer (10 mM Tris, 154 mM 
NaCl, pH 7.4). Protein content was measured by the method of Bradford using 
bovine IgG as standard. Radioligand binding was performed using a 90 min 
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incubation at 37°C with [125I]iodocyanopindolol (ICYP; specific activity 2200 Ci/mmol, 
Perkin Elmer, Zaventem, Belgium) in a total volume of 250 µl. Non-specific binding 
was defined as binding in the presence of 100 µM isoproterenol (Sigma-Aldrich). All 
experiments were performed in duplicates in 96 well plates, and incubations were 
terminated by rapid vacuum filtration over Whatman GF/C using a Filtermate 
harvester (Perkin Elmer). Each filter was washed with approximately 10 ml of buffer. 
Radioactivity adherent to the filters was quantified in a Topcount NXT (Perkin Elmer) 
using Microsint O scintillator (Perkin Elmer). To determine the relative amount of 
β1AR and β2AR, membranes were incubated with ICYP (100 pM) in the presence or 
absence of eight concentrations (range 10-10 to 10-3 M) of the highly selective β1-AR 
antagonist CGP 20712 A [21]. Specific binding was determined as described earlier 
[21]. CGP 20712A is an abbreviation of 1-[2-((3-carbamoyl-4 hydroxy)phenoxy) 
ethylamino]-3-[4-(1-methyl-4-trifluoromethyl-2imidazolyl)phenoxy]-2-propanol 
methanesulfonate. 
 
Components of the β-adrenergic pathway 
Protein expression levels of GRK2 and GRK5, G-proteins (Gs and Gi) and protein 
phosphatase 1 (PP-1) were analyzed by one-dimensional 15% SDS-polyacrylamide 
gel electrophoresis (1D-PAGE) and subsequent Western blotting. Samples were 
applied in concentrations which were within the linear range of detection: 20 µg for 
GRK2, GRK5, Gs and PP-1, and 10 µg for Gi. After 1D separation proteins were 
transferred to Hybond-ECL nitrocellulose membranes. Blots were pre-incubated with 
0.5% milk powder in TTBS (Tween-tris-buffered-saline: 10 mM Tris–HCl pH 7.6, 75 
mM NaCl, 0.1% Tween) for one hour at room temperature. The blots were incubated 
overnight at 4°C with primary rabbit polyclonal antibodies (Santa Cruz) against GRK2 
(dilution 1:1000; sc-562), GRK5 (dilution 1:1000; sc-565), Gs (Gs/olf; dilution 1:1000; 
sc-383), Gi (dilution 1:1000; Gi-1 sc-262, Gi-2 sc-7276, Gi-3 sc-262) or primary mouse 
polyclonal antibody against PP-1 (dilution 1:50; sc-7482, Santa Cruz). After washing 
with TTBS, primary antibody binding was visualized using a secondary horseradish 
peroxidase-labeled goat-anti-rabbit/mouse antibody (dilution 1:2000; Dako-
Cytomation) and enhanced chemiluminescence (ECL plus Western blotting 
detection, Amersham Biosciences). All signals were normalized to actin (dilution 
1:1000; clone KJ43A; Sigma) stained on the same blots. 
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Myofilament protein phosphorylation 
Myofilament protein phosphorylation was determined using Pro-Q Diamond 
Phosphoprotein Stain as described previously.22 To preserve the endogenous 
phosphorylation status, frozen biopsies were homogenized in liquid nitrogen and re-
suspended in 1 ml cold 10% trichloroacetic acid solution (TCA; dissolved in acetone 
containing 0.1% (w/v) dithiothreitol (DTT)). TCA-treated tissue pellets were 
homogenized in sample buffer containing 15% glycerol, 62.5 mM Tris (pH 6.8), 1% 
(w/v) SDS and 2% (w/v) DTT. Tissue samples were separated on gradient gels 
(Criterion tris-HCl 4-15% gel, BioRad) and proteins were stained for one hour with 
Pro-Q Diamond Phosphoprotein Stain. Fixation, washing and de-staining were 
performed according to the manufacturer’s guidelines (Molecular Probes). To assess 
protein content subsequently gels were stained overnight with SYPRO Ruby stain 
(Molecular Probes). Phosphorylation status of myofilament proteins was expressed 
relative to protein expression of cardiac myosin-binding protein C (cMyBP-C) to 
correct for differences in sample loading. Staining was visualized using the LAS-3000 
Image Reader and signals were analyzed with AIDA. 
Bisphosphorylation of cardiac troponin I (cTnI) at PKA sites Ser-23/24 was 
detected with a primary rabbit polyclonal antibody (dilution 1:500; Cell signaling) in 
Western blotting. In addition, the recently developed Phos-tagTM acrylamide (FMS  
Laboratory; Hiroshima University, Japan)23 was used to visualize phosphorylated 
cTnI species using alkoxide-bridged dinuclear metal (Mn2+) complex as phosphate-
binding tag (Phos-tag) molecule. Mn2+-Phos-tag molecules preferentially capture 
phosphomonoester dianions bound to Ser, Thr and Tyr residues. Non-
phosphorylated and phosphorylated cTnI species were separated in 1D-PAGE with 
polyacrylamide-bound Mn2+-Phos-tag and transferred to Western blots. 
Phosphorylated cTnI species in the gel are visualized as slower migration bands 
compared to the corresponding dephosphorylated cTnI form. 
 
SERCA2a and PLB 
SERCA2a protein levels were determined immunochemically by dot-blot analysis, as 
described before, with minor modifications.24 Briefly, homogenized tissue samples 
(typically 0.5 µg total protein) were spotted in triplo onto a nitrocellulose membrane. 
The blot was then incubated with a 1:2500 dilution of a polyclonal antiserum to 
SERCA2a25 and subsequently with 125I-labeled anti-rabbit immunoglobulin G (0.05 
mg/ml, specific activity 7 mCi/mg). To detect PLB expression, blots were first 
incubated with a 1:2500 dilution of a monoclonal anti mouse antibody (Affinity 
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Bioreagents) and subsequently with 125I-labeled anti-mouse immunoglobulin G. 
Blots were exposed to Phosphor Imager screens, which were then scanned and 
spots were quantified using ImageQuant software (Molecular Dynamics). 
All protein values for ISHD and IDCM samples were normalized to the 
average value observed in donor hearts, which was set to 1. 
 
Force measurements in isolated cardiomyocytes 
Force measurements were performed in single, mechanically isolated 
cardiomyocytes as described previously.26,27 Tissue samples were defrosted in 
relaxing solution (in mmol/L: free Mg, 1; KCl, 145; EGTA, 2; MgATP, 4; imidazole, 10;  
pH7.0), mechanically disrupted and incubated for 5 minutes in relaxing solution 
supplemented with 0.5% Triton X-100 to remove all membrane structures. 
Subsequently, cells were washed twice in relaxing solution, after which single 
cardiomyocytes were attached with silicone adhesive between a force transducer and 
a motor. Sarcomere length of isolated cardiomyocytes was adjusted to 2.2 µm. The 
pCa (-10log[Ca2+]) ranged from 9.0 (relaxation solution) to 4.5 (maximal activation). All 
force values were normalized for cardiomyocyte cross-sectional area. Exposure to a 
series of solutions with intermediate pCa values (pCa 6.0-5.0) yielded the baseline 
force-pCa relation. On transfer of the cardiomyocyte from relaxing to activating 
solution, isometric force started to develop. Once a steady state force level was 
reached, the cell was shortened within 1 ms to 80% of its original length to determine 
the baseline of the force transducer. The distance between the baseline and the 
steady force level is the total force (Ftotal). After 20 ms, the cell was restretched and 
returned to the relaxing solution, in which a second slack test, of 10 s duration was 
performed to determine passive force (Fpassive). Active force was obtained by 
subtracting passive force from the total force, i.e. Factive=Ftotal-Fpassive. 
 
Quantitative histomorphometry 
Histomorphologic analysis of tissues was performed on elastica-von-Giesson and 
hematoxylin-eosin stained, 4 µm thick sections of tissue fixed in 5% formalin.27 
Images of these sections were acquired using a projection microscope (x50). 
Subsequent image analysis, using SlidebookTM 4.0 software (3I, Denver, Co), was 
performed to determine cardiomyocyte diameter (MyD, µm) and the extent of 
interstitial fibrosis, which was expressed as collagen volume fraction (CVF, %). Areas 
of reparative and perivascular fibrosis were excluded. As previously validated,27 MyD 
was determined perpendicularly to the outer contour of the cell membrane at nucleus 
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level in 15 representative myocytes of the section, and CVF was calculated as the 
sum of all connective tissue areas divided by the sum of all connective tissue and 
muscle areas averaged over 4-6 representative fields of the section. 
Tissues samples were fixed in 2% (v/v) gluteraldehyde for 30 min and 1.5% 
(w/v) osmium tetroxide for 10 min dehydrated with acetone and embedded in 
Epon812. Ultrathin sections were collected on 300-mesh Formavar-coated Nickel-
grids. The sections were contrasted with uranyl acetate and lead citrate and were 
examined in a Jeol-1200EX electron microscope. Quantitative analysis was 
performed with the above mentioned automated image analyzer. Cardiomyocyte 
myofibrillar density (FibD, %) was calculated from the sum of the myofibrillar areas 
related to total cellular area in 4-6 representative myocytes. 
 
Data analysis 
Competition binding data were analyzed by fitting mono- and biphasic sigmoidal 
functions to the experimental data; a biphasic fit was accepted only if it resulted in a 
significant improvement as judged by an F-test. Resulting IC50 values for the high and 
low affinity component of inhibition were converted to Ki values based upon the 
Cheng-Prusoff equation28 and assuming a Kd value of ICYP of 72 pM (n=4). Due to 
limited tissue availability, receptor density (Bmax) was estimated based upon the 
specific binding (SB) of the single radioligand concentration (L) in the competition 
experiments relative to its Kd using the equation Bmax = SB/(1 - 1/(L/Kd + 1)). The 
statistical significance of inter-group differences was assessed by one-way ANOVA 
followed by Dunnett’s post-hoc tests.  
Force-pCa relations were fit to the Hill equation as described previously.26 
Values are given as mean±SEM of n observations. The mean data values of protein 
and histological analysis and force measurements in ISHD, IDCM and donor samples 
were compared using one-way ANOVA and Bonferroni-post tests. P<0.05 was 
considered significant. All statistical analysis were performed with the Prism program 
(version 4.01, Graphpad Software, San Diego, CA, USA). 
 
Results 
Diverse changes in components of the βAR pathway in IDCM and ISHD 
With one exception competition by the highly β1-selective CGP 20712A resulted in 
biphasic curves in all cases (Fig 1). The high and low affinity sites had –log Ki values 
of 8.84±0.10 and 6.04±0.11, identifying β1AR and β2AR respectively in the non-failing 
donor group (n=7). The -log Ki values were not significantly different in either IDCM 
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(n=8) or ISHD (n=8). The calculated percentages of β1ARs were 52±6%, 50±4% and 
47±9% in donor, IDCM and ISHD, respectively (P>0.05). Single point estimates of 
total βAR density were 13.5±2.2, 6.6±1.5 and 9.9±1.8 fmol/mg protein in donor, IDCM 
and ISHD, respectively (P<0.05 for IDCM vs. non-falling donor). 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Competition curve of radioligand binding as a function of CGP 20712A. These 
measurements  revealed significantly lower βAR density in IDCM compared to non-failing 
donor myocardium, but the receptor distribution remained the same. 
 
An overview of the Western blot analysis of components of the βAR pathway 
in failing and donor myocardium is given in Figure 2. All signals in failing samples 
were normalized to the value observed in donor myocardium, which was set to 1. 
One-way ANOVA revealed significant differences in expression of GRK2 and GRK5 
among groups. The expression level of GRK2 (Fig 2A) was significantly lower in both 
failing groups compared to non-failing tissue, while GRK5 (Fig 2B) was significantly 
higher 
in ISHD compared to IDCM and non-failing myocardium. Gs expression was 
significantly lower in both failing groups compared to donor hearts (Fig 2C). In the 
present study, we have analyzed three forms of inhibitory G-protein: Giα-1, Giα-2 and 
Giα-3. The heterotrimeric G-proteins are composed of α, β and γ subunits, of which 
the α subunit confers specificity to the G-protein.6 The α subunit contains the GTP 
binding site and the intrinsic GTPase activity. Giα-1 expression (Fig 2D) was 
significantly higher in IDCM than in ISHD and donor, while Giα-2 (Fig 2E) was 
significantly higher in both failing groups compared to donor. No significant 
differences were found in Giα-3 expression level (Fig 2F). 
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Figure 2. Western blot examples of the βAR pathway proteins in IDCM, ISHD and donor 
myocardium. The expression of GRK2 was significantly lower in both ISHD and IDCM 
compared to donor (A), while GRK5 expression was significantly higher in ISHD compared to 
IDCM and donor (B).  Expression of Gs was significantly lower in failing compared to donor 
(C). The expression level of the three isoforms of Gi (D, Giα1;  E, Giα2 and F, Giα3) were 
different among groups (P<0.05, in one-way ANOVA).  Post-test Bonferroni analysis revealed 
a significantly higher level of Giα1 in IDCM compared to ISHD and donor, while Giα2 was 
significantly higher in both failing groups compared to donor. *P<0.05 in Bonferroni-post tests, 
CM vs. ISHD; #P<0.05, in Bonferroni-post tests, failing vs. donor. 
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Myofilament protein phosphorylation 
ProQ Diamond phosphostaining was used to detect phosphorylation of myofilament 
proteins. Figure 3A shows ProQ Diamond-stained cardiac samples from ISHD, donor 
(D) and IDCM myocardium separated on a gradient gel. The same gel was 
subsequently stained with SYPRO Ruby for analysis of total protein content (Fig 3B). 
The ProQ signals of phosphorylated proteins were corrected by the SYPRO-stained 
cMyBP-C band to correct for small differences in protein loading. The ProQ Diamond 
stained gel shows lower endogenous phosphorylation of the PKA-target proteins 
cMyBP-C and cTnI in failing compared to non-failing donor myocardium. Noteworthy, 
cTnI phosphorylation was significantly higher in ISHD compared to IDCM (Fig 3C). In 
addition, phosphorylation of cMyBP-C was higher in ISHD, though not significantly 
(P=0.07).  
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Figure 3.  Pro-Q Diamond-stained (A) and SYPRO-stained (B) gel of ISHD, donor (D) and 
IDCM samples. The ProQ Diamond stained gel clearly shows higher phosphorylation of 
cardiac myosin binding protein C (cMyBP-C) and troponin I (cTnI) in donor compared to the 
ISHD and IDCM sample. The mean values are shown in the bar graph (C). Phosphorylation of 
cTnI was significantly higher in ISHD compared to IDCM. Abbreviations: n, number of heart 
samples; MHC, myosin heavy chain; cTnT, troponin T; M, molecular weight marker 
(PeppermintStick Phosphoprotein marker in which ovalbumin (OV) and β-casein (β) are 
phosphorylated). *P<0.05 in Bonferroni-post tests, IDCM vs. ISHD; #P<0.05, in Bonferroni-
post tests, failing vs. donor. 
 
 kDa 
SYPRO 
M
ar
ke
r  
   
IS
H
D
   
 
D
on
or
   
 
ID
C
M
 
116 -
 66 - 
 45 - 
 24 - 
 18 - 
- MHC 
- Actin 
A 
ProQ 
- cTnI 
 - cTnT 
  - MLC-2 
- cMyBP-C 
- Desmin 
M
ar
ke
r 
IS
H
D
   
D
on
or
   
ID
C
M
 
OV - 
β - 
B
C 
cMyBP-C cTnI
0.0
0.5
1.0
1.5
2.0 ISHD
IDCM
DONOR
#
P
ho
sp
ho
ry
la
tio
n 
le
ve
l
#
#
#
*
IDCM versus IDHS 
69
 
Higher PKA-mediated phosphorylation of cTnI (at Ser 23/24, i.e. PKA sites) in ISHD 
compared to IDCM was confirmed in Western blotting (P<0.05, ISHD vs. IDCM; Fig 
4A). Consistent with ProQ Diamond analysis of cTnI phosphorylation, the Western 
blots revealed higher cTnI phosphorylation at PKA-sites in non-failing donor 
myocardium compared to failing hearts.  
Analysis of cTnI species separated by Phos-tag polyacrylamide gels revealed 
three bands upon staining of Western blots with a specific anti-cTnI antibody (8I-7, 
Spectral Diagnostics Inc.) in non-failing donor myocardium, while only two bands 
were observed in the failing sample shown in Figure 4B. The lower band was 
recognized by an antibody directed against cTnI non-phosphorylated at PKA sites 
(22B11, Research Diagnostics). The upper band was recognized by the PKA-specific 
cTnI antibody indicating that this band is the PKA-bisphosphorylated cTnI form. 
Based the latter analysis we assume that the second band is the mono-
phosphorylated form of cTnI. The distribution of the cTnI forms was significantly 
different among the three groups. The non-phosphorylated form was highest in 
IDCM, while the bisphosphorylated form was highest in non-failing donor hearts. 
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Figure 4. A. Western blot analysis of cTnI phosphorylation at the PKA-sites Ser 23/24 
revealed significantly higher cTnI phosphorylation in ISHD compared to IDCM, while cTnI 
phosphorylation was lower in both failing groups compared to donor. B. Phos-tag analysis of 
cTnI species revealed three cTnI bands in non-failing donor myocardium, of which the lowest 
band stained with an antibody directed against non-phosphorylated cTnI (22B11), and the 
highest band stained with the anti-PKA-bis phosphorylated sites in cTnI. C. The distribution of 
cTnI species was significantly different among groups. *P<0.05 in Bonferroni-post tests, IDCM 
vs. ISHD; #P<0.05, in Bonferroni-post tests, failing vs. donor. 
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ProQ Diamond analysis also revealed higher phosphorylation of myosin light chain 2 
(MLC-2) in ISHD compared to both IDCM and donor (Fig 5C), while there were no 
significant differences in phosphorylation of the other myofilament proteins, desmin  
and troponin T (data not shown). MLC-2 protein expression was similar in all groups 
ISHD, IDCM and donor (Fig 5A). The difference in MLC-2 phosphorylation may be in 
part explained by differences in PP-1 expression. Western blot analysis of PP-1 
revealed significantly higher PP-1 expression in IDCM compared to ISHD and donor 
myocardium (Fig 5B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. A. Expression of MLC-2 was similar in all groups. B. Expression of protein 
phosphatase 1 (PP-1) was significantly higher in IDCM compared to ISHD and donor. C. 
Phosphorylation of myosin light chain 2 (MLC-2) was significantly higher in ISHD compared to 
IDCM. *P<0.05 in Bonferroni-post tests, IDCM vs. ISHD; #P<0.05, in Bonferroni-post tests, 
failing vs. donor. 
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Diverse changes in PLB and SERCA2a expression in IDCM and ISHD 
Western immunoblot analysis revealed increased PLB expression (Fig 6A) in IDCM 
and ISHD compared to non-failing donor hearts and a significantly lower SERCA2a 
expression level (Fig 6B) in IDCM compared to both ISHD and donor. The ratio of 
PLB over SERCA2a (Fig 6C) significantly differed among groups, being highest in 
IDCM and lowest in donor. 
 
 
 
Figure 6. Western blot analysis revealed significant differences in protein levels of the Ca2+-
handling proteins phospholamban (PLB) and SERCA2a among groups. PLB was significantly 
higher in both failing groups compared to donor (A), while SERCA2a was significantly lower in 
IDCM compared to ISHD and donor (B). The ratio of PLB over SERCA2a was significantly 
higher in both failing groups compared to donor. The PLB/SERCA2a ratio of IDCM group was 
significantly higher compared to the value observed in the ISHD group (C). *P<0.05 in 
Bonferroni-post tests, IDCM vs. ISHD; #P<0.05, in Bonferroni-post tests, failing vs. donor. 
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Higher Ca2+-sensitivity in IDCM than in ISHD 
Force measurements were performed in single cardiomyocytes isolated from 9 IDCM 
(42 cardiomyocytes), 8 ISHD (27 cardiomyocytes) and 11 donor (41 cardiomyocytes) 
samples. Cross-sectional area of the cardiomyocytes determined at a sarcomere 
length of 2.2 µm was significantly higher in IDCM (556±44 µm2) and ISHD (690±75 
µm2) compared to non-failing donor hearts (339±26 µm2) (P<0.05 in one-way 
ANOVA).  
Factive did not differ (Fig 7A), while Fpassive was significantly lower in failing 
compared to donor (Fig 7B). A significantly higher pCa50 was found in failing heart 
compared to non-failing donor hearts (Fig 7C,D). Noteworthy pCa50 was significantly 
lower in ISHD compared to IDCM (Fig 7C,D). Moreover, the steepness of the force-
pCa relationship (nHill) was significantly higher in ISHD (4.05±0.12) compared to 
IDCM (3.58±0.10) and non-failing donor (3.70±0.14).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Maximal active tension (Factive) did not differ among groups (A). Passive (Fpassive) 
orce was significantly lower in failing hearts compared to donor (B). Ca2+-sensitivity (pCa50) 
was significantly higher in failing hearts compared to the donor group (C,D). The pCa50 was 
significantly lower in ISHD compared to IDCM (C,D). *P<0.05 in Bonferroni-post tests, IDCM 
vs. ISHD; #P<0.05, in Bonferroni-post tests, failing vs. donor. 
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Alterations in cellular structures 
Representative examples of light microscopy images of LV sections from the three 
groups are shown in Figure 8A. MyD did not differ between ISHD and IDCM, 
although MyD values in both failing groups were higher than observed in donor 
myocardium (Fig 8B). CVF was significantly higher in both failing compared to the 
donor group. Moreover, CVF was significantly higher in IDCM compared to ISHD (Fig 
8C). No differences were found in FibD between ISHD and IDCM, while FibD was 
significantly lower in both IDCM and ISHD compared to non-failing donor (P<0.05 in 
post-test Bonferroni analysis; Fig 8D). 
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Figure 8. A. Light microscopy images of LV sections from the three groups. B. Bar graphs 
showing cardiomyocyte diameter (MyD), C. collagen volume fraction (CVF) and D. myofibrillar 
density (FibD). A significant increase was observed in MyD and CVF in both failing groups 
compared to donor. In addition, a significantly lower FibD was present in failing hearts 
compared to donor. CVF in IDCM was significantly higher compared to ISHD. *P<0.05 in 
Bonferroni-post tests, IDCM vs. ISHD; #P<0.05, in Bonferroni-post tests, failing vs. donor. 
Representative example of collagen (arrows) of the IDCM, ISHD and non-failing donor. 
 
Discussion 
Diverse changes in components of the β-adrenergic pathway 
Bristow et al. showed down-regulation of βARs in dilated cardiomyopathy patients,2 
which were mainly attributed to a reduction of the β1AR subtype. In our study, total 
βAR density was significantly reduced in IDCM patients compared non-failing hearts, 
while this reduction was less in ISHD myocardium. No change was found in 
percentage of β1AR among groups. The number of βAR may change as a result of 
reduced mRNA levels.29 In addition, βAR may be degraded upon internalization of 
receptors, which is preceded by the process of receptor uncoupling.6 The regulating 
step in the latter process is receptor phosphorylation, either by second-messenger 
activated kinases, or by GRKs, which only phosphorylate agonist occupied receptors. 
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Studies in transgenic mice overexpressing GRK2 (also known as βARK1, β-
adrenergic receptor kinase 1)13 or GRK530 revealed that both are determinants of 
βAR responsiveness of the heart, as they disrupt the interaction between receptors 
and the heterotrimeric G proteins. This process of receptor uncoupling is thought to 
be an important contributor to βAR desensitization and down-regulation due to 
increased sympathetic tone in cardiac disease. In failing human tissue, Ungerer et 
al.14,15 were the first to show increased GRK2 mRNA and activity in both ISHD and 
IDCM. In contrast, in the present study we observed lower GRK2 protein expression 
in both failing groups compared to non-failing myocardium, while GRK5 protein 
expression was significantly higher in ISHD compared to IDCM and non-failing 
myocardium. Our data indicate that apart from GRKs other mechanisms are involved 
in the reduction of βAR density.  
Previous studies revealed no change in mRNA level and activity of Gs.31,32 In 
contrast, in our study a decreased Gs protein expression was detected in both patient 
groups compared to non-failing donor hearts, while no difference was present 
between IDCM and ISHD. Neumann  et al. and Feldman et al.18,31 were the first to 
report an increase in Gi in preparations from IDCM patients. Noteworthy, in our study, 
Gαi expression levels were highest in IDCM, with a significantly higher expression of 
Gαi-1 in IDCM compared to ISHD.  
 
Diverse changes in protein phosphorylation in ISHD and IDCM 
Analysis of sarcomeric protein phosphorylation revealed significant differences in the 
βAR target proteins cMyBP-C and cTnI. Consistent with previous studies26,33 
phosphorylation of cMyBP-C and cTnI was significantly lower in both failing groups 
compared to donor, which has been explained by reduced PKA-mediated 
phosphorylation due to βAR desensitization and down-regulation in cardiac 
disease.26 Noteworthy, cTnI phosphorylation was significantly lower in IDCM 
compared to ISHD, which may be the resultant of the larger reduction in βAR density 
and larger increase in Gαi-1 expression observed in IDCM compared to ISHD hearts.  
MLC-2 phosphorylation was significantly higher in ISHD than in IDCM. MLC-2 
dephosphorylation depends on expression level and activity of PP-1. The PP-1 level 
was significantly lower in ISHD compared to IDCM. However, it was similar in ISHD 
and non-failing donor. The activity of PP-1 is tightly regulated by its inhibitor, protein 
inhibitor 1 (I1).46 Upon activation of βAR, PP-1 activity is depressed by PKA via 
phosphorylation of I1. Hence, the difference in MLC-2 phosphorylation between ISHD 
and donor myocardium may be caused by a difference in PP-1 activity. 
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Myofilament function 
As PKA-mediated phosphorylation of cMyBP-C and cTnI result in a decrease in 
myofilament Ca2+-sensitivity, the lower myofilament Ca2+-sensitivity in ISHD 
compared to IDCM may be well explained by the significantly higher (PKA-mediated) 
phosphorylation of cTnI observed in ISHD. Interestingly, analysis of cTnI species 
using Phos-tag polyacrylamide gels (Fig 4B,C) showed that the difference in cTnI 
phosphorylation can be largely explained by a difference in the bis-phophorylated 
form of cTnI. Thus it is tempting to speculate that a difference in bis-phosphorylated 
cTnI underlies the difference in Ca2+-sensitivity between IDCM and ISHD. 
Passive cardiomyocyte stiffness was reduced by 20% in ISHD and 32% in 
IDCM compared to donor hearts. The 30% reduction in FibD could have contributed 
to the low Fpassive observed in both failing groups. However, Factive was comparable in 
all groups. Hence, it is unlikely that the reduction in cardiomyocyte stiffness can be 
explained by reduced FibD. Changes in passive stiffness have been ascribed to 
alterations in titin isoform composition.35 The reduction in cardiomyocyte stiffness is 
most likely the resultant of a shift from the stiff N2B to the compliant N2BA titin 
isoform. 
 
Diverse changes in protein expression in IDCM and ISHD 
Increased activity and mRNA level of PP-1 has been reported previously in human 
IDCM.36 Increased activity of PP-1 in a transgenic mouse model resulted in 
decreased contractility and dilated cardiomyopathy underscoring a detrimental role 
for PP-1 in heart failure.34 Increased PP-1 will impair Ca2+-handling by 
dephosphorylation of PLB. The resulting reduction in SR Ca2+ loading will be 
enhanced further by the reduction in SERCA2a expression in IDCM. Although 
several studies did not find differences in SERCA2a and PLB at mRNA levels 
between ISHD and IDCM,37,38 our study showed reduced SERCA2a protein 
expression only in IDCM, while expression of PLB was increased compared to donor 
myocardium in both failing groups. Based on these previous studies34,36 an increase 
in PP-1 and the reduction in SERCA2a expression will impair Ca2+-handling and 
suggests that IDCM patients may benefit from SERCA2 transfection, which has been 
shown to restore cardiomyocyte function and cardiac pump function.47 
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Structural changes in IDCM and ISHD 
Previous studies identified three main structural alterations in patients with IDCM and 
ISHD:  cardiomyocyte hypertrophy,40 myofibrillar loss39 and myocardial fibrosis.40,41 In 
our study, no difference was found in MyD and FibD between IDCM and ISHD, while 
CVF was significantly higher in IDCM compared to ISHD. Fibrosis is thought to result 
in abnormal myocardial stiffness, which can lead to left ventricular diastolic 
dysfunction42 and ultimately systolic dysfunction in IDCM and ISHD.43 Our finding is in 
line with a previous study by Parodi et al,44 which showed more fibrosis in IDCM than 
ISHD. The higher fibrosis in IDCM may be related to the inflammation45 and warrants 
further research.  
 
Clinical implications 
As all patients received medication, which have been shown to reverse detrimental 
changes in cellular structure and expression of components of the βAR pathway, 
drug treatment may have obscured disease-related changes. Nevertheless, our 
results suggest that differences in. βAR signalling result in alterations in cellular 
structure, function and protein composition and that responsiveness of patients to 
antagonist therapy may depend on the underlying cause of heart failure. 
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Abstract 
Early detection of myocardial dysfunction in Fabry disease (FD) cardiomyopathy 
suggests possible compromise of myofilaments. Six males with untreated FD 
cardiomyopathy were submitted to cardiac studies, including Tissue Doppler imaging 
(TDI) and left ventricular endomyocardial biopsy. Active and resting tension before 
and after treatment with protein kinase A were determined in isolated Triton-
permeabilized cardiomyocytes. Cardiomyocyte cross sectional area, area of 
glycosphingolipid vacuoles, myofibrillolysis and extent of fibrosis were also 
determined.  Biopsies of donor hearts and mitral stenosis patients served as controls. 
Active tension was five times lower in FD cardiomyocytes and correlated with extent 
of myofibrillolysis. Resting tension was three times higher in FD than in controls. 
Protein kinase A treatment of FD cardiomyocytes decreased resting tension, but did 
not affect active force. Protein analysis revealed degradation products of troponin I 
and desmin. FD cardiomyocytes were significantly larger and filled with 
glycosphingolipids. Fibrosis was mildly increased compared with controls. TDI 
lengthening velocities were reduced in FD patients vs controls and correlated with 
resting tension. TDI shortening velocities were also reduced and correlated with 
active tension. In conclusion myofilament degradation and dysfunction appear as 
major determinants of FD cardiomyopathy. Partial reversal of cardiomyocytes high 
resting tension after protein kinase A suggests a potential benefit from enzyme 
replacement therapy and/or energy releasing agents. 
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Introduction 
Fabry disease (FD) is an X linked lysosomal storage disorder caused by the 
deficiency of the enzyme α-galactosidase A, resulting in progressive intracellular 
glycosphingolipid deposition in multiple organ systems, including the heart. 1  
In patients with FD, cardiac involvement is characterized by progressive left 
ventricular (LV) wall thickening, mimicking hypertrophic cardiomyopathy,2-3 with 
diastolic LV dysfunction and a preserved LV ejection fraction that may decline in the 
end stage of the disease.4  The diastolic LV dysfunction has usually been ascribed to 
myocardial fibrosis in addition to cardiomyocyte hypertrophy and engulfment by 
glycosphingolipids. Recently however, Tissue Doppler imaging (TDI) revealed 
reduced diastolic and systolic velocities even in the prehypertrophic phase of the 
disease,5 suggesting an early and direct involvement of cardiomyocyte function.  
The present study therefore investigated in male patients with untreated FD 
active and resting tension of isolated cardiomyocytes, myofilament protein 
composition, myocardial collagen deposition and glycosphingolipids accumulation 
and correlated them with TDI myocardial long axis shortening and lengthening 
velocities.  
 
Material and Methods 
Patient population 
From January 1996 to July 2005, 12 consecutive male patients with LV hypertrophy 
were diagnosed to have FD by means of biochemical, genetic and endomyocardial 
biopsy studies. Eight patients  had not yet begun enzyme replacement therapy, 6 of 
them (47.1±8.3 yrs) had a complete clinical, morphometric and force measurement 
evaluation and constituted our patient population (Table 1). The patients belonged to 
unrelated families. Reduced peripheral blood alpha-galactosidase A activity was 
detected in all patients as previously described6 and causal mutations were identified 
by direct sequencing of alpha-galactosidase A gene in all families. The investigation 
conforms with the principles outlined in the Declaration of Helsinki. 
 
Clinical studies 
Extensive clinical examination, including the assessment of FD systemic 
manifestations, ECG, 2D echocardiography with Doppler analysis and cardiac 
magnetic resonance imaging (MRI) with late gadolinium enhancement, were 
performed in all patients. TDI analysis was performed in the pulsed Doppler mode to 
Chapter 4 
86
 
record mitral annulus velocities at septal and lateral corners.5,7 Systolic (Sa), early 
diastolic (Ea) and late diastolic (Aa) velocities were measured and the E/Ea ratio was 
computed. Maximal wall thickness (MWT) was defined as the greatest thickness of 
any segment of the LV wall. Ten age-matched men with no evidence of LV 
hypertrophy or cardiac and systemic disease were used as controls. MRI was 
performed as previously described.7 Late enhancement assessment was performed 
10-15 minutes after injection of gadolinium–DTPA (Shering AG) (0.2 mmol/kg of body 
weight), by using a 3D-Inversion Recovery T1-weighted sequence.  
 
Cardiac catheterization and endomyocardial biopsy 
All invasive studies were approved by the Ethical Committees of our Institutions and 
the patients provided written informed consent. 
All FD patients underwent coronary and biventricular angiography with biventricular 
or LV endomyocardial biopsy. LV end-diastolic pressure >16 mm Hg was considered 
as indicative of LV diastolic dysfunction. Eight to 10 endomyocardial samples, 
approximately 3 mm3 each, were obtained from each patient. Five to 6 myocardial 
samples were processed for routine histological and histochemical analyses. Two 
samples were fixed in 2% glutaraldehyde in 0,1 M phosphate buffer (pH=7.3) and 
embedded in Epon resin; semi-thin sections were processed for Azur II staining and 
ultra-thin sections were stained with uranyl acetate and lead hydroxide for 
transmission electron microscopy (TEM).7 One-two endomyocardial biopsy samples 
were snap frozen in liquid nitrogen and used for cardiomyocyte force measurements 
and protein analysis. 
 
 
 
 
 
 
 
Table 1. Characteristics of Fabry Disease Patients 
A=arrhythmias; † CNS=central nervous system, AP=acroparesthesias, H=hypohidrosis; ‡ 
Values are the mean (± SD) results of three independent determinations on peripheral blood 
lymphocytes;§ EDP= left ventricular end diastolic pressure; ║LV=left ventricular, EDD=end 
diastolic diameter, MWT= maximal wall thickness, EF=ejection fraction; LVEDP= left 
ventricular end diastolic pressure; # MRI= Magnetic resonance imaging.  
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 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 
Age (y) 50 46 53 58 41 35 
Cardiac manifestations* Dyspnea, Chest pain, A 
Dyspnea, Chest 
pain, A 
Dyspnea, Chest 
pain, A 
Dyspnea, Chest 
pain, A 
Dyspnea, Chest 
pain, A 
Dyspnea, Chest 
pain, A 
Extracardiac manifestations† Skin, CNS, ears eyes, kidneys, H 
Skin, CNS, ears 
eyes, kidneys, 
AP, H 
Skin, eyes, 
kidneys, H 
Eyes, ears, 
kidneys 
Skin, eyes, ears, 
kidneys 
Skin, CNS, eyes, 
ears, kidneys 
 
Enzymatic activity‡ 
(nmol/hr/mg of protein) 70.3±9.6 20.9±1.5 79.2±8.5 50.2±5.6 23.1±2.6 15.2±0.8 
LVEDP, mmHg§ 26 24 21 19 20 22 
Echocardiography║       
LVEDD (mm) 49 46 44 43 45 40 
MWT(mm) 20 21 23 19 18 18.5 
LVEF (%) 50 51 67 65 63 65 
Fractional shortening (%) 38 43 48 44 40 47 
E/A ratio 0.82 0.93 0.91 0.89 0.94 0.95 
Isovolumic relaxation time (ms) 115 110 108 111 107 108 
E-wave deceleration time (ms) 285 270 275 240 205 210 
MRI data #       
LV mass index, g/m2 150.3 132.0 143.2 133.4 99.9 114.1  
Late enhancement, % 6.7 6.3 4 7.4 1.6 7.9 
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Morphometric studies 
Paraffin-embedded histologic sections stained with Masson’s trichrome were 
examined at 400x magnification with a reticule containing 42 sampling points 
(105844, Wild Heerbrugg Instruments, Gals, Switzerland) to determine the percent 
area occupied by cardiomyocytes and by interstitial and replacement fibrosis.8 
Cardiomyocyte cross sectional area was computed measuring the cardiomyocyte 
diameter across the nucleus in 50-100 cells cut transversely (78±14 cells, range 58-
97).9 At that level, the diameter of the perinuclear vacuoles was also measured and 
the percent cardiomyocyte area occupied by vacuoles was computed. In addition, 
endocardial thickness was determined. These measurements were performed in 
glutaraldehyde-fixed, Epon resin embedded, semi-thin sections stained with Azur II to 
visualize glycolipids droplets. Images of the histologic sections were analyzed using 
Lucia G software (version 4.82, Nikon, Japan). 
Morphometric analysis of myofibrillolysis area was performed on ultra-thin 
sections, stained with uranyl acetate and lead hydroxide. Photographic negatives of 
TEM sections were analyzed using KS-300 software (Carl Zeiss Co, Germany, 
1995).10 Ten surgical specimens of papillary muscles from age-matched male 
patients with mitral stenosis and normal LV function were used as normal controls for 
morphometric measurements. 
 
Force Measurements in Isolated Cardiomyocytes 
Biopsies were stored in liquid nitrogen for up to 41 months (20.2±16.7, range, 3 to 41 
months). Previous studies have shown that these samples can be used for force 
measurements in single cardiomyocytes.11 Force measurements were performed in 
mechanically isolated single cardiomyocytes of the six patients at 15°C as described 
previously.11–13 The control group consisted of surgical biopsies from five age-
matched male patients with mitral stenosis and normal LV end-diastolic pressure, 
chamber dimensions, and contractile function. Briefly, frozen biopsies were defrosted 
within 10 seconds in cold relaxing solution (in mmol/L: free Mg, 1; KCl, 100; EGTA, 2; 
MgATP, 4; imidazole, 10; pH7.0). Cells were mechanically isolated and incubated for 
5 minutes in relaxing solution supplemented with 0.5% Triton X-100 to remove all 
membranes. Thereafter, cells were washed twice in relaxing solution and a single 
cardiomyocyte was attached between a force transducer and a piezoelectric motor 
using silicone adhesive (Fig 1, A and B). To enable attachment between the force 
transducer and motor single preparations were selected for measurements on the 
basis of cell length (~100 µm long). Resting sarcomere length of isolated 
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cardiomyocytes was ~1.7 µm and was adjusted to 2.2 µm for measurements of 
isometric force. The composition of the relaxing [pCa (-10log{Ca2+}), 9.0] and 
activating (pCa, 4.5) solution was previously described.14 All force values were 
normalized for cardiomyocyte cross-sectional area. A typical contraction-relaxation 
sequence in a cardiomyocyte from a Fabry sample is shown in Figure 1C. After 
curing of the glue for 50 minutes, the cardiomyocyte was transferred from the 
isolating solution on the mounting area to a small temperature-controlled well 
(volume, 80µl) containing relaxing solution. Isometric force was measured, after the 
preparation was transferred, by moving the stage of the inverted microscope to a 
temperature-controlled well containing activating solution.12 On transfer of the 
cardiomyocyte from relaxing to activating solution, isometric force started to develop. 
Once a steady-state force level was reached, the cell was shortened within 1 ms to 
80% of its original length to determine the base line of the force transducer. The 
distance between the base line and the steady force level is the total force (Ftotal). 
After 20 ms the cell was restretched and returned to the relaxing solution, in which a 
second slack-test of 10 seconds duration was performed to determine resting or 
passive force (Fpassive). The difference between Ftotal and Fpassive is the active force 
(Factive) developed by the cardiomyocyte. After measurements of Ftotal and Fpassive, the 
cardiomyocytes were incubated for 40 minutes at 20°C in relaxing solution containing 
the catalytic subunit of protein kinase A (PKA) (100 U/ml, batch 12K7495; Sigma, 
Brooklyn, NY) and 6-mmol/L dithiothreitol (MP Biochemicals, Irvine, CA). 
Subsequently, force measurements were repeated. Control incubations in relaxing 
solution with 6 mmol/L dithiothreitol, but without PKA, did not alter Fpassive and Factive of 
cardiomyocytes. 
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Figure 1. Single FD (A) and control (B) cardiomyocyte attached between a force transducer 
and a piezoelectric motor. C. Contraction-relaxation sequence in FD cardiomyocyte before 
(left) and after (right) treatment with PKA. The abrupt changes in force mark the transitions of 
the preparation through the interface between solution and air (i.e. transfers between wells 
containing relaxing and activating solutions). 
 
Protein analysis 
Protein analysis was performed on cardiomyocytes, which were not used for force 
measurements. After isolation and Triton treatment the remaining cell pellet was 
freeze dried and homogenized in sample buffer. To detect myofilament proteolysis, 
myofilament proteins were separated by one-dimensional gel electrophoresis 
containing 15% total acrylamide (acrylamide to bis-acrylamide ratio 37.5:1) followed 
by Western immunoblotting.15 Five µg (dry weight) of the tissue samples were applied 
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to the gels. Western immunoblot analysis was performed using specific monoclonal 
antibodies against troponin I (TnI) (clone 8I-7, Spectral Diagnostics Inc.; dilution 
1:1000), desmin (clone DE-U-10, Sigma; dilution 1:1000), myosin light chain 1 (clone 
F109.16A12, Alexis biochemicals; dilution 1:200), myosin light chain 2 (clone 
F109.3E1, Alexis biochemicals; dilution 1:200) and α-actinin (clone EA-53, Sigma; 
dilution 1:1000) and signals were visualized using a secondary horseradish 
peroxidase-labeled goat-anti-mouse antibody and enhanced chemiluminescence 
(ECL plus Western blotting detection, Amersham Biosciences). 
 
Statistical analysis 
Normal distribution of variables was assessed with Kolmogorov Smirnov and 
Shapiro–Wilk tests. Variables showing normal distribution are presented as 
mean±SD.  Variables not showing normal distribution are presented as median 
(interquartile range). Categorical variables are presented as proportions or 
percentages. Continuous variables, showing a normal distribution, were compared 
with Student t-test for independent samples (cases vs. controls). Continuous 
variables not showing a normal distribution were compared with Mann-Whitney test 
(cases vs. controls). Bivariate correlations were analyzed by Spearman rho 
coefficient computation. A two tailed p<0.05 was considered statistically significant. 
Statistical analysis was performed with SPSS ver. 11.0.1 software (SPSS Inc., USA). 
 
Results 
Clinical studies 
Patient’s clinical characteristics, echocardiographic and MRI data c are reported in 
Table 1. Alpha-galactosidase A activity was very low (mean value 43.4±7.4 
nmol/h/mg of protein, normal range 3252-1623 nmol/h/mg of protein) and all patients 
had extra-cardiac clinical manifestations of the disease. All patients were 
normotensive, satisfied the ECG and echocardiographic criteria for LV hypertrophy, 
and showed an increase in LV mass index. Diastolic function was impaired in all 
patients but no restrictive filling pattern was detected. Conversely, systolic function, 
as measured by ejection fraction and fractional shortening, was within the normal 
range in all FD patients.  
Gadolinium contrast-enhancement MRI study showed late enhancement in all 
patients typically localized in the basal or basal-medium segment of the lateral and 
infero-lateral wall (Fig 2A). Two patients (n°2 and n°6 of Table 1) showed additional 
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focal late enhancement in the apex. The mean percentage of myocardium involved 
was 5.7±2.4% (range 1.6 to 7.9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. A. Cardiac MRI short (left) and long (right) axis view showing basal infero-lateral 
hyperenhancement in FD patient n°3 of Table 2. B. LV endomyocardial biopsy from the same 
patient showing mild interstitial and focal replacement fibrosis (F) and severe glycolipids 
engulfment of cardiomyocytes (Masson staining, magnification 40x). C) Volume composition 
of the myocardium in endomyocardial biopsies of FD compared with controls revealing no 
significant difference in percent of cardiomyocytes (M) and other interstitial components (O), 
while interstital (IF) and replacement (RF) fibrosis showed a mild significant increase. Results 
are mean ±SD.*p<0,05 compared with controls. 
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On TDI examination all patients had significant reduction of long axis lengthening and 
shortening velocities measured at the septal and lateral corner of the mitral annulus  
(Table 2) 
 
Table 2. TDI, morphometric and force measurements in patients with Fabry disease 
compared with controls 
 
* Controls for TDI were n=10, for morphometric studies were n=10, for force measurements 
were n=8. † p values obtained comparing FD versus controls. ‡ p<0.001 versus after PKA 
treatment. Data are present as mean value ±SD; p<0.05 was considered statistically 
significant. 
 
LV angiography revealed normal wall motion in all patients and coronary angiography 
showed absence of significant coronary stenoses.  
On TDI examination all patients had significant reduction of long axis 
lengthening and shortening velocities measured at the septal and lateral corner of  
the mitral annulus (Table 2). LV angiography revealed normal wall motion in all 
patients and coronary angiography showed absence of significant coronary stenoses.  
 
 Fabry disease Controls * p† 
TDI velocities    
Septal Sa (cm/s) 5.9±0.4 14.6±1.2 <0.001 
Septal Ea (cm/s) 5.7±0.5 15.5±1.3 <0.001 
Septal Aa (cm/s) 6.0±0.5 10.3±0.9 <0.001 
Septal E/Ea 11.2±0.5 6.0±1.3 <0.001 
Lateral Sa (cm/s) 6.0±0.2 13.7±2 <0.001 
Lateral Ea (cm/s) 5.9±0.4 14.0±0.4 <0.001 
Lateral Aa (cm/s) 6.1±0.6 10.1±1.5 <0.001 
Lateral E/Ea 10.5±0.3 5.8±1.2 <0.001 
 
Morphometric data    
Fibrosis (%) 8.7±4.4 4.1±2.5   0.02 
Interstitial 6.7±3.1 3.4±2.0   0.02 
Replacement 1.9±1.5 0.7±0.6   0.03 
Cardiomyocytes (%) 81.2±7.2 88.1±6.1   0.06 
Cardiomyocyte area (µm2) 861.0±208.4 215.4±90.1 <0.001 
Cardiomyocyte area occupied by vacuoles (%) 57.3±4.1 0 <0.001 
Myofibrillolysis area (%) 15.2±4.9 0 <0.001 
 
Cardiomyocytes function    
Ftotal (kN/m2) 13.7±3.9‡ 17.6±5.3 NS 
Factive (kN/m2) 3.9±3.5 15.9±5.4 <0.001 
Fpassive (kN/m2) 9.8±2.3‡ 1.6±0.6 <0.001 
Ftotal after PKA (kN/m2) 11.1±2.6 18.2±5.4   0.02 
Factive after PKA (kN/m2) 4.3±3.3 16.8±5.4 <0.001 
Fpassive after PKA (kN/m2) 6.6±2.6 1.4±0.6 <0.001 
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Histologic and morphometric studies 
Histological examination of FD endomyocardial biopsies revealed regularly arranged 
and severely hypertrophied cardiomyocytes with large perinuclear vacuoles 
containing material that, on frozen sections, stained positively with periodic acid-
Schiff and Sudan black stains. Fibrosis was predominantly interstitial (Fig 2B) with 
focal areas of replacement fibrosis. Computer-assisted histomorphometry showed 
only a mild, though significant, increase in fibrosis in FD patients compared to 
controls. The percent tissue area occupied by cardiomyocytes was similar (Fig 2C). 
Cardiomyocyte cross-sectional area was significantly increased in FD patients and 
more than 50% of it was occupied by glycosphingolipids vacuoles. The endocardium 
was thickened (mean FD value=535±201 µm, normal value= 18±5 µm). 
On ultrastructural electron microscopic examination intracellular vacuoles 
appeared to be represented by concentric lamellar structures in single-membrane 
bound vesicles, indicative of lysosomal glycosphingolipid accumulation. The 
cytoplasmic inclusions frequently displaced cardiac myofibrils to the periphery of the 
cell (Fig 3A). Focal areas of myofibrillolysis were also detected (Fig 3B) and 
myofibrillolysis area was calculated as 15±5%. Lamellar inclusions were present also 
in the endothelial cells, smooth muscle cells and fibroblasts.Cardiomyocyte area and 
percent area occupied by glycolipid vacuoles closely correlated (correlation 
coefficient=0.99, p<0.0001). This indicates that the increase of cardiomyocyte size is 
mainly due to intracytoplasmic glycosphingolipids vacuoles. 
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Figure 3. A. Electron microscopy showing in comparison with the normal arrangement of 
myofilaments in a normal cardiomyocyte (A), myofilaments dislodgment and disarray due to 
glycosphingolipids accumulation in FD cardiomyopathy (B). B. Electron microscopy of FD 
cardiomyopathy showing myofibrillolysis areas (M) around glycolipid deposits (G). 
 
A 
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Force measurements in isolated cardiomyocytes and protein analysis 
Force measurement data of six FD patients (number of cardiomyocytes _ 17) and of 
five controls (number of cardiomyocytes _ 10) are presented in Table 2 as average 
value and in Table 3 as single patient value, in addition to the patients’ gene 
mutation. When isolated cardiomyocytes were stretched to a sarcomere length of 
2.2µm a significantly higher Fpassive and a lower Factive was observed in FD patients 
compared to controls. Treatment with PKA significantly decreased Fpassive, but it 
remained higher compared to controls. Factive was not altered (Fig 4A). PKA treatment 
did not alter Fpassive and Factive in controls.  
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Figure 4. A. Graph showing total (Ftotal), active (Factive) and passive (Fpassive) force before and 
after PKA in FD cardiomyocytes (p=0.02 total force before vs after, p=0.4 Factive before vs after 
p=0.004, Fpassive before vs after. B. Protein analysis using one-dimensional gel 
electrophoresis. Degradation products of TnI (left) and desmin (right) are shown in a control 
sample (non-failing donor heart), which was kept at 20°C for one hour. Similar degradation 
products were found in FD samples.  
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Analysis of myofilament proteolysis revealed degradation products of TnI and 
desmin in FD patients (Fig 4B). No degradation products of myosin light chains or of 
a-actinin were observed. Degradation of TnI was found in three of six samples and 
amounted on average to 3.1±1.4% of total TnI (Table 3). Desmin degradation 
products were present in four of six samples and amounted to 9.7±5.8% of total 
desmin (Table 3). 
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Table 3. α-Gal A mutations, force measurements, and protein analysis in Fabry disease patients 
 
 
 
 
  Force before PKA (kN/m2) Force after PKA (kN/m2)   
Patient α-Gal A mutation  Ftotal Factive Fpassive Ftotal Factive Fpassive TnI  degradation 
(%) 
Desmin degradation 
(%) 
1 M42fsX5516 14.9 1.2 13.7 11.4 1.5 9.9 0.0 28.6 
2 D315fsX31516 12.0 1.7 10.3 11.0 1.3 9.7 0.0 0.0 
3 Y216C* 9.2 2.0 7.3 9.1 3.1 6.0 7.9 2.2 
4 N215S17 15.6 5.6 10.0 13.2 6.2 6.0 5.3 27.4 
5 R220X18 10.4 2.9 7.6 7.4 3.7 3.7 0.0 0.0 
6 Q279K19 19.9 10.3 9.6 14.4 10.0 4.4 5.2 0.3 
99
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Correlation between TDI, morphometric and force measurements 
To establish if alterations in cardiac systolic and diastolic function could be ascribed 
to changes in morphometry or myofilament function or a combination of both, in vivo 
measurement of cardiac function by TDI were correlated with fibrosis, cardiomyocyte 
area, percent area of glycosphingolipids vacuoles and myofilament Factive and Fpassive. 
The average Factive of each individual correlated with TDI shortening velocities at both 
corners of the mitral annulus (Fig 5A and B; correlation coefficient=0.99, p<0.001, for 
septal Sa and 0.90, p<0.05, for lateral Sa). The average of F passive of all 
cardiomyocytes of each individual correlated closely with TDI long axis lengthening 
velocities (Fig 5C and D; correlation coefficient=0.99, p<0.001, for septal E/Ea and 
0.94, p<0.05 for lateral E/Ea).  
Factive inversely correlated with myofibrillolysis area (Fig 5E, correlation 
coefficient=0.94, p<0.05). After PKA treatment, Fpassive closely correlated with area of 
glycosphingolipid deposits (Fig 5 F, correlation coefficient= 0.99, p<0.001).  
TDI lengthening and shortening velocities did not correlate with cardiomyocyte area, 
percent area occupied by glycosphingolipids vacuoles and extent of fibrosis. 
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Figure 5. Scatter plot of the correlations between active force and septal Sa (A, correlation 
coefficient=0.99, p<0.001), active force and lateral Sa (B, correlation coefficient 0.90, p<0.05), 
passive force and septal E/Ea (C, correlation coefficient=0.99, p<0.001), passive force and 
lateral E/Ea (D, correlation coefficient=0.94, p<0.05), active force and myofibrillolysis area (E, 
correlation coefficient=0.94, p<0.05), passive force after PKA treatment and area of 
glycosphingolipid vacuoles (F, correlation coefficient=0.99, p>0.001). 
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Discussion 
Recent studies5,20 using TDI imaging provided evidence for diastolic and systolic LV 
dysfunction in FD patients even before the development of wall thickening. The basis 
of these functional abnormalities, which become more prominent as LV hypertrophy 
progresses, is still unclear. Especially the relative contribution of myocardial fibrosis 
and cardiomyocyte dysfunction remains uncertain. The present study therefore 
analyzed mechanical properties of isolated cardiomyocytes, degree of 
glycosphingolipid accumulation, and myocardial fibrosis in endomyocardial biopsy 
samples of FD patients and correlated these parameters with TDI evaluation of LV 
function. Altered cardiomyocyte relaxation and contraction, derived mainly from 
myofilament degradation and dysfunction, was found to be a major determinant of FD 
cardiomyopathy. These preliminary data, obtained in a limited number of patients, 
generate new hypotheses on myocardial dysfunction of FD and open new areas of 
research for possible additional therapeutic strategies.  
 
Compromise of cardiomyocyte contractility in fabry cardiomyopathy  
Despite a normal LV ejection fraction on routine echocardiography, TDI and strain 
rate echocardiography5,20 demonstrated reduced contractility in FD 
cardiomyopathyand suggested an early global and regional systolicfunction deficit, 
progressively deteriorating in untreated patients. To clarify the mechanism of the 
contractile deficit we evaluated the maximal isometric tension of single 
cardiomyocytes and demonstrated that it was reduced. Moreover it correlated with 
the decreased TDI systolic velocities and with the ultrastructural evidence of 
myofibrillolysis. 
In addition, myofibrillolysis was associated with degradation of myofilament 
proteins. In several models of ischemia/reperfusion the decrease in maximal force of 
the myofilaments has been ascribed to degradation of TnI. TnI degradation may be 
triggered by activation of the calcium-dependent protease calpain-121 or by 
increased preload22 and has been observed in human ischemic cardiac disease.23 
Moreover, degradation of desmin was shown to play a significant role in calpain-1-
induced myofilament dysfunction24 and desmin degradation has been 
demonstratedto correlate with reduced cardiac function in ischemic human heart 
failure.25 Because degradation products of both TnI and desmin were observed in FD 
biopsies, and were paralleled by ultrastructural evidence of myofibrillolysis, part of the 
reduction in cardiomyocyte contractility may be explained by proteolysis. An 
additional obstacle to cell contraction is represented by myofilament derangement 
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resulting from intracellular glycosphingolipid storage that causes loss of vectorial 
orientation and a detrimental functional effect. Whatever the mechanism of 
myofilament and cell dysfunction, they can trigger at the end, similarly to hypertrophic 
cardiomyopathy,26 trophic stimuli leading to cell hypertrophy. Indeed, it has been 
recently shown in FD patients the presence of circulating growth-promoting factors27 
able to induce in vitro a hypertrophic response of cardiomyocytes. In substance, 
opposite biological events of myofilament degradation/dysfunction and synthesis, in 
attempt of structural and functional cell repair, occur in human cardiomyocytes with 
FD. In this regard, the elevation of electrocardiography voltages associated to 
disease progression is partially attributable to synthesis of contractile elements and 
possibly to the accumulation of glycosphingolipids intracellularly and on the plasma 
membrane,28 affecting the intracellular resistivity to the activation wave front and the 
conduction velocity. 
 
Increased cardiomyocyte stiffness in fabry cardiomyopathy 
The present study showed Fpassive of isolated cardiomyocytes to be six times higher in 
FD patients than in controls. In vivo measures of LV diastolic function, such as TDI 
long axis lengthening velocity correlated with the in vitro measurements of Fpassive. 
This indicated that in Fabry cardiomyopathy diastolic LV dysfunction is related to 
cardiomyocyte stiffening. These data are in agreement with recent studies on 
diastolic heart failure, which reported involvement of cardiomyocyte stiffness in the 
pathogenesis of diastolic LV dysfunction.13,29 Because the endomysial collagen 
structure was removed and the integrity of sarcolemmal and sarcoplasmic 
membranes was disrupted during cardiomyocyte isolation and permeabilization, the 
increased Fpassive cannot be related to modifications of sarcoplasmic proteins and/or 
channels, but should be ascribed to alterations in myofilament or cytoskeletal 
proteins. 
Modifications of contractile and cytoskeletal proteins may be posttranslational 
and involve altered phosphorylation, oxidative changes, and proteolysis. Cardiac 
relaxation is enhanced via β-adrenergic activation of PKA and subsequent 
phosphorylation of myofilament proteins including TnI, myosin binding protein C, and 
titin. Partial correction of Fpassive after PKA treatment suggests hypophosphorylation of 
these PKA target proteins, but the incomplete recovery of Fpassive after PKA treatment 
implied additional intracellular mechanisms to account for the altered passive 
properties of the cardiomyocytes. Because glycosphingolipid deposits occupied more 
than half of the cardiomyocyte area and because they were organized in structurally 
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complex concentric lamellar bodies, they probably hinder cardiomyocyte relaxation. 
The percent area occupied by glycosphingolipid vacuoles indeed closely correlated 
with increased Fpassive after PKA treatment. Thus, our results suggest that increased 
stiffness of cardiomyocytes contributes to diastolic dysfunction in FD cardiomyopathy. 
This increased stiffness is explained both by mechanical hindrance because of the 
glycosphingolipid storage material and by hypophosphorylation of myofilament and/or 
cytoskeletal proteins. 
 
Role of fibrosis 
Although fibrosis in endomyocardial tissue increased with progression of FD 
cardiomyopathy and was paralleled by expansion of cardiomyocyte area and 
glycosphingolipid vacuoles, its extent was only slightly increased compared with 
controls and did not correlate with TDI measurements of systolic or diastolic LV 
function. In addition, late myocardial MRI gadolinium enhancement, which is ascribed 
to focal fibrosis,30 was mild and typically localized in the infero-lateral region of the left 
ventricle, with little involvement of the remaining LV segments. However, because 
fibrosis is unequally distributed along the LV wall, the percent detected in the 
endomyocardium is compatible with the presence of different, yet limited, amounts in 
the middle and subepicardial layers. 
In summary, myocardial fibrosis does not appear to be the predominant 
mechanism causing diastolic dysfunction in FD cardiomyopathy with preserved LV 
contractility. Nevertheless, the limited number of patients studied requires to be 
cautious in the interpretation of these negative results and do not exclude a 
prominent role of myocardial fibrosis in the more advanced stages of the disease. 
 
Clinical implications and conclusions 
Cardiomyocyte dysfunction and structural alterations of myofilaments seem to 
significantly contribute to the LV dysfunction observed in FD cardiomyopathy. 
Prospective studies using sequential endomyocardial biopsies during enzyme 
replacement therapy could establish the reversibility of cardiomyocyte dysfunction 
and structural myofilament alteration. Partial reversal of the high cardiomyocyte 
resting tension after PKA could provide an inroad for pharmacological correction of 
the diastolic LV dysfunction observed in FD. 
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Abstract 
Left ventricular (LV) myocardial structure and function differ in heart failure (HF) with 
normal (N) and reduced (R) LV ejection fraction (EF). This difference could underlie 
the unequal outcome of trials with β-blockers in HFNEF and HFREF with mixed 
results observed in HFNEF and positive results in HFREF. To investigate if β-
blockers have distinct myocardial effects in HFNEF and HFREF, myocardial 
structure, cardiomyocyte function and myocardial protein composition were 
compared in HFNEF and HFREF patients without or with β-blockers. 
Patients, free of coronary artery disease, were divided into β-HFNEF (n=16), 
β+HFNEF (n=16), β-HFREF (n=17) and β+HFREF (n=22) groups. Using LV endomyocardial 
biopsies, we assessed collagen volume fraction (CVF) and cardiomyocyte diameter 
(MyD) by histomorphometry, phosphorylation of myofilamentary proteins by ProQ-
Diamond phosphostained 1D-gels and expression of β-adrenergic signaling and 
calcium handling proteins by Western immunoblotting. Cardiomyocytes were also 
isolated from the biopsies to measure active force (Factive), resting force (Fpassive) and 
calcium sensitivity (pCa50). 
Myocardial effects of β-blocker therapy were either shared by HFNEF and 
HFREF, unique to HFNEF or unique to HFREF. Higher Factive, higher pCa50, lower 
phosphorylation of troponin I and myosin-binding protein C, and lower β2-adrenergic 
receptor expression were shared. Higher Fpassive, lower CVF, lower MyD and lower 
expression of stimulatory G protein were unique to HFNEF and lower expression of 
inhibitory G protein was unique to HFREF. 
Myocardial effects unique to either HFNEF or HFREF could contribute to the 
dissimilar outcome of β-blocker therapy in both HF phenotypes. 
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Introduction 
Over the last two decades it became evident that more than 50% of all heart failure 
patients suffer of heart failure with normal left ventricular (LV) ejection fraction (EF).1 
In heart failure with normal LVEF (HFNEF) and in heart failure with reduced LVEF 
(HFREF), LV structure adapts differently with concentric LV remodeling in HFNEF 
and eccentric LV remodeling in HFREF.2-4 Corresponding differences were observed 
at the myocardial ultrastructural level with prominent cardiomyocyte hypertrophy in 
HFNEF and low myofibrillar density in HFREF.4 When cardiomyocytes were isolated 
from LV myocardium, cardiomyocyte resting tension (Fpassive) was also higher in 
HFNEF than in HFREF.4-6 These structural and functional differences between LV 
myocardium in HFNEF and HFREF could underlie the unequal outcome of trials 
using β-blockers, angiotensin converting enzyme inhibitors (ACE-I) or angiotensin II 
receptor blockers (ARB) which usually yielded positive results in HFREF and mixed 
results in HFNEF. In line with this unequal outcome of trials, prognosis of HFREF 
patients improved over the last two decennia whereas no such trend was observed in 
HFNEF patients.1 Large clinical trials have convincingly shown that β-blocker therapy 
reduces mortality and improves LV function in HFREF patients.7-9 In HFNEF patients, 
favourable effects of β-blocker therapy on mortality and LV function have not been 
convincingly demonstrated. After hospital discharge, HFNEF patients had improved 
survival when using β-blockers10 and in a community-based registry, carvedilol use 
was accompanied by similar 1 year mortality in HFNEF and HFREF patients but less 
reduction in hospitalizations in HFNEF patients.11 In the SWEDIC trial, carvedilol had 
no effect on mortality or hospitalizations but ameliorated E/A ratio of HFNEF 
patients.12 In a similar study however, 6 months of atenolol use had no effect on 
diastolic LV function of HFNEF patients with unchanged pulmonary capillary wedge 
pressure.13 Because of these inconsistent results, the use of β-blockers in  
 
HFNEF patients is further evaluated in clinical trials such as the Japanese DHF 
study.14 To investigate if heart failure therapy has indeed disparate effects on LV 
myocardial structure and function in HFNEF and HFREF, the present study 
compared LV myocardial structure, function and protein composition in HFNEF and 
HFREF patients with and without β-blockers. The current widespread use of ACE-I 
precluded a similar comparison in patients with and without ACE-I. Endomyocardial 
biopsies procured in the four patient groups were used for: 1) histomorphometry of 
light and electron microscopic images to determine cardiomyocyte diameter, collagen 
volume fraction and myofibrillar density; 2) isolation of single cardiomyocytes to 
Chapter 5 
112
 
measure active force (Factive), resting force (Fpassive) and Ca2+-sensitivity (pCa50) and 3) 
protein analysis to assess phosphorylation of myofilamentary proteins and 
expression of proteins involved in β-adrenergic signaling and in Ca2+-handling.  
 
Material and Methods 
Patients 
All patients included in the study (n=71) had been hospitalized for worsening heart 
failure and were referred for cardiac catheterization and LV biopsy procurement 
because of suspicion of infiltrative or inflammatory myocardial disease. No patient 
had significant (>50%) coronary artery stenoses, a history of myocardial infarction, 
percutaneous coronary intervention or coronary bypass surgery. Histological analysis 
of the biopsies showed no myocardial infiltration or inflammation. Patients were 
classified as HFREF if LVEF<40% and as HFNEF if LVEF>50% and LVEDP>16 
mmHg.1 Patients with a LVEF>40% but <50% were not included. Patients were 
considered as being on chronic β-blocker therapy if therapy was initiated at least 1 
month prior to biopsy procurement. The mean duration of β-blocker therapy was 
similar in both groups (HFNEF: 12±3 months; HFREF: 12±4 months). Half of the 
patients on β-blocker therapy were using a non-selective β-blocker (carvedilol) and 
half were using a selective β-blocker (metoprolol, bisoprolol).  Characteristics of the 
β-HFNEF, β+HFNEF, β-HFREF, and β+HFREF groups are given in Table 1. Indications for β-
blocker therapy in the HFNEF patients were control of arterial hypertension (n=14) 
and/or a history of atrial tachyarrhythmias (n=4). Most of the β-HFREF patients (14/17) 
were started on β-blocker therapy after the study. At the time of study all patients 
were in normal sinus rhythm. Hemodynamic data were derived from LV angiograms 
(LVEDVI, LVEF) and high-fidelity LV pressure catheters (LVPSP, LVEDP, 
LVdP/dtmax, LVdP/dtmin). LV wall thickness was derived from 2D-echocardiograms. 
Hemodynamic and echocardiographic data were combined to determine LV Mass 
Index (LVMI). After procurement, LV endomyocardial biopsies (n=6 per patient; ±3.5 
mg wet weight each) were fixated in formalin or stored in liquid nitrogen. The local 
ethics committee approved the study protocol of Vrij Universiteit medical center 
(Vumc). Written informed consent was obtained from all patients, and there were no 
complications related to catheterization or biopsy procurement. The investigation 
conforms with the principles outlined in the Declaration of Helsinki [Cardiovasc Res 
1997;35:2–4].
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Table 1. Clinical, hemodynamic and echocardiographic characteristics. 
 
 
β-HFNEF 
 
 
β+HFNEF 
 
 
β-HFREF 
 
 
β+HFREF β- vs β+ HFNEF vs HFREF 
 
 
Interaction 
N 16 16 17 22    
Age (y) 66±3 68±4 54±5 60±3 NS 0.01 NS 
Sex (M/F) 11/5 8/8 10/7 17/5 NS NS NS 
Hypertension 11/16 11/16 4/17 1/22 NS <0.0001 NS 
Diabetes Mellitus 8/16 3/16 6/17 8/22 NS NS NS 
Obesity (BMI > 30 kg/m2) 6/16 4/16 4/17 2/22 NS NS NS 
Medication        
    ACE-I 9 7 12 15 NS NS NS 
    Diuretic 12 9 14 18 NS NS NS 
    CCB 5 3 0 3 NS 0.04 NS 
    ARB 3 4 0 1 NS 0.03 NS 
    Digoxin 1 4 4 8 NS NS NS 
    Amiodarone 3 2 1 4 NS NS NS 
    Statin 4 6 2 5 NS NS NS 
    Nitrate 2 0 0 1 NS NS NS 
Hemodynamics        
    Heart rate (bpm) 77±3 70±3 89±5 72±5 0.008 NS NS 
    LVPSP (mmHg) 169±7 168±10 120±4 116±5 NS <0.0001 NS 
    LVEDP (mmHg) 29± 2 25±2 25±2 20±2 0.02 0.01 NS 
    LVEDVI (mL/m2) 81±5 79±4 127±8 133±7 NS <0.0001 NS 
    LVEF (%) 53±4 63±3 31±2 30±2 NS <0.0001 NS 
    LVdP/dtmax (mmHg/s) 1547±111 1480±110 938±200 902±100 NS 0.0005 NS 
    LVdP/dtmin (mmHg/s) 1655±171 1752±67 1058±229 1000±116 NS 0.0007 NS 
Echocardiography         
    LVWT (mm) 11.4±0.6 11.3±0.2 9.5±0.4 8.8±0.4 NS <0.0001 NS 
    LVMI/LVEDVI ratio 1.8±0.1 1.7±0.1 1.1±0.1 1.1±0.1 NS <0.0001 NS 
P
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Abbreviations: n, number of patients; M, male; F, female; BMI, Body Mass Index; ACE-I, 
angiotensin-converting-enzyme-inhibitors; CCB, calcium channel blockers; ARB, angiotensin 
II receptor blockers; bpm, beats per minute; LVPSP: LV peak systolic pressure; LVEDP: LV 
end-diastolic pressure; LVEDVI: LV end-diastolic volume index; LVWT: LV wall thickness; 
LVMI: LV mass index. 
 
Quantitative histomorphometry 
Light microscopy 
Histomorphological analysis of biopsies was performed on elastica-von-Giesson and 
hematoxylin-eosin stained, 4 µm thick, sections of tissue placed in 4% buffered 
formaldehyde solution.2,3 Images of these sections were acquired using a projection 
microscope (x50). Subsequent image analysis, using SlidebookTM 4.0 software (3I, 
Denver, Co), was performed to determine cardiomyocyte diameter (MyD, µm) and 
extent of reactive interstitial fibrosis, which was expressed as collagen volume 
fraction (CVF, %). Areas of reparative and perivascular fibrosis were excluded. As 
previously validated,2,4 MyD was determined perpendicularly to the outer contour of 
the cell membrane at nucleus level in 15 representative myocytes of the section, and 
CVF was calculated as the sum of all connective tissue areas divided by the sum of 
all connective tissue and muscle areas averaged over 4-6 representative fields of the 
section.2,4 In our laboratory, normal values of MyD and CVF for LV endomyocardial 
biopsy material are 13.1±0.3µm and 5.4±2.2 % respectively. 
 
Electron microscopy 
Endomyocardial biopsies were fixed in 2% (v/v) gluteraldehyde for 30 min and 1.5% 
(w/v) osmium tetroxide for 10 min, dehydrated with acetone and embedded in 
Epon812. Ultrathin sections were collected on 300-mesh Formavar-coated Nickel-
grids. The sections were contrasted with uranyl acetate and lead citrate and were 
examined in a Jeol-1200EX electron microscope. Quantitative analysis was 
performed with the above mentioned automated image analyzer. Cardiomyocyte 
myofibrillar density (FibD) was calculated as the sum of myofibrillar areas related to 
total cellular area in 4-6 representative myocytes, and expressed as a percentage. 
 
Force measurements in isolated cardiomyocytes 
Force measurements were performed in single, mechanically isolated 
cardiomyocytes as described previously.2-4 Biopsy samples were defrosted in 
relaxing solution (in mmol/L: free Mg, 1; KCl, 100; EGTA, 2; MgATP, 4; imidazole, 10; 
pH7.0), mechanically disrupted and incubated for 5 minutes in relaxing solution 
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supplemented with 0.5% Triton X-100 to remove all membrane structures. 
Subsequently, cells were washed twice in relaxing solution, after which single 
cardiomyocytes were attached with silicone adhesive between a force transducer and 
a motor (2.7±0.2 cardiomyocytes per patient). Sarcomere length of isolated 
cardiomyocytes was adjusted to 2.2 µm and myocytes were subjected to both 
relaxing and activating solutions (Fig 2A). Their pCa (-10log[Ca2+]) ranged from 9.0 
(relaxing) to 4.5 (maximal activation), which was used to calculate maximal calcium-
activated isometric force. All force values were normalized for cardiomyocyte cross-
sectional area. Exposure to a series of solutions with intermediate pCa yielded the 
baseline force-pCa relation. On transfer of the myocyte from relaxing to activating 
solution, isometric force started to develop. Once a steady force level was reached, 
the cell was shortened within 1 ms to 80% of its original length (slack test) to 
determine the baseline of the force transducer. The distance between the baseline 
and the steady force level is the total force (Ftotal) (Fig 2B). After 20 ms, the cell was 
restretched and returned to the relaxing solution, in which a second slack test of 10-
seconds’ duration was performed to determine passive Fpassive. The difference 
between Ftotal and Fpassive equalled Factive. Ca2+-sensitivity of the contractile apparatus  
(pCa50) corresponded to the pCa, at which Factive reached 50% of the value observed 
at maximal activation. After measurement of the baseline force-pCa relation, 
myocytes were incubated for 40 minutes in relaxing solution supplemented with the 
catalytic subunit of protein kinase A (PKA, 100 U/mL; Sigma, batch-12K7495) and 6 
mmol/L dithiothreitol (DTT, MP-Biochemicals). Subsequently, a second force-pCa 
relation was determined. In our laboratory, Fpassive, Factive  and pCa50 of normal human 
cardiomyocytes are 3.5±0.4 kN/m2, 20.7±3.1 kN/m2 and 5.82±0.02 respectively.  
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Figure 2. A. Single cardiomyocyte from a HFREF patient glued between a force transducer 
and a piezoelectric motor; B. Contraction-relaxation sequence recorded in a single 
cardiomyocyte of a HFREF patient before (black line) and after (grey line) treatment with PKA, 
during maximal activation (pCa 4.5) and submaximal activation (pCa 5.4). 
 
Protein analysis 
Myofilament protein phosphorylation 
Myofilament protein phosphorylation was determined using Pro-Q Diamond 
Phosphoprotein Stain.5 To preserve the endogenous phosphorylation status, frozen 
biopsies were homogenized in liquid nitrogen and resuspended in 1 mL cold 10% 
trichloroacetic acid solution (TCA; dissolved in acetone containing 0.1% (w/v) 
dithiothreitol (DTT)). TCA-treated tissue pellets were homogenized in sample buffer 
containing 15% glycerol, 62.5 mmol/L Tris (pH 6.8), 1% (w/v) SDS and 2% (w/v) DTT 
(final concentration 2.5 µg dry weight/µL). Tissue samples (20 µg dry weight/lane) 
were separated on gradient gels (Criterion tris-HCl 4-15% gel, BioRad) and proteins 
were stained for one hour with Pro-Q Diamond Phosphoprotein Stain. Fixation, 
pCa 4.5 pCa 5.4 
20µm
A 
B 
Beta-Blocker Therapy 
117
 
washing and de-staining were performed according to the manufacturer’s guidelines 
(Molecular Probes). Subsequently gels were stained overnight with SYPRO Ruby 
stain (Molecular Probes). Phosphorylation status of myofilament proteins was 
expressed relative to the SYPRO-stained myosin binding protein-C (MyBP-C) band 
to correct for differences in sample loading and expressed in arbitrary units (a.u.). 
Staining was visualized using the LAS-3000 Image Reader (FUJI; 460 nm/605 nm 
Ex/Em) and signals were analyzed with AIDA. 
 
β-Adrenergic signaling proteins 
Protein expression levels of β1 adrenoreceptor (AR), β2AR, G-protein-coupled 
receptor kinases (GRK2 and GRK5), stimulatory G protein (Gs) and inhibitory G 
protein (Gi) were analyzed by one-dimensional 15% SDS-polyacrylamide gel 
electrophoresis (1D-PAGE) and subsequent Western immunoblotting. Samples (dry 
weight) were applied in a concentration, which was within the linear range of 
detection: 25 µg for β1AR and β2AR, 20 µg for GRK2, GRK5, and Gi and 10 µg for Gs. 
After 1D separation proteins were transferred to Hybond-ECL nitrocellulose 
membranes. Blots were pre-incubated with 0.5% milk powder in TTBS (Tween-tris-
buffered-saline; 10 mmol/L Tris–HCl pH 7.6, 75 mmol/L NaCl, 0.1% Tween) for one 
hour at room temperature. The blots were incubated overnight at 4°C with primary 
rabbit polyclonal antibodies (Santa Cruz) against β1AR (dilution 1:200; sc-568), β2AR 
(dilution 1:200; sc-9042), GRK2 (dilution 1:1000; sc-562), GRK5 (dilution 1:1000; sc-
565), Gs (Gαs/olf; dilution 1:1000; sc-383) and against Gi (Gαi-3; dilution 1:1000; sc-
262). After washing with TTBS, primary antibody binding was visualized using a 
secondary horseradish peroxidase-labeled goat-anti-mouse antibody (dilution 1:2000; 
DakoCytomation) and enhanced chemiluminescence (ECL plus Western blotting 
detection, Amersham Biosciences). All signals were normalized to actin (dilution 
1:1000; clone KJ43A; Sigma) stained on the same blots 
 
Calcium handling proteins 
Sarcoplasmic reticular Ca2+-ATPase (SERCA2a) protein levels were determined 
immunochemically by dot-blot analysis. Briefly, homogenate tissue samples (typically 
0.5 µg total protein) and standard SERCA2a protein samples were spotted onto a 
nitrocellulose membrane. The blot was then incubated with a 1:2500 dilution of a 
polyclonal antiserum to SERCA2a and subsequently with 125I-labeled anti-rabbit 
immunoglobulin G (0.05 µg/ml, specific activity 7 µCi/µg). To detect phospholamban 
(PLB), expression blots were incubated with a 1:2500 dilution of a monoclonal mouse 
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antibody (Affinity Bioreagents) and subsequently with 125I-labeled anti-mouse 
immunoglobulin G. Blots were exposed to Phosphor Imager screens, which were 
then scanned and spots were quantified using ImageQuant software (Molecular 
Dynamics). 
 
Data analysis 
Values are given as mean±SEM of the observations in each patient group. Data of 
the β-HFNEF, β+HFNEF, β-HFREF, and β+HFREF groups were compared by 2-factor ANOVA 
testing for β-blocker use, HFNEF/HFREF status, and their interaction (Tables 1-2). 
Subsequent comparisons (β-HFREF versus β+HFREF and β-HFNEF versus β+HFNEF) were 
performed with a Bonferroni adjusted t test. 
 
Results 
Clinical and hemodynamic characteristics 
Clinical, hemodynamic and echocardiographic data are presented in Table 1. 
Patients on β-blocker therapy had lower heart rate and LVEDP in both HFNEF and 
HFREF groups. HFNEF patients were older and more frequently suffered of arterial 
hypertension with a concomitant higher use of calcium channel and angiotensin II  
receptor blockers. HFNEF patients also had higher LVPSP, LVEDP, LVEF, 
LVdP/dtmax, LVdP/dtmin, LVWT, LVMI/LVEDVI ratio and smaller LVEDVI.  
 
 
 
 
 
 
 
 
 
 
Table 2. Histomorphometry, cardiomyocyte force measurements, and protein analysis. 
Abbreviations: pTnI, Phosphorylated Troponin I; pTnT, Phosphorylated Troponin T; pMyBP-C, 
Phosphorylated myosin-binding protein C; pDesmin, Phosphorylated Desmin; pMLC-2, 
Phosphorylated myosin light chain-2.  
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Histomorphometry 
 β-HFNEF β+HFNEF β-HFREF Β+HFREF β- vs β+ 
 
HFNEF vs 
HFREF 
Interaction 
CVF (%) 13.2±0.3 10.8±0.2 15.9±0.2 16.7±0.3 0.0007 <0.0001 <0.0001 
MyD (µm) 20.7±0.5 18.7±0.3 16.5±0.3 16.0±0.3 <0.0001 <0.0001 0.04 
FibD (%) 43.2±1.2 42.8±1.4 34.1±1.0 34.2±1.0 NS <0.0001 NS 
 
Cardiomyocyte Force Measurements 
Before PKA 
Factive (kN/m2) 13.2±1.7  17.7±1.2 15.1±2.0 17.0±1.7 0.01 NS NS 
Fpassive(kN/m2) 5.6±0.8 8.0±0.7 4.7±0.3 4.8±0.3 0.03 0.0006 0.02 
pCa50  5.83±0.02 5.86±0.02  5.82±0.01 5.87±0.01 0.01 NS NS 
After PKA 
Factive (kN/m2) 15.5±1.6 18.2±1.4  17.4±2.2 19.9±2.1 NS NS NS 
Fpassive(kN/m2) 3.0±0.4 5.1±0.6 2.7±0.2 3.0±0.3 0.001 0.0007 0.01 
pCa50  5.54±0.04 5.66±0.03 5.54±0.02 5.54±0.02 0.007 0.01 0.009 
 
Phosphorylation of Myofilament Proteins 
pTnI (a.u.) 0.20±0.03 0.15±0.01 0.39±0.09 0.18±0.06 0.02 NS NS 
pTnT (a.u.) 1.03±0.13 1.15±0.13 1.14±0.13 0.90±0.11 NS NS NS 
pMyBP-C (a.u.) 0.26±0.02 0.23±0.01 0.26±0.02 0.21±0.02 0.01 NS  NS  
pDesmin (a.u.) 0.86±0.10 1.01±0.07 1.06±0.10 0.79±0.09 NS NS 0.046 
pMLC-2 (a.u.) 0.34±0.04 0.38±0.04 0.37±0.10 0.41±0.08 NS NS NS 
 
Expression of the β-Adrenergic Signaling Proteins 
β1AR (a.u.) 0.45±0.09 0.35±0.06 0.9±0.18 0.8±0.2 NS 0.01 NS 
β2AR (a.u.) 0.32±0.15 0.28±0.13 0.33±0.05 0.18±0.02 0.01 NS NS 
GRK2 (a.u.) 0.89±0.25 0.84±0.20 3.6±1.2 3.2±0.9 NS 0.004 NS 
GRK5 (a.u.) 9.4±1.8 9.3±2.3 40.0±8.3 29.9±9.0 NS 0.0006 NS 
Gs (a.u.) 4.0±0.9 1.5±0.2 1.4±0.3 1.1±0.2 0.03 0.03 0.09 
Gi (a.u.) 0.80±0.20 0.70±0.16 1.75±0.20 1.02±0.25 0.04 0.001 0.1 
 
Expression of Calcium Handling Proteins 
SERCA2a 10.2±1.7 8.8±1.9 10.1±3.2 7.5±1.9 NS NS NS 
PLB 19.3±2.6 22.6±2.9 15.3±3.5 18.8±6.9 NS NS NS 
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Histomorphometry 
Histomorphometric data are summarized in Table 2 and Figure 1. Myocardial CVF 
was significantly lower in HFNEF than in HFREF (p<0.0001) and only in HFNEF was 
β-blocker therapy associated with lower myocardial CVF (p=0.0007). MyD was 
significantly higher in HFNEF than in HFREF (p<0.0001) and only in HFNEF was β-
blocker therapy associated with reduced MyD (p<0.0001). FibD was also higher in 
HFNEF than HFREF (p<0.0001) but was unrelated to β-blocker therapy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
β- HFREF β- HFNEF 
β+ HFNEF β+ HFREF 
A 
CVF
CVF
CVF
CVF
20µm 
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Figure 1. A. Representative examples of LV myocardial histology in the four patient groups; 
B. Bar graphs showing effects of β-blocker therapy on CVF, MyD and FibD in HFNEF and 
HFREF patients. Only in HFNEF patients, did β-blocker therapy reduce CVF and MyD. 
(*P<0.001, -β versus +β) 
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Force measurements in isolated cardiomyocytes 
Single cardiomyocytes were attached between a force transducer and a motor (Fig 
2A,B) and their sarcomere length was adjusted to 2.2µm. Force measurements are 
summarized in Table 2 and Figure 2C. Factive and pCa50 were similar in HFNEF and 
HFREF but Fpassive was higher in HFNEF (p=0.0006). In both HFNEF and HFREF 
patients, β-blocker therapy resulted in a significant increase in Factive (p=0.01) and 
pCa50 (p=0.01). Only in HFNEF patients did β-blocker therapy raise Fpassive (p=0.03). 
After PKA administration to the cardiomyocytes, Factive was comparable in all four 
patient groups. After PKA, Fpassive fell in all 4 groups but remained significantly higher 
in HFNEF patients with β-blockers (p=0.001)(Fig 3A). pCa50 followed a trend similar 
to Fpassive by decreasing in all 4 groups and by remaining higher in HFNEF patients 
with β-blockers (p=0.007)(Fig 3B). Hence, in-vivo β-blocker therapy was associated 
with multiple in-vitro changes in baseline and PKA-stimulated contractile function of 
isolated cardiomyocytes, which differed between HFNEF and HFREF groups.  
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Figure 2. Bar graphs showing effects of β-blocker therapy on Factive, Fpassive and pCa50 of 
single cardiomyocytes. β-blocker therapy increased Factive and pCa50 in both HFNEF and 
HFREF and increased Fpassive only in HFNEF. (*P<0.05, -β versus +β) 
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Figure 3. A. PKA treatment significantly reduced Fpassive in all groups but Fpassive remained 
higher in the β+HFNEF patients; B. PKA treatment significantly reduced pCa50 in all groups but 
pCa50 remained higher in the β+HFNEF patients. (*P<0.01, -β versus +β; #P<0.01, before PKA 
versus after PKA) 
 
Protein analysis 
Myofilament protein phosphorylation 
To explore changes in myofilamentary protein phosphorylation related to β-blocker 
therapy, Pro-Q Diamond-stained gels of biopsies were obtained as shown in Figure 
4A. Phosphorylation status of myofilamentary proteins did not differ between HFNEF 
and HFREF groups. β-blocker therapy was associated with lower phosphorylation of 
troponin I (TnI) and of myosin-binding protein C (MyBP-C) in both HFNEF and 
HFREF patients (Fig 4B) and had no effect on phosphorylation status of other 
myofilamentary proteins (Table 2). Effect of β-blocker therapy on phosphorylation 
status of desmin differed with opposite changes in HFNEF and HFREF patients 
(p<0.05). 
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Figure 4. A. Representative Pro-Q Diamond-stained gels of a β-HFNEF, β+ HFNEF, β-HFREF and 
β+HFREF myocardial sample; B. Phosphorylation status of TnI and of MyBP-C were 
significantly lower in β+HFNEF and β+HFREF patients compared to respectively β-HFNEF and β-
HFREF patients. (*P<0.05, -β versus +β) 
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β-Adrenergic Signaling Proteins 
Expression levels of proteins involved in β-adrenergic receptor signaling were 
determined by Western immunoblotting (Table 2). Expression of β1AR, GRK2 and 
GRK5 were higher in HFREF than in HFNEF but unaffected by β-blocker therapy. β-
blocker therapy related to downregulated expression of β2AR in HFREF and HFNEF. 
Effects of β-blocker therapy on expression of Gs and Gi differed in HFNEF and 
HFREF with Gs downregulated in HFNEF and Gi downregulated in HFREF. 
 
Figure 5. A and B. Represent Gi and Gs expression of a β-HFNEF, β+ HFNEF, β-HFREF and 
β+HFREF myocardial sample. Gi expression was significantly lower in β+HFREF and Gs was 
significantly lower in β+HFNEF patients compared to respectively β-HFREF and β-HFNEF patients. 
(*P<0.05, -β versus +β) 
 
Calcium handling proteins 
Expression levels of SERCA2a and PLB were determined by Western 
immunoblotting (Table 2). No differences related to HFNEF-HFREF status or to β-
blocker therapy were observed. The ratio of SERCA2a/PLB was higher in HFREF 
(1.0±0.2) than in HFNEF (0.5±0.08; p=0.02) and unaffected by β-blocker therapy in 
both groups. 
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Discussion 
In endomyocardial biopsies of HFNEF or HFREF patients, β-blocker therapy was 
associated not only with structural and functional myocardial changes shared by both 
heart failure phenotypes but also by changes unique to each heart failure phenotype. 
The shared effects of β-blocker therapy consisted of enhanced pCa50, higher Factive at 
saturated [Ca2+], lower phosphorylation status of TnI and MyBP-C and lower 
expression of β2AR. Effects of β-blocker therapy unique to HFNEF were reduced 
interstitial fibrosis, regression of cardiomyocyte hypertrophy, elevated Fpassive before 
and after PKA, elevated pCa50 after PKA and reduced expression of Gs. An effect of 
β-blocker therapy unique to HFREF was the reduced expression of Gi. Effect of β-
blocker therapy on phosphorylation status of desmin also differed between HFNEF 
and HFREF with opposite changes in both groups. 
 
Myocardial effects of β-blocker therapy present in both HFNEF and 
HFREF 
Chronic β-blocker therapy was associated with increased pCa50 of cardiomyocytes 
isolated from biopsies of both HFNEF and HFREF patients. Increased pCa50 implies 
improved cardiomyocyte contractile performance within the physiological range of 
Ca2+ concentrations and could be explained by the observed fall in phosphorylation 
status of TnI.15 Chronic β-blocker therapy increased Factive at saturated [Ca2+]. 
Although this Ca2+ concentration is outside the physiological range, higher Factive also 
reflects an increased cardiomyocyte force generating capacity. The present study 
observed reduced phosphorylation of MyBP-C in both β-blocker therapy groups. This 
reduction could relate to the lack of preload dependence of LV dP/dtmax, which was 
evident in both β-blocker therapy groups from the unchanged LV dP/dtmax despite 
lower LVEDP. Preload dependence of early LV pressure rise was recently 
demonstrated in transgenic mice to derive from phosphorylation of MyBP-C.16,17  
Reduced phosphorylation of MyBP-C during chronic β-blocker therapy could have 
resulted both from lower PKA activity and from lower activity of Ca2+-calmodulin-
dependent kinase (CaM-kinase). CaM-kinase can phosphorylate MyBP-C and its 
activity is also enhanced by β-adrenergic receptor stimulation. 18-20 
 In longitudinal studies performing serial hemodynamic investigations in HFREF 
patients, before and during chronic β-blocker therapy, improved myocardial 
contractile performance was evident from higher LVEF and lower LV filling 
pressures.21-25 The present study confirmed lower LVEDP with β-blocker therapy in 
both HFNEF and HFREF groups. The enhanced pCa50 and increased Factive observed 
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in isolated cardiomyocytes of β-blocker treated patients suggested improved 
cardiomyocyte contractile performance to contribute to the in-vivo lowering of LVEDP 
induced by β-blocker therapy. The enhanced pCa50 and increased Factive could also 
have contributed to the lower LVEDP in the HFNEF patient group despite the 
increased Fpassive of the β+HFNEF cardiomyocytes. 
In sequential right ventricular biopsies of patients with dilated cardiomyopathy, 
cardiac β-receptor density increased during metoprolol22 and carvedilol therapy.24 A 
subsequent study using explanted hearts corroborated these findings and also 
observed restoration of cardiac β-receptor density by carvedilol treatment.26 In the 
present study, which used LV biopsies, chronic β-blocker therapy had no effect on 
β1AR expression but downregulated β2AR expression. The present study however 
did not look at βAR density in membrane fractions but at βAR protein expression in 
homogenates. Downregulation of β2AR is beneficial for cardiac contractile 
performance because of less negative inotropy resulting from coupling of β2AR to Gi 
proteins.27 Coupling of β2AR to Gi was recently also suggested to cause the apical LV 
dysfunction in patients with Takotsubo cardiomyopathy.28  
Previous investigations24 demonstrated that β-blocker therapy induced LV 
functional improvement in HFREF patients by altering expression of genes 
responsible for cardiomyocyte contractility. The present study also related LV 
functional amelioration during β-blocker therapy to improved cardiomyocyte 
contractility and did so in both HFREF and HFNEF patient groups. In contrast to 
previous studies, contractility of single cardiomyocytes was directly assessed and its 
improvement was evident from both higher pCa50 and Factive and linked to lower 
phosphorylation of TnI and MyBP-C and to reduced expression of β2AR. 
 
Myocardial effects of β-blocker therapy unique to HFNEF. 
Only in HFNEF patients CVF was lower in the group with β-blockers. The absence of 
an effect of β-blockers on CVF in HFREF patients supports previous studies, which 
identified high myocardial fibrosis as an important predictor for poor outcome on β-
blocker therapy in HFREF.29,30 The lower CVF observed in β+HFNEF patients was 
paralleled by a reduction of cardiomyocyte hypertrophy evident from lower MyD. In 
spontaneously hypertensive rats, the β-blocker bisoprolol did not reverse 
cardiomyocyte hypertrophy in contrast to the ACE-I perindopril.31 This study suggests 
that reduced renin-angiotensin system activity could possibly be involved in the 
observed regression of cardiomyocyte hypertrophy in the β+HFNEF patients. 
Previous longitudinal studies showed LV mass to decrease in both HFNEF13 
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and HFREF patients 21,23,25 as a result of β-blocker therapy. Because of smaller 
LVEDVI, reduction of LV mass resulted in unaltered relative wall thickness in HFREF 
patients. In HFNEF patients, LV volumes remained unchanged and reduction of LV 
mass resulted in decreased relative wall thickness. The present study also observed 
unchanged LVMI/LVEDVI ratio in the HFREF group and a trend for reduced 
LVMI/LVEDVI ratio in the HFNEF group. The reversal of LV remodeling with β-
blocker therapy therefore parallels the regression of cardiomyocyte hypertrophy 
observed in the present study with unchanged MyD in HFREF and decreased MyD in  
HFNEF. 
Skinned cardiomyocytes isolated from biopsies of HFNEF patients have an 
elevated Fpassive, which was higher than Fpassive of HFREF cardiomyocytes4 or of 
normal cells.5 In-vitro administration of PKA corrected the high Fpassive of HFNEF 
cardiomyocytes, which was therefore attributed to phosphorylatable myofilamentary 
proteins.4 Within the HFNEF patient group, the present study observed higher Fpassive 
in β+HFNEF patients than in β-HFNEF patients. After in-vitro administration of PKA, Fpassive 
was still higher in β+HFNEF patients. This finding suggests the effect of β-blocker 
therapy on cardiomyocyte Fpassive in HFNEF relates not only to hypophosphorylation 
but also to structural or other posttranslational modifications of myofilamentary 
proteins. The persistent elevation of pCa50 after PKA observed in β+HFNEF 
cardiomyocytes also supports β-blocker therapy to induce additional modifications of 
myofilamentary proteins. 
HFREF is usually associated with reduced β1AR density and translocation of 
GRK2 to the plasma membrane. These changes in β-adrenergic signaling were not 
observed in a recently published HFNEF rat model.32 Although the present study did 
not look at βAR density in membrane fractions but at βAR protein expression in 
homogenates, it found important differences in expression of β1AR and GRK2 
proteins between patient groups with higher myocardial expression of both proteins in 
HFREF than in HFNEF irrespective of the use of β-blockers. This unequal expression 
of β-adrenergic signaling proteins in both heart failure phenotypes could explain 
changes in other components of the β-adrenergic system by β-blocker therapy 
unique for each heart failure phenotype. Of the different components of the β-
adrenergic system, Gs protein was significantly lower in HFNEF patients with β-
blockers. Downregulation of β2AR-Gs signalling could be beneficial as it would favor 
β2AR-Gi signalling, which is known to exert antiapoptotic effects.33 Because of normal 
contractile LV function, potential negative inotropic effects resulting from increased  
β2AR-Gi signalling are less important for HFNEF patients. 
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Myocardial effects of β-blocker therapy unique to HFREF 
The reduced expression of Gi in HFREF patients treated with β-blockers could be 
beneficial, because Gi is upregulated in HFREF patients with a dilated 
hypocontractile LV and contributes to the blunted inotropic response to adrenergic 
stimulation observed in these patients.34,35 Desmin phosphorylation responded 
differently to β-blocker therapy with increased phosphorylation in HFNEF and 
decreased phosphorylation in HFREF. Most previous studies on myofilamentary 
proteins looked at desmin expression and not at desmin phosphorylation. Desmin 
loss has been observed in ischaemic cardiomyopathy,36 disrupted desmin in 
doxorubicin induced cardiotoxicity37 and desmin accumulation in restrictive 
cardiomyopathy.38 Only one study reported on desmin phosphorylation and linked 
desmin phosphorylation to myofibrillar disarray in cardiomyopathic hamster hearts.39 
Based on this study, the reduced desmin phosphorylation in β+HFREF could be 
beneficial as it would limit myofibrillar disarray in HFREF hearts. 
 
Limitations 
Patient recruitment of the present study was based on referral for diagnostic 
endomyocardial biopsy procurement. This resulted in a cross-sectional, non-
randomised study design. Ethical restrictions only allowed for diagnostic biopsy 
procurement. This  prevented a serial, randomised study design because follow-up 
biopsies would no longer serve diagnostic purposes. The cross-sectional, non-
randomised study design could cause untreated patients to systematically differ from 
treated patients because of presence of certain comorbidities for which β-blockers 
were contraindicated. Such comorbidities, that could have significantly confounded 
the study results, were however unlikely. Failure to use β-blockers in the β-HFREF 
group resulted mainly from the referring physician non-adhering to current guidelines 
as the majority of these patients (14/17) were started on β-blocker therapy during the 
same hospitalization. Furthermore, β-blockers were used in the β+HFNEF group for 
control of arterial hypertension (14/16) and/or previous atrial tachyarrhythmias (4/16). 
Prevalence of arterial hypertension was however similar in the β+HFNEF and β-HFNEF 
groups (Table 1) and at the time of study all patients were in regular sinus rhythm. 
The comparable LVEF in the β-HFREF and β+HFREF groups probably also resulted from 
patient recruitment based on referral for diagnostic endomyocardial biopsy 
procurement. This recruitment procedure introduced a bias consisting of more 
frequent referral for endomyocardial biopsy procurement in patients with a poor 
functional response to β-blocker therapy. 
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Conclusions 
Myocardial effects associated with β-blocker therapy are either shared by HFNEF 
and HFREF groups, unique to HFNEF or unique to HFREF. Higher pCa50, higher 
Factive, lower TnI phosphorylation and lower β2AR expression are shared and 
beneficial for cardiomyocyte contractile performance. Lower MyD and higher Fpassive 
are unique to HFNEF and probably relate to the hypertrophied and stiff 
cardiomyocytes characteristic of HFNEF. Unchanged CVF in HFREF confirms poor 
clinical outcome of β-blocker therapy in HFREF patients with intense myocardial 
fibrosis whereas lower Gi in HFREF contributes to improve myocardial contractile 
performance. Unequal outcome of β-blocker therapy in HFNEF and HFREF could 
relate to myocardial effects of β-blocker therapy, which are unique to either HFNEF 
or HFREF. 
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Abstract 
High diastolic left ventricular (LV) stiffness is an important contributor to heart failure 
in patients with diabetes. Diabetes is presumed to increase stiffness through 
myocardial deposition of collagen and advanced glycation endproducts (AGEs). 
Cardiomyocyte resting tension also elevates stiffness especially in heart failure with 
normal LV ejection fraction (EF). The contribution to diastolic stiffness of fibrosis, 
AGEs and cardiomyocyte resting tension was assessed in diabetic heart failure 
patients with normal or reduced LVEF. 
LV endomyocardial biopsies were procured in 28 patients with normal and 36 
patients with reduced LVEF, all without coronary artery disease. Sixteen patients with 
normal and 10 patients with reduced LVEF had diabetes. Biopsies were used for 
quantification of collagen and AGEs and for isolation of cardiomyocytes to measure 
resting tension. 
Diabetic heart failure patients had higher diastolic LV stiffness irrespective of LVEF. 
Diabetes raised myocardial collagen volume fraction only in patients with reduced 
LVEF (from 14.6±1.0 to 22.4±2.2%; p<0.001) and raised cardiomyocyte resting 
tension only in patients with normal LVEF (from 5.1±0.7 to 8.5±0.9 kN/m2; p=0.006). 
Diabetes increased myocardial AGEs deposition in patients with reduced LVEF (from 
8.8±2.5 to 24.1±3.8 score/mm2; p=0.005) and less so in patients with normal LVEF 
(from 8.2±2.5 to 15.7±2.7 score/mm2; NS).  
Mechanisms responsible for the increased diastolic stiffness of the diabetic 
heart differ in heart failure with reduced and normal LVEF: fibrosis and AGEs are 
more important when LVEF is reduced while cardiomyocyte resting tension is more 
important when LVEF is normal. 
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Introduction 
High diastolic left ventricular (LV) stiffness is recognized as the earliest manifestation 
of LV dysfunction induced by diabetes mellitus (DM)1-5 and frequently becomes the 
main functional deficit of the diabetic heart as many diabetic patients present with 
heart failure (HF) and normal LV ejection fraction (EF)6,7. This high diastolic LV 
stiffness also modifies ischemic LV dysfunction as evident from the reduced LV 
remodeling and the raised incidence of HF after acute myocardial infarction8,9.   
In the absence of coronary artery disease (CAD), the high diastolic LV 
stiffness of the diabetic heart has been related to myocardial fibrosis10 and to 
circulating advanced glycation end products (AGEs)11 although associations of 
histological and biochemical data with in-vivo LV function are largely lacking. 
Furthermore, a contribution to this high diastolic LV stiffness of an elevated 
cardiomyocyte resting tension (Fpassive) has so far not been assessed. In patients with 
HF and normal LVEF (HFNEF), Fpassive of cardiomyocytes isolated from LV 
endomyocardial biopsies was recently demonstrated to be elevated and an important 
determinant of LV stiffness12. In patients with HF and reduced LVEF  (HFREF), 
Fpassive was lower and failed to correlate with LV stiffness13. The high Fpassive in HFNEF 
was paralleled by cardiomyocyte hypertrophy and concentric LV remodeling12,13. As 
myocardial hypertrophy is associated with insulin resistance14 and as HFNEF is 
common in type 2 DM patients7, high Fpassive could be an important contributor to the 
high diastolic LV stiffness of the diabetic heart. 
Using LV endomyocardial biopsies, the present study therefore compared 
myocardial fibrosis, AGEs deposition and Fpassive of isolated cardiomyocytes between 
diabetic (DM+) and non-diabetic (DM-) HFNEF patients (DM+HFNEF; DM-HFNEF) and 
between DM+ and DM- HFREF patients (DM+HFREF; DM-HFREF). All patients had been 
hospitalized for worsening HF and had no evidence of CAD on their coronary 
angiogram or of myocardial infiltration or active inflammation in their LV 
endomyocardial biopsies. 
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Methods 
Patients 
The study population consisted of 90 patients hospitalized for worsening HF between 
October 2003 and December 2006. Patients were referred for cardiac catheterization 
and LV endomyocardial biopsy procurement because of suspicion of infiltrative or 
inflammatory myocardial disease. Fifty-eight patients suffered of new onset HF and 
32 of acute decompensation superimposed on chronic HF. Modes of presentation 
were similar in HFNEF versus HFREF patients and in DM+ versus DM- patients. 
Patients were studied following medical recompensation. No patient had undergone 
cardiac transplantation. Coronary angiography showed epicardial coronary artery 
stenoses in 20 patients. These patients were excluded.  Histological analysis of the 
biopsies revealed active inflammatory infiltration or myocardial deposits in 6 patients. 
A histologically positive biopsy in 8.6% of the study population is comparable to 
previous studies, which reported active lymfocytic infiltration in 8.3% of patients with 
dilated cardiomyopathy15 and amyloid deposits in 6.3% of patients with LV restrictive 
physiology16 of hemodynamic severity comparable to the present study population.   
Patients with a positive biopsy were also excluded. The final study cohort therefore 
consisted of 64 patients. From 44 of these 64 patients, myocardial collagen volume 
fraction (CVF) and cardiomyocyte Fpassive were included in previous studies12,13. 
In accordance to a recent consensus document on the diagnosis of HFNEF17, 
patients had HFNEF (n=28) if LVEF > 50 %, if left ventricular end-diastolic volume 
index (LVEDVI) < 97 ml/m2 and if LV end-diastolic pressure (LVEDP) > 16 mmHg17. 
Patients had HFREF (n=36) if LVEF < 45%. A patient had DM, if a history of DM  
was evident from use of glucose-lowering medications and/or insulin, or if fasting 
plasma glucose ≥7.0 mmol/L18. No patient was using thiazolidinediones.  Three 
HFREF patients had type 1 DM, 7 HFREF and all 16 HFNEF patients had type 2 DM. 
In  DM+HFREF and DM+HFNEF patients, which were not on insulin therapy, fasting insulin 
plasma levels were elevated and equalled respectively 20.1±4.3 µU/ml and 22.4±3.0 
µU/ml. The local ethics committee approved the study protocol. Written, informed 
consent was obtained from all patients.  
 
Quantitative histomorphometry – light and electron microscopy 
Light microscopic quantification of cardiomyocyte diameter and CVF has previously 
been described and validated12,13. Biopsy samples used for CVF averaged 2.8±0.2 
samples per patient. The same automated image analyzer was also used for electron 
microscopic quantification13 of sarcomeric Z-disc thickness of cardiomyocytes. For 
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each patient, 30 Z-disc thickness measurements were averaged. 
 
Quantitative histomorphometry - immunohistochemistry 
Deposition of AGEs was inferred from measurement of the AGE, N-
ε(carboxymethyl)lysine (CML). Development of the used anti-CML monoclonal 
antibody and immunohistochemical staining techniques for CML and E-selectin have 
previously been described19,20. AGE and E-selectin positivity was scored for intensity. 
The sum of all positivities times their score was subsequently divided by the area of 
the slide to yield an immunohistochemical score/mm2.  
 
Quantitative histomorphometry - immunofluorescence light microscopy 
For analysis of Z-line thickness, fixed slides with isolated cardiomyocytes were 
stained with anti-α-actinin for 60 min at room temperature (1:50, mAb, Monosan, 
Uden, The Netherlands). After washing in phosphate buffered saline tween (PBST), 
the cells were subsequently incubated for 30 min with rabbit-anti-mouse AlexaFluor 
488 secondary antibody (1:40, Molecular Probes, Invitrogen) and again washed in 
PBST. Slides were covered and sealed by mounting medium and ultrathin glass 
cover slips. Z-disc thickness analysis was performed under a 3D MarianasTM 
widefield deconvolution microscopy workstation (Intelligent Imaging Innovations, 
Denver, CO, USA). For each patient, 3D stacks (stepsize in z = 0.2 µm) of isolated 
cardiomyocytes were made and 30 Z-disc thickness measurements were averaged.  
       
Force measurements in isolated cardiomyocytes 
Force measurements were performed in single, mechanically isolated 
cardiomyocytes as described previously12,13. Biopsy samples (5 mg wet weight) were 
defrosted in relaxing solution, mechanically disrupted and incubated for 5 minutes in 
relaxing solution supplemented with 0.2 % TritonX-100 to remove all membrane 
structures. Single cardiomyocytes were subsequently attached with silicone adhesive 
between a force transducer and a piezoelectric motor (2.7±0.4 cardiomyocytes per 
patient). Sarcomere length of isolated cardiomyocytes was adjusted to 2.2 µm. To 
assess reversibility of elevated Fpassive, myocytes were also incubated in relaxing 
solution supplemented with the catalytic subunit of protein kinase A (PKA, 100 U/mL; 
Sigma, batch-12K7495). After 40 minutes incubation with PKA, Fpassive measurements 
were repeated.  Force values were normalized for myocyte cross-sectional area. 
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Data analysis 
LVEDV, LVEDVI, LV stroke volume (LVSV) and LVEF were derived from biplane LV 
angiograms. Effective arterial elastance (Ea) equalled LV end-systolic pressure 
divided by angiographic LVSV. Total arterial compliance (Art Compl) equalled 
angiographic LVSV divided by aortic pulse pressure (PP).  
LV diastolic internal diameter (LVIDd), diastolic septal and posterior wall 
thicknesses (SWTd, PWTd), relative wall thickness (RWT), LV mass (LVM) and LV 
mass index (LVMI) were derived from 2D-echocardiograms. LV mass and RWT were 
calculated in accordance to the recent recommendations for cardiac chamber 
quantification21: 
LVM = 0.8 x {1.04 [(LVIDd + PWTd + SWTd)3 – LVIDd3]} + 0.6 g 
RWT = 2 x PWTd/LVIDd. 
To calculate LV peak systolic wall stress (LVPSs) and LV myocardial stiffness 
modulus (Stiff Mod), hemodynamic, angiographic and 2D-echocardiographic data 
were combined. Circumferential LVPSs was computed using a thick wall ellipsoid 
model of the left ventricle as follows22: 
LVPSs = LVPSP x D/(2 PWTs) x [1 – (PWTs/D) – (D2/2L2)] x 1.332 dyne/cm2 where 
LVPSP is LV peak systolic pressure, PWTs is corresponding systolic 
echocardiographic posterior wall thickness and D and L are corresponding 
angiographic LV systolic diameter and length.  
To assess diastolic LV material properties, a radial LV Stiff Mod was derived23. 
Stiff Mod was defined as the increment of radial stress (∆σ) divided by the increment 
of radial strain (∆ε) (Stiff Mod = ∆σ/∆ε). ∆σ is equal but opposite in sign to the 
increment of LV pressure (P) at the endocardium (-∆LVP) and ∆ε equals the 
increment in 2D-echocardiographic PWT relative to the instantaneous PWT 
(∆PWT/PWT). Early diastolic LV relaxation pressure was extrapolated from the 
exponential curve fit to isovolumic LV pressure decay, which was used to calculate 
Tau, the time constant of isovolumic LV pressure decay. Early diastolic LV relaxation 
pressure was subtracted from measured LVP to yield residual LV diastolic pressure 
(LVPres). Substitution of LVP by LVPres allowed Stiff Mod to be calculated also in early 
diastole, when LVP is still declining23. As ∆PWT/PWT = ∆lnPWT, Stiff Mod equals the 
slope of a plot of LVPres against corresponding ∆lnPWT data points.  
Values are given as mean ± SEM. Data of the DM-HFREF, DM+HFREF, DM-HFNEF and 
DM+HFNEF groups were analysed by two-factor ANOVA testing for DM status, HFREF-
HFNEF status and their interaction. Subsequent comparisons (DM-HFREF vs.     
DM+HFREF and DM-HFNEF vs. DM+HFNEF) were performed using a Bonferroni adjusted t 
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test.  Single comparisons were assessed by an unpaired Student’s t test. Relations 
between two continuous variables were assessed with linear regression analysis. 
Statistical analysis was performed using SPSS (version 9.0). 
   
142 
 
Table 1. Clinical and hemodynamic characteristics 
DM-HFREF (n=26) DM+HFREF (n=10) DM-HFNEF (n=12) DM+HFNEF (n=16)                       p value 
     DM- vs DM+ HFREF vs HFNEF 
Age (y) 60.2±3.4 62.4±4.1 63.2±4.1 65.3±2.7 NS NS 
Sex (M/F) 10/16 7/3 6/6 9/7 NS NS 
Hypertension 3/26 1/10 10/12 13/16 NS <0.001 
DM1/DM2  3/7  0/16   
FastingGlucose (mmol/L) 4.97±0.23 7.10±0.56* 5.78±0.28 8.64±0.94§ <0.001 0.048 
Glycated hemoglobin (%) 5.54±0.20 7.04±0.58* 5.50±0.04 7.26±0.51§ <0.001 NS 
Body Mass Index (kg/m2) 26.4±0.95 28.9±1.71 25.9±1.86 32.6±1.98‡ 0.007 NS 
DM duration (y)  6.9±0.7  6.4±0.4   
Creatinine (µmol/L) 94.3±4.0 101.0±3.0 94.8±4.0 96.2±3.0 NS NS 
GFR (mL/min/1.73m2) 75±3.0 69±1.5 74±3.0 72±1.7 NS NS 
Microalbuminuria  3/10  3/16   
Medication       
 ACEI 20/26 9/10 9/12 13/16 NS NS 
 β-blocker 14/26 4/10 5/12 8/16 NS NS 
 Diuretic 24/26 10/10 11/12 16/16 NS NS 
 CCB 1/26 2/10 3/12 5/16 NS NS 
 ARB 3/26 0/10 2/12 3/16 NS NS 
 Digoxin 10/26 5/10 3/12 2/16 NS 0.035 
 Amiodarone 2/26 1/10 2/12 3/16 NS NS 
 Statin 4/26 5/10 6/12 10/16 NS NS 
 Insulin  3/10  5/16   
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M, male; F, female; DM1, type 1 DM; DM2, type 2 DM; GFR, glomerular filtration rate; ACEI, ACE inhibitors; CCB, calcium channel blockers; ARB, 
angiotensin II receptor blockers; RAP, right atrial pressure; SVR, systemic vascular resistance; CO, cardiac output; CI, cardiac index. *  p < 0.05 vs. DM-
HFREF; † p < 0.001 vs. DM-HFREF; ‡ p < 0.05 vs. DM-HFNEF; § p < 0.01 vs. DM-HFNEF; ‖ p < 0.001 vs. DM-HFNEF. For all variables listed, two-factor ANOVA 
showed no significant interaction between DM status and HFNEF-HFREF status.   
DM-HFREF (n=26) DM+HFREF (n=10) DM-HFNEF (n=12) DM+HFNEF (n=16)                       p value 
     DM- vs DM+ HFREF vs HFNEF 
 
LVPSP (mmHg) 
 
117.4±3.4 
 
126.4±8.2 
 
166.0±8.5 
 
172.0±9.7 
 
NS 
 
<0.001 
LVEDP (mmHg) 19.9±1.7 27.8±2.5* 22.2±1.9 28.0±1.7 0.002 NS 
RAP (mmHg) 6.7±1.0 9.5±1.9 8.1±1.0 8.4±1.2 NS NS 
Tau (ms) 66.5±10 63.0±8.5 58.3±5.3 72.5±5.7 NS NS 
Ea (mmHg/mL) 2.2±0.2 2.5±0.7 2.3±0.2 2.7±0.3 NS NS 
PP (mmHg) 49.1±2.9 51.2±6.2 82.9±5.0 97.9±7.6 NS <0.001 
Art Compl(mL/mmHg) 1.7±0.2 1.4±0.2 1.4±0.2 1.0±0.1 NS NS 
SVR (dyne/sec/cm5) 1832±101 1963±114 1781±158 1913±263 NS NS 
LVEDV (mL) 236.6±12.5 226.1±17.6 176.3±17.8 148.0±10.9 NS <0.001 
LVEDVI (mL/m2) 127.9±6.6 117.8±7.2 88.0±7.2 77.0±4.2 NS <0.001 
LVEF (%) 33.0±1.8 26.0±2.9 60.5±2.2 60.2±3.2 NS <0.001 
CO (L/min) 3.9±0.2 3.6±0.2 5.3±0.6 5.1±0.1 NS <0.001 
CI (L/min/m2) 2.1±0.1 1.9±0.1 2.7±0.3 2.7±0.1 NS <0.001 
LVIDd (cm) 7.1±0.1 6.9±0.2 5.4±0.2 5.1±0.1 NS <0.001 
PWTd (mm) 9.0±0.3 10.3±0.4* 10.3±0.4 11.4±0.3 0.002 0.002 
RWT  0.25±0.01 0.30±0.02* 0.40±0.02 0.45±0.02‡ 0.005 <0.001 
LVM (g) 298.8±18.1 338.6±16.3 227.9±14.6 231.0±10.6 NS <0.001 
LVMI (g/m2) 163.1±10.1 181.2±11.1 114.6±5.5 121.3±4.4 NS <0.001 
LVMI/LVEDVI (g/mL) 1.3±0.1 1.4±0.1 1.4±0.1 1.6±0.1 NS NS 
LVPSs (dyne/cm2) 243.4±8.0 255.0±7.0 137.8±8.4 130.3±9.9 NS <0.001 
Stiff Mod (kN/m2) 2.5±0.2 6.3±2.0† 4.5±0.8 7.4±0.7‖ <0.001 <0.001 
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Results 
DM and LV function 
As evident from the higher LVEDP at similar LVEDVI, LV end-diastolic distensibility 
was reduced in DM+HFREF and DM+HFNEF patients (Fig 1A). Stiff Mod was also higher in 
DM+HFREF and DM+HFNEF patients when compared respectively to DM-HFREF and DM-
HFNEF patients (Table, Fig 1B). 
 
Figure 1. A. LVEDP-LVEDVI relations in DM-HFREF, DM+HFREF, DM-HFNEF and DM+HFNEF 
patients. Reduced LV end-diastolic distensibility in DM+HFREF and DM+HFNEF patients is evident 
from higher LVEDP at similar LVEDVI. B. Higher LV stiffness modulus in DM+HFREF and 
DM+HFNEF patients (# p<0.001). 
 
Myocardial AGEs deposition and fibrosis 
AGEs deposition was inferred from CML immunostaining and occurred mainly in the 
wall of small intramyocardial vessels (Fig 2A). In two-factor ANOVA, CML deposition 
depended on presence of DM (p<0.001) but not on HFNEF-HFREF status. CML 
deposition was especially evident when DM+HFREF patients were compared to DM-
HFREF patients (24.1±3.8 vs. 8.8±2.5 score/mm2; p=0.005) and less so when DM+HFNEF 
patients were compared to DM-HFNEF patients (15.7±2.7 vs. 8.2±2.5 score/mm2; NS) 
(Fig 2B). CML deposition correlated with the myocardial stiffness modulus in HFREF 
(r=0.48; p=0.014). The DM-induced rise in myocardial CML deposition in HFREF was 
paralleled by a rise in E-selectin expression from 3.6±0.9 score/mm2 to 9.2±1.9 
score/mm2 (p=0.022). E-selectin is a marker of inflammatory endothelial activation 
(Fig 2C).  
In two-factor ANOVA, myocardial CVF depended on DM (p=0.006) and on 
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HFNEF-HFREF status (p<0.001). Moreover, the effect of DM on CVF depended on 
HFNEF-HFREF status (p=0.007). CVF was higher when DM+HFREF patients were 
compared to DM-HFREF patients (22.4±2.2 vs. 14.6±1.0%; p<0.001) and similar when 
DM+HFNEF patients were compared to DM-HFNEF patients (11.6±1.1 vs. 11.7±1.1%; NS) 
(Fig 2D). In HFREF patients, CVF correlated with Stiff Mod (r=0.37; p=0.039) and 
with plasma glycated hemoglobin (r=0.61; p=0.0014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. A. Representative example of CML deposition in small myocardial vessels (arrows) 
of DM+HFREF patients. B. Higher CML deposition score in DM+HFREF patients (*p<0.01). C. 
Representative example of endothelial (arrows) E-selectin expression in DM+HFREF patients. D. 
Higher CVF in DM+HFREF patients (#p<0.001).  
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Myocyte Fpassive,  myocyte hypertrophy and LV remodeling  
In all cardiomyocytes, Fpassive was measured at the same sarcomere length of 2.2µm 
(Fig 3A). In two-factor ANOVA, Fpassive depended on DM (p=0.009) and on HFNEF-
HFREF status (p<0.001). Similar to myocardial CVF, the effect of DM on Fpassive was 
depended on HFNEF-HFREF status (p=0.021). Fpassive of DM+HFNEF cardiomyocytes 
was higher than Fpassive of DM-HFNEF cardiomyocytes (8.5±0.9 vs. 5.1± 0.7 kN/m2; 
p=0.006) while Fpassive of DM+HFREF cardiomyocytes was comparable to Fpassive of DM-
HFREF cardiomyocytes (3.9±0.5 vs. 3.7±0.4 kN/m2; NS) (Fig 3B). Higher Fpassive of 
DM+HFNEF cardiomyocytes was unrelated to isolation-associated cell damage, 
because active force development at saturating calcium concentration (pCa=4.5) was 
comparable in DM+HFNEF (14.7±1.3 kN/m2) and DM-HFNEF (16.9±1.9 kN/m2) 
cardiomyocytes. After administration of PKA, Fpassive fell especially in DM+HFNEF 
cardiomyocytes (from 8.5±0.9 to 4.0± 0.3 kN/m2; p<0.001) and the values of Fpassive 
became comparable in all patient groups (Fig 3C). The higher Fpassive in DM+HFNEF 
compared to DM-HFNEF cardiomyocytes was paralleled by widening of the sarcomeric 
Z-disc, which was significantly larger in DM+HFNEF than in DM-HFNEF both on 
immunofluorescent images stained for α-actinin (+16.9%; p=0.045; Fig 3D) and on 
electronmicroscopy images (+15.2%; p<0.001; Fig 3E). In HFNEF patients, Fpassive 
correlated with Stiff Mod (r=0.55; p=0.022) and with the DM duration (r=0.35; 
p=0.04).  
In control conditions, Fpassive rose progressively from HFREF to DM-HFNEF and to 
DM+HFNEF (Fig 3B). This trend was paralleled by the rise of cardiomyocyte diameter 
(MyD), PWTd and RWT. MyD rose from 16.0±1.5 µm in HFREF, to 19.8±1.7 µm in 
DM-HFNEF and to 22.4±0.9 µm in DM+HFNEF cardiomyocytes (r=0.98; p<0.001). PWTd 
rose from 9.4±0.3 mm in HFREF, to 10.3±0.4 mm in DM-HFNEF and to 11.4±0.3 mm in 
DM+HFNEF (r=0.98; p=0.037). RWT rose from 0.27±0.01 in HFREF, to 0.40±0.02 in 
DM-HFNEF and to 0.45±0.02 in DM+HFNEF (r=0.97;p=0.03). The progressive rise in RWT 
indicates a shift from eccentric to concentric LV remodeling. 
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Figure 3. A. Cardiomyocyte mounted between force transducer and piezoelectric motor to 
measure Fpassive. B. Fpassive is higher in DM+HFNEF patients (*p<0.01). C. After PKA 
administration, Fpassive is comparable in all patient groups; D. Representative example of 
immunofluorescent image of cardiomyocytes, stained for α-actinin and used for Z-disc 
thickness measurement (arrows indicate Z discs); E. Representative example of 
electronmicroscopic Z-disc thickness measurement (arrows indicate Z discs).
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Discussion 
The prevalence of DM in heart failure is increasing24,25 and mortality or hospitalization 
rates in diabetic patients with heart failure remain particularly high26-28. Although CAD 
is the most important contributor to the myocardial dysfunction observed in DM, DM-
related disturbances, such as hyperglycemia, insulin resistance and hyperlipidemia 
can also directly act on the myocardium29 and induce myocardial dysfunction 
because of a shift in myocardial energy production from glucose utilization to fatty 
acid oxidation30-32. In the first clinical description of DM-induced myocardial 
dysfunction, LV dilatation and systolic LV dysfunction were prominent features33 and 
DM-induced myocardial dysfunction was therefore classified as a dilated 
cardiomyopathy. Subsequently, diastolic LV dysfunction was recognized as an earlier 
manifestation of DM-induced myocardial dysfunction1-5. The present study confirmed 
diastolic LV stiffness to be higher in failing hearts of diabetic patients in the absence 
of significant CAD. Mechanisms responsible for this DM-induced diastolic myocardial 
stiffening were identified in endomyocardial biopsies of these patients. The main 
finding of the study is that DM elevated diastolic LV stiffness by different mechanisms 
in HFREF and HFNEF patients. In HFREF, DM elevated diastolic LV stiffness 
through myocardial AGEs deposition and fibrosis whereas in HFNEF, DM raised 
diastolic LV stiffness mainly through higher Fpassive of hypertrophied cardiomyocytes. 
 
Myocardial AGEs deposition and fibrosis 
DM+HFREF patients had higher diastolic LV stiffness than DM-HFREF patients. This 
higher diastolic LV stiffness was related both to AGEs deposition and interstitial 
fibrosis. AGEs deposition results from longstanding hyperglycemia and affects 
diastolic LV stiffness by direct and indirect mechanisms29,34,35. AGE crosslinking of 
collagen increases its tensile strength and this altered biophysical property of 
collagen raises diastolic LV stiffness. AGEs deposition can also indirectly augment 
diastolic LV stiffness through enhanced collagen formation and reduced NO 
bioavailability. Enhanced collagen formation in the presence of AGEs was observed 
in the present study. AGEs quench endothelially produced NO and low myocardial 
NO bioavailability was previously demonstrated to raise diastolic LV stiffness in 
HFREF patients36.  
Previous myocarditis and not DM is the most likely cause for the dilated 
cardiomyopathy in the majority of the DM+HFREF patients because fasting glucose, 
glycated hemoglobin and DM duration were all similar in the DM+HFREF and DM+HFNEF 
groups. Even in the absence of cellular infiltration, patients with post myocarditis 
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HFREF frequently have persistent myocardial microvascular inflammation37. 
Inflammation facilitates AGEs deposition20,38 and persistent microvascular 
inflammation could therefore explain the preferential CML deposition in small 
intramyocardial vessels of the DM+HFREF patients. In rodent DM animal models, AGEs 
deposition occurs also in the myocardial interstitium39. Failure to observe interstitial 
CML deposition in the present study probably relates to better glycemia control in 
patients treated with glucose lowering medication or insulin than in untreated rodent 
animal models. The clinical importance of endothelial AGEs deposition was recently 
confirmed in hypertensive patients in whom a crosslink breaker improved endothelial 
function40.  
The present study observed a higher CVF in DM+HFREF than in DM-HFREF 
patients. Activation of fibroblasts in DM+HFREF patients may have resulted from the 
aforementioned AGEs deposition, from protein kinase C activation or from high 
intracellular glucose concentrations35,41. 
 
Cardiomyocyte resting tension 
DM+HFNEF patients had a higher Stiff Mod than DM-HFNEF patients. The higher Stiff Mod  
related to cardiomyocyte Fpassive and less to AGEs deposition. Correction of high 
cardiomyocyte Fpassive by PKA suggests a phosphorylation deficit of myofilamentary or 
cytoskeletal proteins12,13 because the cardiomyocytes had been pretreated with Triton 
X-100 to remove all membranes. High Fpassive of DM+HFNEF cardiomyocytes was 
accompanied by Z-disc widening. Z-disc widening has been observed in transgenic 
mice after nebulin or muscle LIM protein knock-out42,43. The present study is the first 
to report Z-disc widening in humans and because of the simultaneous elevation of 
Fpassive, suggests Z-disc widening to result from altered elastic properties of 
cytoskeletal proteins, which pull at and open up adjacent Z-discs. In a previous study 
comparing HFREF to HFNEF13, a significant correlation was observed between 
cardiomyocyte hypertrophy and Fpassive. In the present study, Fpassive rose 
progressively from HFREF to DM-HFNEF and to DM+HFNEF and this rise was again 
paralleled by a rise in MyD and by a shift from eccentric to concentric LV remodeling. 
As LVPSP and LVPSs were similar in DM+HFNEF and DM-HFNEF, excess cardiomyocyte 
hypertrophy in DM+HFNEF was unrelated to pressure overload and probably induced by 
insulin resistance14. All DM+HFNEF patients indeed had type 2 DM and elevated fasting 
insulin plasma level. Furthermore, hyperinsulinemia is known to stimulate 
prohypertrophic signaling in insulin responsive tissues, such as the myocardium29.  
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Limitations 
The clinical characteristics of the HFNEF patients differed from clinical characteristics 
observed in epidemiological studies. In the present study, HFNEF patients were 
younger (mean age: 64 years) and less often female (46%) in contrast to 
epidemiological studies44 where patients are typically older (mean age: 76 years) and 
more often female (55%). Patient recruitment from tertiary referral because of 
suspicion of inflammatory or infiltrative myocardial disease explains this discrepancy. 
In the present study, diastolic LV material properties were analyzed by a 
radial LV stiffness modulus. Use of a radial LV stiffness modulus avoids geometrical 
assumptions on LV shape. Furthermore, substitution of measured LVP by LVPres 
allows early diastole to be included in the LV stiffness analysis as it corrects for the 
upward displacement of the early diastolic LV pressure-volume relation45. In a 
previous study46 of HFREF patients, close agreement was observed between the 
radial LV stiffness modulus and the LV chamber stiffness constant derived from a 
curve fit to multiple LV end-diastolic pressure-volume points during balloon caval 
occlusion.  
Higher LVEDP at similar or smaller LVEDV can result from altered myocardial 
material properties and from external constraints on the left ventricle by the right 
ventricle or by the pericardium47. Right ventricular constraints because of the shared 
interventricular septum are prominent in patients with hypertrophic cardiomyopathy 
but not in patients with HFNEF who usually have hypertensive heart disease47. Right 
atrial pressure (RAP) was determined as a measure of intrapericardial pressure or 
pericardial constraint and was comparable in all patient groups.  
Because of microvascular CML deposition, relative reduction of the number of 
microvessels in hypertrophied myocardium could have lowered the CML score in the 
DM+HFNEF patients. A similar CML score in DM-HFNEF and DM-HFREF patients however 
argues against such an artifact. Isolation of cardiomyocytes and assessment of 
myocardial tissue properties was performed on a limited number of samples procured 
by endomyocardial biopsy technique and potentially overlooks tissue heterogeneity. 
Extent of tissue heterogeneity was assessed in the present and previous12,48 studies. 
Sampling related variability was < 5% for cardiomyocyte force measurements and < 
15% for histomorphometric data. 
Development of HFNEF results from diastolic LV dysfunction44, deficient chronotropic 
or vasomotor responses49,50 and arterial stiffening45. In DM, not only diastolic LV 
dysfunction but also arterial stiffness becomes a more important contributor to 
HFNEF. 
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Conclusions 
In the absence of CAD, the failing diabetic heart has an elevated diastolic LV 
stiffness. Mechanisms responsible for this increase in diastolic LV stiffness differ 
between HFREF and HFNEF patients. Deposition of AGEs and collagen are 
important determinants of the increased LV stiffness in diabetic patients with HFREF, 
while high cardiomyocyte Fpassive is the main determinant of the increased LV stiffness 
in diabetic patients with HFNEF. 
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Abstract 
The present study was designed to investigate if antibodies against β-adrenergic 
receptors (βARs) can be used to determine expression of βAR in human 
myocardium. 
Western blotting was performed to investigate the specificity of antibodies 
directed against β1AR and β2AR in human left ventricular (LV) tissue.  A comparison 
was made between cardiac tissue from patients with idiopathic dilated 
cardiomyopathy (IDCM) and ischemic heart disease (ISHD), and non-failing donors.  
The antibodies directed against β1AR and β2AR recognized several protein 
bands at different molecular weights. Moreover, both antibodies also recognized 
multiple proteins in Chinese hamster ovary (CHO) cells expressing β1AR, β2AR and 
even β3AR.  
βAR antibodies are not specific and are not suited to study expression of βAR 
in human myocardium. 
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Introduction 
The β-adrenergic pathway is activated upon an increase in catecholamine levels. 
Binding of catecholamines to the βARs increases contractility of the cardiomyocytes 
via protein kinase A-mediated phosphorylation of down-stream target proteins 
involved in calcium handling1 and myofilament contraction.2 In the human 
myocardium at least three types of βARs are present, including β1AR, β2AR and 
β3AR.3 Analysis of βARs in crude membrane fractions using radioligand binding 
studies revealed a ratio of 80:20 for β1AR and β2AR in non-failing human donor 
tissue,3 with β1AR as the predominant receptor. In failing idiopathic dilated 
cardiomyopathy (IDCM) myocardium a down-regulation of β1AR has been observed, 
leading to a relative increase in β2AR, as illustrated by the altered ratio of β1AR and 
β2AR to 60:40 in the failing heart.3-5  Diverse alterations in myocardial βAR density 
have been reported in IDCM and ischemic heart disease (ISHD) patients.6,7 In failing 
IDCM myocardium a down-regulation of β1AR has been observed,6 while β2AR 
remained unchanged.7 In contrast, a reduction of both β1AR and β2AR was reported 
in ISHD patients.4,5,7  
Apart from radioligand binding studies, Western blotting is often used to 
determine expression levels of βAR. The present study was designed to investigate 
specific binding of antibodies directed against β1AR and β2AR in different human 
heart samples. LV tissue from patients with IDCM and ISHD was compared with non-
failing donor myocardium. Moreover, specific binding of βAR antibodies was 
investigated in CHO cells expressing human βARs.8 
 
Methods and Materials 
Human ventricular tissue 
LV transmural tissue samples were obtained during heart transplantation surgery 
from end-stage heart failure patients (NYHA III-IV) with IDCM  (n=21) and ISHD 
(n=19). LV tissue from donor hearts (n=10) served as reference for non-failing 
myocardium. Tissue was collected in cardioplegic solution and stored in liquid 
nitrogen. Samples were obtained after informed consent and with approval of the 
local Ethical Committee (St Vincents' Hospital Human Research Ethics Committee: 
File number: H03/118; Title: Molecular Analysis of Human heart Failure). 
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Cell culture  
Our experiments are based on CHO cells expressing either the human β1AR, β2AR or 
β3AR at densities (Bmax) of 118±28, 202±27 and199±59 fmol/mg proteins as 
previously described (Niclauss et al. 2006).8 CHO cells were stably transfected with 
human βAR subtypes using a pSW104 vector and grown in an atmosphere of 5% 
CO2/95% air at 37°C in F-12 HAM medium supplemented with 10% heat-inactivated 
fetal calf serum, 1 mM glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin. 
Subconfluent cells were subcultured every 3–4 days with a 2.5 g/liter trypsin and 0.2 
g/liter Na4EDTA solution. To maintain selection pressure the antibiotic G418 (400 
mg/ml) was added to all growing cells in regular intervals, but was not present during 
the experiments. For all experiments the cells were cultured in the absence of serum 
for 24 h preceding the experiments to avoid interference of serum factors with cell 
growth and related signal transduction.  
 
Detection of βARs 
Antibodies against β1AR and β2AR 
Two different primary rabbit polyclonal antibodies directed against the β1AR and 
β2AR were used for Western blotting. Both antibodies were from Santa Cruz (β1AR 
(V-19): catalogue: sc-568; β2AR (H-73): catalogue: sc-9042). The antibody directed 
against β1AR was raised against amino acids 420-470 at the C-terminus of β1AR of 
mouse origin, while the β2AR antibody was raised against amino acids 338-413 
mapping at the C-terminus  of the β2AR of human origin. 
 
Western blotting 
Protein expression levels of β1AR and β2AR were analyzed by one-dimensional 15% 
SDS-polyacrylamide gel electrophoresis (1D-PAGE) and subsequent Western 
blotting. Cardiac tissue homogenates (in sample buffer containing 15% glycerol, 62.5 
mmol/l Tris (pH 6.8), 1% (w/v) SDS and 2% (w/v) DTT) were applied in a 
concentration, which was within the linear range of detection: 20 µg protein/lane for 
β1AR and β2AR. After 1D separation proteins were transferred to Hybond-ECL 
nitrocellulose membranes. Blots were pre-incubated with 0.5% milk powder in TTBS 
(Tween-tris-buffered-saline; 10 mmol/L Tris–HCl pH 7.6, 75 mmol/L NaCl, 0.1% 
Tween) for one hour at room temperature. The blots were incubated overnight at 4°C 
with primary rabbit polyclonal antibodies against β1AR (dilution 1:200) and β2AR 
(dilution 1:200). After washing with TTBS, primary antibody binding was visualized 
using a secondary horseradish peroxidase-labeled goat-anti-rabbit antibody (dilution 
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1:2000; DakoCytomation) and enhanced chemiluminescence (ECL plus Western 
blotting detection, Amersham Biosciences). All signals were normalized to actin 
(dilution 1:1000; clone KJ43A; Sigma) stained on the same blots. 
 
Results 
Detection of βARs in human myocardium 
Figure 1A shows Western blots of failing and non-failing cardiac samples. The 
antibodies against β1AR and β2AR recognized multiple bands at different molecular 
weights (mw) (Fig 1A). A similar pattern of protein bands was obtained when we 
replaced milk by albumin (BSA, bovine serum albumin 2%) as blocking agent. The 
molecular weight of the detected protein bands was calculated on the basis of the 
molecular weight marker (Precision Plus Protein Standards Dual Color).  
The most prominent band visualized upon β1AR labeling was observed at 33 
kDa, and two more faint bands of higher molecular weight were found.  All of these 
were no longer visible in the presence of blocking peptide against β1AR (dilution 
1:200; sc-568p; Santa Cruz)  (Fig 1B).  
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Figure 1. Western blot staining of a failing (F) and nonfailing (NF) cardiac samples separated 
by 1D-PAGE. A illustrates protein bands (indicated by arrows) detected by antibodies against 
β1AR and β2AR. Molecular weight of the protein bands was calculated on the basis of the 
molecular weight marker (mwm). The predicted molecular weight for the βARs is shown in 
bold. B. Western blots incubated with β1AR antibody without blocking peptide (left panel) and 
with blocking peptide (right panel) of F and NF samples.  
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The β2AR antiserum recognized a large number of bands among which those at 32, 
48 and 75 kDa were most prominent. None of the detected protein bands 
corresponded with the predicted molecular weight of the β2AR, which is ~65 kDa.  
Immunoreactivity levels of different protein bands detected by the βAR 
antibodies were expressed relative to actin expression. Bar graphs are shown in 
Figure 1C for the mean data (sum of all signals obtained with antibodies directed 
against βAR) obtained in IDCM and ISHD samples in comparison to donor 
myocardium, which was set to 1. One-way ANOVA revealed no significant differences 
in the immunoreactivity of β1AR and β2AR between all groups. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. C. Analysis of βARs revealed no significant differences between IDCM, ISHD, and 
NF donor myocardium 
 
Analysis of βARs in CHO cells 
Subsequently, specificity of antibodies directly against β1AR and β2AR was tested in 
CHO cells expressing β1AR, β2AR and β3AR (Fig 2). In addition failing and non-failing 
samples were used as controls. The antibodies directed against β1AR and β2AR all 
recognized several protein bands with molecular weights ranging between 25 and 
120 kDa in CHO cells expressing β1AR, β2AR, and even β3AR, while no band was 
observed at the expected molecular weight of ~65 kDa. All protein bands stained with 
the β1AR antibody disappeared in the presence of the blocking peptide against β1AR 
(Fig 3). 
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Figure 2. Western blots illustrating the binding of antibodies directed against β1AR (A) and 
β2AR (B) in failing and nonfailing human samples and CHO cells expressing β1AR, β2AR and 
β3AR. 
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Figure 3. A. Western blots illustrating the Western blot analysis using antibodies directed 
against β1AR in combination with a blocking peptide in CHO cells, failing and non-failing 
donor. B. Western blots illustrating the binding of antibodies directed against β1AR in CHO 
cells, failing and non-failing donor. All protein bands stained with the β1AR antibody 
disappeared in the presence of the blocking peptide against β1AR, both in tissue and CHO 
cells 
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Discussion  
Most of the antibodies known to interact with βARs described in the literature did not 
exhibit subtype selectivity.9-11 Moxham et al. (1986)9 investigated β1ARs and β2ARs in 
membrane preparations from rat lung and rat heart, respectively, and observed that 
antibodies directed against β1AR and β2AR, interacted with both receptor subtypes. In 
these previous studies antibodies were raised against isolated receptor subtypes, 
while the antibodies used in our study were directed against a peptide sequence, 
which might increase their selectivity. 
Our study shows that antibodies directed at a specific part of the βARs are still not 
specific and do not allow determination of βAR expression levels, since both 
antibodies detected a range of protein bands at different molecular weights in failing 
and non-failing human cardiac samples. Noteworthy, no bands were observed at the 
predicted molecular weight of 65 kDa. Several studies have shown that the 65 kDa 
subunit exists in a dimeric form in the cell membrane, with a molecular size of 109 
kDa as determined by immunoaffinity chromatography using monoclonal 
autoantibodies and SDS-polyacrylamide gels.12,13 We did not find evidence for a 
dimeric form in our study using the   β1AR and β2AR antibodies. 
It has been proposed that the different bands detected upon βAR antibody 
binding represent different forms of the βARs resulting from complex formation and/or 
post-translational modifications such as glycosylation as described by Rybin et al. 
(2000).14 Both antibodies against  β1AR and β2AR detected a band with a molecular 
weight of 75 kDa in all samples. Glycosylation may alter molecular weight of βARs by 
8 to 11 kDa (George et al. 1986),15 and hence it is possible that the band detected at 
75 kDa is the putative βAR.  
Based on the assumption that all signals represent different forms of βARs, we 
averaged the sum of all βAR signals for the different cardiac samples. No significant 
difference was observed in βAR expression level (sum of all βAR signals relative to 
actin) between failing and non-failing samples. It should be noted that tissue 
preparation might have interfered with analysis of βAR expression. In the present 
study, expression of β1AR and β2AR was determined in whole cardiac homogenates, 
and therefore lacks information about receptor density at the membranes (i.e. 
functionally available receptors for ligand binding). However, the fact that multiple 
protein bands were stained with both β1AR and β2AR antibodies in CHO cells 
expressing βARs, even in cells with the β3AR, indicates that the antibodies are not 
specific. Moreover, all protein bands stained with the β1AR antibody disappeared in 
the presence of the blocking peptide against β1AR, both in tissue and CHO cells (Fig 
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3A and B), illustrating that the Western blot analysis using antibodies directed against 
βAR in combination with a blocking peptide is invalid and cannot be used for 
quantitative analysis of βAR densities. 
In conclusion, Western blot analysis cannot be used for quantitative analysis of βAR 
receptors because they do not show specific binding to their target protein. Further 
investigations have to be performed to clarify the selectivity and specificity of 
antibodies against βAR receptor proteins.  
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Abstract 
In healthy human myocardium a tight balance exists between receptor-mediated 
kinases and phosphatases coordinating phosphorylation of regulatory proteins 
involved in cardiomyocyte contractility. During heart failure, when neurohumoral 
stimulation increases to compensate for reduced cardiac pump function, this balance 
is perturbed. The imbalance between kinases and phosphatases upon chronic 
neurohumoral stimulation is detrimental and initiates cardiac remodelling, and 
phosphorylation changes of regulatory proteins, which impair cardiomyocyte function. 
The main signalling pathway involved in enhanced cardiomyocyte contractility 
during increased cardiac load is the β-adrenergic signalling route, which becomes 
desensitised upon chronic stimulation. At the myofilament level, activation of protein 
kinase A (PKA), the down-stream kinase of the β-adrenergic receptors (βAR), 
phosphorylates troponin I, myosin binding protein C and titin, which all exert 
differential effects on myofilament function. As a consequence of βAR down-
regulation and desensitization, phosphorylation of the PKA-target proteins within the 
cardiomyocyte may be decreased and alter myofilament function. Here we discuss 
involvement of altered PKA-mediated myofilament protein phosphorylation in different 
animal and human studies, and discuss the roles of troponin I, myosin binding protein 
C and titin in regulating myofilament dysfunction in cardiac disease. Data from the 
different animal and human studies emphasize the Importance of careful biopsy 
procurement, and the need to investigate localization of kinases and phosphatases 
within the cardiomyocyte, in particular their co-localization with cardiac myofilaments 
upon receptor stimulation. 
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Introduction 
In healthy humans, the sympathetic nervous system (SNS) as well as the renin-
angiotensin-aldosterone system are important mechanisms to maintain adequate 
perfusion of vital organs via peripheral vasoconstriction, an increase in heart rate and 
an improvement of myocardial contractility. Although aimed at maintaining cardiac 
pump function, chronic neurohumoral stimulation in patients with cardiovascular 
disease is detrimental for cardiac function1 illustrated by the negative correlation 
between noradrenaline plasma levels2 and prognosis of the patient and by the 
improvement of symptoms and prolonged survival of patients treated with 
neurohumoral antagonists.3 
Activation of the β-adrenergic receptors by SNS is the main signalling route 
responsible for increasing cardiomyocyte contractility. Beta-adrenergic receptor 
(βAR) stimulation induces protein kinase A (PKA)-mediated phosphorylation of L-type 
Ca2+ channels and ryanodine receptors, increasing cytosolic Ca2+, and of 
phospholamban, increasing activity of the SR Ca2+-ATPase pump and SR Ca2+ 
uptake and loading.4 At the myofilament level, PKA-mediated phosphorylation of 
troponin I (cTnI) and myosin binding protein C (cMyBP-C) decrease myofilament 
Ca2+-sensitivity5,6 and contributes to an acceleration of cardiac relaxation.7-9 Stelzer et 
al. (2007)10 have proposed a dominant role for cMyBP-C phosphorylation in 
regulating the rate of cross-bridge cycling and force development upon β-AR 
stimulation.10 Moreover, several studies revealed a role for PKA-mediated 
phosphorylation of titin in regulating cardiomyocyte stiffness.11-13 
Chronic SNS activation in cardiovascular disease results in down-regulation 
and uncoupling of β-adrenergic receptors14,15 and thereby limits cardiac 
responsiveness during increased cardiac load as occurs during exercise. In human 
heart failure, down-regulation and uncoupling of the βAR pathway leads to  
decreased PKA-mediated phosphorylation of Ca2+ handling and myofilament 
proteins. Here we present data from different animal (mouse, rat, pig) and human 
heart failure models in support for reduced βAR-mediated signalling and defects in 
myofilament function. 
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Materials and methods 
Cardiac tissue 
All animal experiments were performed in accordance with the Guide for the Care 
and Use of Laboratory Animals (NIH Publication 86-23, revised 1996), and with 
approval of the Animal Care Committee of the VU Medical Center and of the 
Erasmus Medical Center. Cardiac samples from the left (LV) or right (RV) ventricular 
wall were obtained from control and diseased: mouse (myocardial infarction, MI), rat 
(pressure overload), pig (MI) and human (ischemic heart disease, ISHD; idiopathic 
dilated cardiomyopathy, IDCM) myocardium.  
 
Mice: In mice (C57B1/6J of either sex) myocardial infarction (n=7) was produced by 
permanent ligation of the left anterior descending coronary artery as described 
before.16 Sham animals (n=6) underwent the operation without infarct induction. 
Cardiomyocyte measurements and protein analysis were performed in tissue from 
remodelled LV myocardium. 
 
Rats: Animals (male, Wistar; body weight 175 g) received a single subcutaneous 
injection of 80 mg kg–1 monocrotaline (n=10).17 During its first passage through the 
pulmonary circulation monocrotaline damages the pulmonary endothelium, thereby 
inducing pulmonary hypertension, causing right ventricular (RV) hypertrophy resulting 
eventually in RV heart failure.18,19 Sham animals (control, n=11) received a saline 
injection. Cardiomyocyte measurements and protein analysis were preformed in 
isolated skinned cardiomyocytes obtained from RV tissue of quiescent control and 
failing hearts. 
 
Pigs: In pigs (2-3 month old Yorkshire-Landrace pigs of either sex) the left circumflex 
coronary artery was permanently ligated to produce a myocardial infarction (n=6). 20,21 
In sham animals (n=7) the suture was removed. Three weeks after surgery 
(transmural, 0.5 mg wet weight) needle biopsies were taken from the LV anterior free 
wall myocardium (in MI pigs: remodelled non-infarcted tissue) and immediately frozen 
and stored in liquid nitrogen.22 Cardiomyocyte measurements and protein analysis 
were performed in the subendocardial part of the biopsies. 
 
Human: Within the human studies LV tissue samples were obtained during heart 
transplantation surgery from patients with end-stage ischemic (n=10) and dilated 
cardiomyopathy (n=5) (NYHA class IV).23,24 Non-failing heart tissue was obtained 
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from donor hearts (n=10) when no suitable transplant recipient was found. The 
donors had no history of cardiac disease, a normal cardiac examination, normal ECG 
and normal ventricular function on echocardiography within 24 h of heart 
explantation. The tissue was collected in cardioplegic solution and stored in liquid 
nitrogen. Samples were obtained after informed consent and with approval of the 
local Ethical Committee (St Vincents' Hospital Human Research Ethics Committee: 
File number: H03/118; Title: Molecular Analysis of Human heart Failure). 
 
Cardiomyocyte measurements 
Single cardiomyocytes were obtained via mechanical isolation from left or right 
ventricular tissue samples, and incubated for 5 min with Triton X-100 (0.5%) to 
remove all membranes. Isometric force was measured at various calcium 
concentrations (pCa, -log[Ca2+], ranged from 4.5 to 9) at 15°C and sarcomere length 
of 2.2 µm. Figure 1A shows a single human cardiomyocyte glued between a force 
transducer and a motor. After maximal activation 4 to 5 measurements were carried 
out at submaximal [Ca2+] followed by a maximal activation. Force values obtained in 
solutions with submaximal [Ca2+] were normalized to the interpolated maximal force 
values. In a number of cells force measurements were repeated after incubation with 
the catalytic subunit of protein kinase A (PKA, 40 min; 20ºC; 100 U/mL, Sigma). 
Force registrations before and after PKA at maximal [Ca2+] (pCa 4.5) and 
submaximal [Ca2+] (pCa 5.6) are shown in Figure 1B. Maximal calcium activated 
tension (Factive, i.e. maximal force/cross-sectional area) was calculated by subtracting 
passive force (Fpassive) from the total force (Ftotal) at saturating [Ca2+] (pCa 4.5) (Fig 
1B). Passive tension (Fpas) was determined by shortening the cell in relaxation 
solution (pCa 9.0) by 20%. Ca2+-sensitivity is denoted as pCa50, i.e. pCa value at 
which 50% of Factive is reached. 
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Figure 1. Force measurements in single permeabilized cardiomyocytes. A. Single 
human cardiomyocyte at a sarcomere length of 2.2 µm. B. Isometric force measured at 
maximal [Ca2+] (pCa 4.5) and submaximal [Ca2+] (pCa 5.6) before and after protein kinase A 
in a cardiomyocyte from a patient with heart failure. 
 
In vitro motility assay 
Thin filament Ca2+ regulatory function of human troponin was studied with the 
quantitative in vitro motility assay. Regulation of TRITC-Phalloidin labelled actin 
(actin-Φ) filaments movement over immobilised rabbit fast muscle heavy 
meromyosin23,25 was defined as fraction of filaments motile and filament sliding 
speed. The actomyosin was reconstituted in a flow cell, constructed from a 
microscope slide and a siliconised coverslip. Actin-Φ was premixed with tropomyosin 
and troponin at a 10x working concentration prior to dilution and infusion into the 
assay flow cell. Thin filament movement over a bed of immobilised rabbit fast muscle 
 20 µm
A 
B 
pCa 5.6 pCa 4.5 
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heavy meromyosin (100 µg/ml) was performed and analysed as before.26 Affinity 
chromatography on immobilised monoclonal anti-troponin I antibody was used for 
purification of the whole troponin complex from human failing (IDCM) and non-failing 
donor myocardium as described previously.23 
 
Phosphorylation status of myofilament proteins 
ProQ phosphostaining 
Cardiac tissue samples (~0.5-5.0 mg dry weight) were TCA (tri-chloro acetic acid)-
treated as described previously.22 Phosphorylation status of β-AR target proteins, 
myosin binding protein C (cMyBP-C) and troponin I (cTnI), and other myofilament 
proteins (desmin, troponin T (cTnT) and myosin light chain 2 (MLC2)) was 
determined using Pro-Q Diamond phosphostaining (Molecular Probes). Samples 
were separated on a gradient gel (Criterion tris-HCl 4-15% gel, BioRad) and proteins 
were stained for one hour with Pro-Q Diamond Phosphoprotein Stain. Fixation, 
washing and de-staining were performed according to the manufacturers guidelines. 
Staining was visualized using the LAS-3000 Image Reader (FUJI; 460 nm/605 nm 
Ex/Em; 2 min illumination) and signals were analyzed with AIDA. All protein signals 
were within the linear range. Subsequently gels were stained overnight with SYPRO 
Ruby stain (Molecular Probes) and visualized with the LAS-3000 (460 nm/605 nm 
Ex/Em; 2 s illumination). The phosphorylation signals of myofilament proteins were 
normalized to SYPRO-stained cMyBP-C to correct for minor differences in protein 
loading. 
 
 Western immunoblotting 
Gel electrophoresis (15% acrylamide gels) and Western immunoblotting was 
performed to analyze bisphosphorylation of cTnI at Ser-23/24 (i.e. PKA sites, rabbit 
polyclonal Ab, dilution 1:500, Cell signaling). All signals were normalized to Ponceau-
stained actin to correct for differences in protein loading. 
 
Statistical analysis 
Data are given as means ± SEM. Data of control and failing animals/human were 
compared using unpaired Student t-tests. Effects of PKA were tested by paired 
student t-tests. The differences in pCa50 between groups were tested with one-way 
analysis of variance (ANOVA). Significance was accepted when P<0.05. All protein 
signals were visualized using the LAS-3000 Image Reader (FUJI) and signals were 
analyzed with AIDA software (Raytest). 
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Results 
Enhanced myofilament Ca2+-sensitivity in cardiac disease 
Force measurements in single cardiomyocytes revealed an increase in myofilament 
Ca2+-sensitivity in diseased (failing) myocardium in comparison to control/sham (non-
failing) hearts. Figure 2 illustrates a leftward shift of the force-pCa relationship in all 
failing models. The difference in pCa50 between failing and non-failing tissue differed 
significantly among groups (1-way ANOVA, P<0.001) and was smallest in the mouse 
myocardial infarction model (∆pCa50 = 0.05±0.01), and amounted to 0.07±0.01 in rat, 
0.12±0.01 in pig and 0.14±0.02 in human. 
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Figure 2. Ca2+-sensitivity of myofilaments in different species. A. Ca2+-sensitivity of the 
myofilaments was significantly higher in failing compared to non-failing controls in all studies. 
B. A reduction in maximal force generating capacity.was observed in post-infarct remodeled 
myocardium. C. †P<0.05, animal vs. human in Bonferroni post-test analysis. 
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Correction of enhanced myofilament Ca2+-sensitivity by exogenous 
protein kinase A 
Cardiomyocyte force measurements were repeated after incubation with exogenous 
protein kinase A. Consistent with previous studies, PKA reduced Ca2+-sensitivity of 
the myofilament in all samples.27,28 This is illustrated by the reduction in force 
development after PKA at submaximal [Ca2+] (pCa 5.4) in Figure 1B. Incubation with 
PKA abolished the difference in baseline Ca2+-sensitivity in all groups (Fig 3A). The 
reduction in pCa50 was significantly larger in failing compared to non-failing hearts in 
all models (Fig 3B). Among the failing groups the shift in pCa50 (∆pCa50) was smallest 
in MI mice and largest in end-stage failing human cardiomyocytes. 
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Figure 3. Effect of protein kinase A on myofilament Ca2+-sensitivity. A. Force-pCa 
relations after incubation with PKA. After PKA myofilament Ca2+-sensitivity did not differ 
between failing and non-failing cardiomyocytes. B. Change in pCa50 (∆pCa50) upon PKA in all 
groups. *P<0.05, failing vs. non-failing in unpaired student t-test. 
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Altered thin filament regulation 
To study if changes in troponin phosphorylation account for altered contractile 
function, Ca2+-regulation of reconstituted thin filaments was studied using quantitative 
in vitro motility assay. Ca2+-regulation of actin motiltity by troponin was studied 
comparing troponin from failing (IDCM) and non-failing (donor) human myocardium. 
In Figure 4A thin filament sliding speed and motile fraction are plotted as a function of 
[Ca2+] (i.e. pCa). Failing heart thin filament Ca2+-sensitivity was always significantly 
higher than non-failing for both sliding speed (∆pCa50 = 0.39) and fraction motile 
(∆pCa50 = 0.38). Ca2+-sensitivity of thin filament regulation was decreased when non-
failing troponin was reconstituted with recombinant PKA-phosphorylated human cTnI 
(not shown).23 When failing and non-failing donor troponin were reconstituted with 
recombinant human cTnI phosphorylated with PKA, Ca2+-regulation of thin filaments 
was similar for failing and non-failing troponin (Fig 4B). 
 
Figure 4. Ca2+-regulation of thin filaments by human troponin. Ca2+-regulation of thin 
filament motility by non-failing and failing heart troponin was compared in dual chambered 
motility cells. A. Thin filament Ca2+-sensitivity was higher for failing than non-failing troponin, 
both for sliding speed and fraction motile. B. The difference was abolished when failing and 
non-failing troponin were reconstituted with PKA-phosphorylated recombinant human cTnI. 
A 
B 
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Reduction in maximal force generating capacity in cardiac disease 
While force generation at low calcium concentrations was higher in cardiomyocytes 
from failing compared to non-failing hearts, the maximal force (Factive) generating 
capacity was significantly lower in the infarct mouse (sham: 18.5±1.8 kN/m2 and MI: 
14.6±1.1 kN/m2) and pig model. Figure 2B illustrates the absolute force values plotted 
as function of pCa in the pig model, illustrating the reduction in myofilament force 
development in cardiomyocytes from post-infarct remodeled myocardium. PKA did 
not abolish the difference in Factive (not shown). Factive did not differ in the failing rat 
model (control: 24.4±2.6 kN/m2 and failing: 29.0±2.1 kN/m2) and between human 
ISHD (33.1±3.0 kN/m2) and donor (33.8 ±2.5 kN/m2) cardiomyocytes. 
 
Correction of enhanced cardiomyocyte stiffness by protein kinase A 
Passive force did not significantly differ between cells from failing and non-failing 
hearts in the mouse, rat and pig model, while cardiomyocyte stiffness was 
significantly lower in ISHD compared to non-failing donor (Fig 5A).  PKA reduced 
Fpassive in all models. Noteworthy, recent studies in cardiomyocytes isolated from 
human biopsies,12,29 which were taken during cardiac catheterization revealed 
enhanced cardiomyocyte stiffness in patients with heart failure. The Fpassive was 
significantly lowered upon incubation with PKA. Figure 5B shows Fpassive in 
cardiomyocytes from heart failure patients with reduced left ventricular ejection 
fraction (HFREF; NYHA II-III) in comparison to controls. In both HFREF and controls 
PKA significantly reduced cardiomyocyte stiffness. The reduction in Fpassive upon PKA 
is also illustrated in Figure 1B. 
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Figure 5. Cardiomyocyte stiffness. A. Protein kinase A (PKA) reduced cardiomyocyte 
passive force (Fpassive). B. Force measurements in cardiomyocytes from human cathether 
biopsies revealed enhanced cardiomyocyte stiffness in heart failure patients with reduced left 
ventricular ejection fraction (HFREF) compared to controls. *P<0.05, failing vs non-failing in 
unpaired student t-test; #P<0.05, effect PKA in paired student t-test. 
 
 
MOUSE
Before PKA After PKA
0
1
2
3
4
5
SHAM
MI
#
#
Fp
as
 (k
N
/m
2 )
RAT
Before PKA After PKA
0
1
2
3
4
5
6 SHAM
FAILING
#
#
Fp
as
 (k
N
/m
2 )
A 
PIG
Before PKA After PKA
0
2
4
6
8
10 SHAM
MI
Fp
as
 (k
N
/m
2 )
HUMAN
Before PKA After PKA
0
1
2
3
4
5 DONOR
ISHD
*
#
#
Fp
as
 (k
N
/m
2 )
HUMAN
Before PKA After PKA
0
2
4
6
8
10 CONTROL
HFREF
*
#
#
Fp
as
(k
N
/m
2 )
B 
F p
as
si
ve
 
  F
pa
ss
iv
e 
   
F p
as
si
ve
 
   
F p
as
si
ve
 
  F
pa
ss
iv
e 
Myofilament Dysfunction in Cadiac Disease From Mice to Men 
185
 
Phosphorylation status of myofilament proteins  
ProQ Diamond staining of a pig sample incubated with and without PKA showed 
increased phosphorylation of the β-AR myofilament target proteins, cMyBP-C and 
cTnI, while MLC2 phosphorylation was decreased during the incubation (Fig 6A). 
ProQ Diamond stained samples from mouse, rat, pig and human samples are shown 
in Figure 6B. Phosphorylation signals were normalized to the SYPRO-stained 
cMyBP-C band in the same samples to correct for small differences in protein 
loading. Moreover, to correct for differences in staining between gels the 
PeppermintStick Phosphoprotein marker (PPM, Molecular Probes) was used as 
described previously22 (see PPM in Figure 7). This marker contains phosphorylated 
ovalbumin. The ProQ Diamond signal for ovalbumin is divided by the SYPRO-stained 
ovalbumin band, which is subsequently used as correction factor for inter-gel 
differences.  
Analysis of the average values for myofilament protein phosphorylation, 
obtained after correction for protein loading and inter-gel differences, revealed 
reduced phosphorylation of cMyBP-C and cTnI in failing human compared to non-
failing donor myocardium (Fig 6C). No significant changes in myofilament protein 
phosphorylation were observed between failing and non-failing mouse and rat 
samples. In pig myocardium, MLC2 phosphorylation was significantly lower in MI 
compared to sham. A similar reduction in MLC2 phosphorylation was observed in 
failing rat hearts compared to shams, although the difference was not significant 
(P=0.08). In contrast, MLC2 phosphorylation was significantly higher in end-stage 
human ISHD than in non-failing donor hearts. 
 Noteworthy, phosphorylation of cTnI is was much higher in mice cardiac 
samples in comparison to myocardium from other species, in particular pig and 
human. To determine if PKA is able to increase cTnI phosphorylation in human 
myocardium to values observed in mice myocardium, a donor and failing human 
sample were treated with exogenous PKA. The gels shown in Figure 7 illustrate that 
the effect of PKA on protein phosphorylation was only minor in the non-failing donor 
sample (5% increase in cMyBP-C, no effect on cTnI), while PKA increased cMyBP-C 
and cTnI phosphorylation in the failing sample by 27% and 130%, respectively. 
These data show that PKA-phosphorylation in non-failing donor myocardium is 
almost saturated. The relatively high phosphorylation status of cTnI observed in 
particular in mouse myocardium might reflect phosphorylation at other sites, possibly 
targeted by PKC, and may be related to differences between species and/or tissue 
handling. 
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Figure 6. ProQ-phosphostaining of myofilament proteins. A. Pig samples treated with and 
without PKA, stained with ProQ diamond. B. ProQ diamond staining of cardiac samples from 
mouse, rat, pig and human cardiac samples. Mean values for protein phosphorylation (relative 
to SYPRO-stained cMyBP-C) are given in C. Abbreviations: MHC, myosin heavy chain; 
cMyBP-C, myosin binding protein C; cTnT, troponin T; cTnI, troponin I; MLC2, myosin light 
chain 2; F, failing; D, donor; ISHD, ischemic heart disease. n, number of heart samples. 
*P<0.05, failing vs non-failing in unpaired student t-test. 
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Figure 7. SYPRO and ProQ-phospho staining of human cardiac samples treated with 
PKA. PKA incubation of a donor sample slightly increased cMyBP-C, but did not increase 
cTnI phosphorylation, while an increased ProQ-staining of cMyBP-C and cTnI was observed 
in failing myocardium treated with PKA. Please note that MLC2 phosphorylation was 
preserved during PKA treatment as the specific PP1 inhibitor, calyculin A, was present during 
incubation. Abbreviations: PPM, PeppermintStick Phosphoprotein marker; oval, ovalbumin; 
MHC, myosin heavy chain; cMyBP-C, myosin binding protein C; cTnT, troponin T; cTnI, 
troponin I; MLC2, myosin light chain 2. 
 
Western immunoblot analysis of cTnI phosphorylation at serines 23/24 
revealed significantly lower phosphorylation at the PKA-sites of cTnI in ISHD 
compared to non-failing donor myocardium (Fig 8A,B), while no significant 
differences were observed in the animal models. It should be noted that the antibody 
only detects the PKA-bis-phosphorylated form of cTnI and not mono-phosphorylated 
cTnI forms. As our analysis cannot distinguish between mono-phosphorylation of 
PKA-sites, a difference in the mono-phosphorylated forms of cTnI may still be 
present between failing and non-failing myocardium. 
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Figure 8. PKA-mediated cTnI phosphorylation. A. Western immunoblot analysis revealed 
reduced PKA-mediated phosphorylation at Ser 23/24 in cTnI in ISHD compared to non-failing 
human myocardium. B. Phosphorylation signals of cTnI were normalized to Ponceau-stained 
actin to correct for differences in protein loading. n, number of heart samples. *P<0.05, ISHD 
vs. donor in unpaired student t-test. 
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Discussion 
Activation of the βAR pathway results in enhanced cardiac contractile performance in 
response to increased circulatory demand. However, reduced responsiveness to βAR 
stimulation in heart failure is thought to limit cardiac performance during exercise. 
Functional data from all our animal and human studies are in support of reduced 
βAR-signalling, as baseline myofilament dysfunction (i.e. enhanced Ca2+-sensitivity 
and cardiomyocyte stiffness) was restored upon incubation with exogenous protein 
kinase A. However, analysis of the phosphorylation status of βAR target proteins 
revealed reduced PKA-mediated phosphorylation only in end-stage failing human 
myocardium. Moreover, the reduction in maximal force generating capacity was only 
observed in post-infarct remodelled myocardium early after MI (mouse and pig 
model), and could not be restored by PKA. The discrepancies in myofilament function 
and protein phosphorylation are discussed below. 
 
Enhanced myofilament Ca2+-sensitivity and stiffness 
In healthy myocardium, myofilament Ca2+-sensitivity is reduced upon βAR stimulation 
and is thought to exert a positive lusitropic effect on cardiac performance.30 The 
reduction in myofilament Ca2+-sensitivity has been ascribed to PKA-mediated 
phosphorylation of cTnI and cMyBP-C.5,6 As a consequence of reduced βAR 
signalling in heart failure, reduced PKA-mediated phosphorylation would result in an 
enhanced myofilament Ca2+-sensitivity. Our functional measurements in single 
cardiomyocytes revealed an increase in myofilament Ca2+-sensitivity in all failing 
heart models (Fig 2A), which could be corrected by exogenous PKA (Fig 3). In vitro 
motility analysis of regulation of thin filament movement by troponin from failing and 
non-failing human myocardium revealed a similar increase in Ca2+-sensitivity in failing 
myocardium (Fig 4A). Moreover, troponin regulation of thin filaments was similar 
when failing and non-failing human troponin was reconstituted with PKA-
phosphorylated recombinant human cTnI (Fig 4B). This indicates that reduced 
phosphorylation of the PKA-sites in cTnI (Ser 23/24) accounts for the enhanced 
myofilament Ca2+-sensivity observed in end-stage failing human myocardium. 
The difference in Ca2+-sensitivity between failing and non-failing hearts was 
smallest in mice and largest in human. The relatively small difference between MI 
and sham mice (Fig 2A) and small effects of PKA (Fig 3A) may be explained by the 
relatively high baseline cTnI phosphorylation status (Fig 6) in these animals. Defects 
in βAR signalling may be difficult to uncover in mice due to the small dynamic range 
in response to βAR stimulation. Although, the direction of the change in pCa50 was 
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similar in all heart failure models, Bonferroni post-test analysis revealed that the 
difference in pCa50 (∆pCa50) between failing and non-failing cardiomyocytes was 
significantly larger in human compared to the mouse and rat model, while ∆pCa50 
(failing vs. non-failing) did not differ from the pig model (Fig 2C). Hence, large animal 
models may be more representative to investigate consequences of βAR stimulation 
on myofilament protein phosphorylation and function. 
Alternatively, the smaller differences in pCa50 in rodents and absence of 
reduced phosphorylation of βAR target proteins in animal models in contrast to 
human, may be a reflection of disease progression, as the human studies involve 
end-stage heart failure. During earlier stages of heart failure, such as present in the 
animal studies, defects in βAR signalling may be less severe, and the functional and 
proteomic phenotype observed in less severe stages of cardiac disease may be the 
resultant of changes in other signalling pathways as well. Within our human studies 
we observed a striking difference in cardiomyocyte stiffness, which may relate to 
severity of cardiac disease. In agreement with previous studies31-33 cardiomyocyte 
stiffness in end-stage human heart failure was lower in comparison to non-failing 
donors (Fig 5A). It has been proposed that the reduction in Fpassive is due to a shift in 
titin isoform composition, from the stiff N2B to the more compliant N2BA isoform.31,32 
In contrast, recent measurements in cardiomyocytes isolated from catheter biopsies 
from patients with less severe forms of heart failure (NYHA II-III) revealed enhanced 
cardiomyocyte stiffness in all heart failure patients, which was largely corrected with 
PKA.12,29,34 In these samples, a similar shift in titin isoform composition was found as 
observed in end-stage heart failure. However, analysis of titin phosphorylation 
indicated differential titin isoform phosphorylation as possible cause for enhanced 
cardiomyocyte stiffness and may involve reduced protein kinase G-mediated 
phosphorylation.35,36 
The functional consequences of impaired PKA-mediated phosphorylation may 
be balanced by changes in other kinases. In congestive heart failure models in rat 
(pressure overload and MI), reductions in Fmax and in Ca2+-sensitivity were 
associated with increased protein kinase C (PKC) expression.37 Increased 
phosphorylation of cTnI was observed in failing rat myocardium and deficits in 
myofilament function were corrected by phosphatase treatment. It has been 
proposed that the relative balance of phosphorylation of the 3 PKC-sites on cTnI (Ser 
43/45 and Thr 144) is important for the regulation of its function.38 
Pseudophosphorylation of Ser 43/45 significantly reduced myofilament response to 
Ca2+ 39 and phosphorylation of Thr 144 induced an increase in sensitivity to Ca2+.40 
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Increased PKC activity and isoform expression has been reported in human heart 
failure.41-43 However, it remains to be investigated if PKC targets the myofilament 
proteins in vivo.44 Recent mass spectrometry analysis revealed a novel in vivo 
phosphorylation site in human cTnI (Ser 76/Thr 77), which may be target of PKC.45 
To establish if PKC-mediated protein phosphorylation impacts myofilament function 
in human cardiac disease quantitative mass spectrometry should be performed in 
cardiac samples, which are obtained under well-defined conditions, preferably before 
and after in vivo receptor stimulation. 
 
Reduced maximal force generating capacity 
The maximal force generating capacity of cardiomyocytes from remodelled 
myocardium early after a myocardial infarction was reduced and, unlike pCa50 and 
Fpassive, was not corrected by PKA. An important role has been assigned to PKC-
mediated phosphorylation of cTnT at Thr 206,40 and cTnI at Ser 43/45 39 in reducing 
myofilament Factive. However, up to date, no changes in cTnT phosphorylation have 
been reported in any heart failure model (Fig 6). Moreover, using an elegant troponin 
exchange method in failing and non-failing rat cardiomyocytes, Belin et al. (2006)46 
showed that replacement of failing troponin by non-failing troponin restored 
myofilament Ca2+-sensitivity to values observed in non-failing cardiomyocytes, but not 
Factive. Hence, alterations in troponin phosphorylation underlie changes in myofilament 
Ca2+-sensitivity, but are not the cause of reduced maximal force generating capacity. 
 In our previous study in MI mice,16 exercise prevented the reduction in Factive, 
which was associated with an increase in MLC2 phosphorylation, although MLC2 
phosphorylation was not significantly reduced in MI (Fig 6B,C). A transmural gradient 
in MLC2 phosphorylation has been described in rodent studies.47-49 A reduction in 
MLC2 phosphorylation in myocardium from MI mice may have been obscured by 
regional differences, as a significant reduction in MLC2 phosphorylation was 
observed in subendocardial tissue from MI pigs (Fig 6B,C). Accordingly, a recent 
study in rats with ischaemic heart failure50 revealed impaired contractile function and 
reduced MLC2 phosphorylation only in subendocardial cardiomyocytes, which were 
both restored by exercise training. It has been proposed that the overall pattern of 
cardiac contraction depends on a spatial gradient of MLC2 phosphorylation,47 and 
loss of the MLC2 phosphorylation gradient may impair cardiac performance.47,49 
Hence, myofilament function may be hampered by alterations in MLC2 
phosphorylation. Investigation of transmural biopsies taken under well-controlled 
hemodynamic conditions allow careful analysis of MLC2 phosphorylation at rest and 
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during enhanced cardiac load (i.e. upon receptor stimulation) and would allow 
investigation of the importance of a transmural MLC2 phosphorylation gradient for 
cardiac contraction in a large animal model. As the opposite changes in MLC2 
phosphorylation in animal models with ischemic heart disease (reduction) and end-
stage failing human ischemic cardiomyopathy (increase) may relate to severity of 
cardiac disease, changes during the progression of cardiac disease should be 
addressed as well. 
In conclusion, cardiomyocyte force measurements revealed enhanced 
myofilament Ca2+-sensitivity and passive stiffness, which were both largely corrected 
with exogenous PKA indicative for hypo-phosphorylation of βAR target proteins. 
When translated to in vivo cardiac performance, an enhancement in myofilament 
Ca2+-sensitivity and cardiomyocyte stiffness would both limit cardiac relaxation. This 
is illustrated by the positive correlation between high left ventricular end-diastolic 
pressures (LVEDP) in heart failure patients and high cardiomyocyte stiffness.12 As 
high LVEDP could not be solely attributed to increased cardiac collagen, high LV 
filling pressures may be in part explained by high intrinsic stiffness of the 
cardiomyocytes. Though limiting relaxation, the enhanced myofilament Ca2+-
sensitivity might increase cardiomyocyte force development and increase cardiac 
contractility.  
Although the enhanced myofilament Ca2+-sensitivity in failing myocardium 
would enhance cardiomyocyte contractility, a reduction in Factive would counteract this. 
This is illustrated by the relationship between absolute force development and pCa in 
Figure 2B. In vivo, the impact of altered myofilament function depends on cytosolic 
[Ca2+] during the different phases of the cardiac cycle. As systolic calcium levels are 
reduced in failing cardiomyocytes, it may be speculated that myofilament  
dysfunction in remodelled myocardium after MI further deteriorates cardiac 
performance. 
 
Future perspectives 
Our data illustrate the need for careful tissue handling under well-defined conditions, 
preferably at the time of hemodynamic measurements, and careful analysis of the 
myofilament phosphoproteome. Research on the cellular mechanisms underlying 
human heart failure is hampered by the limited availability of biopsy material and, 
since biopsies are routinely obtained at one time point, by the lack of information on 
the dynamic aspects of the processes involved. The dynamic changes in cellular 
signalling critically depend on the phosphorylation status of a number of target 
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proteins. Analysis of dynamic changes in intracellular signalling pathways and the 
interaction between kinases and phosphatases and their specific myofilament target 
proteins within intact cells is essential to establish a direct relation between changes 
in myofilament protein phosphorylation and myofilament dysfunction in heart failure. 
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Summary 
In this thesis alterations in cellular function and structure were studied in heart failure 
with different underlying cause and phenotype to obtain insight into the cellular 
pathomechanisms underlying progressive deterioration of left ventricule pump 
function in human heart failure. The results obtained may be used to develop new-
targeted therapeutic interventions for the treatment of heart failure in the future. Here, 
the main findings of the studies are presented and the implications of the findings for 
clinical practice and future research are discussed. 
 
Chapter 1. In this chapter an introduction to the background and methods of the 
studies is given. The aim of this thesis is defined.  
 
Chapter 2. In this chapter we focused on the functional role of individual sarcomeric 
protein isoforms and of post-translational protein modifications such as proteolysis and 
phosphorylation in diseased myocardium. In failing myocardium, sarcomeric 
dysfunction includes depressed maximum force development, increased calcium-
sensitivity and increased passive stiffness. These changes could be largely explained 
by altered phosphorylation of sarcomeric proteins including troponin I, titin, myosin 
binding protein C and myosin light chain 2. Changes in phosphorylation are most 
likely caused by neurohumoral-induced alterations in the kinase-phosphatase 
balance inside the cardiomyocytes. A therapy which specifically targets 
phosphorylation sites within sarcomeric proteins or the kinases and phosphatases 
involved might be used to improve cardiac function in heart failure.  
 
Chapter 3. Abnormalities in β-adrenergic receptor (βAR) signal transduction are not 
only involved in impairment of cardiac function, but they also play a role in the 
structural changes observed in heart failure. An increase in catecholamines resulted 
in down regulation and desensitization of the βAR. Moreover, it is evident that 
prolonged adrenergic stimulation causes alterations of the expression and activity of 
downstream components of the βAR signal transduction cascade.  
In Chapter 3 a comparison was made between left ventricular tissue samples 
from patients with ischemic cardiomyopathy (ISHD) and idiopathic cardiomyopathy 
(IDCM) in order to investigate whether changes in the βAR signal transduction 
pathway translate into diverse functional and structural alterations. Donor hearts 
served as non-failing controls. Diverse changes were found in cellular function and 
structure in failing human myocardium with different underlying cause. In both groups 
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a marked reduction was found in the number of β1AR and β2AR. Different alterations 
in the expression level of G-coupled recptor kinase 5, G-inhibitory, protein 
phosphatase 1 and myosin light chain 2 phosphorylation were found between ISHD 
and IDCM. Furthermore, differences in sarcoplasmic reticulum calcium ATPase 
(SERCA2a) expression and phospholamban/SERCA2a ratio between ISHD and 
IDCM were found. Cardiomyocyte force measurements showed differences in 
calcium sensitivity, which could be explained by a difference in TnI phosphorylation. 
A lower collagen volume fraction in ISHD was found compared to IDCM using 
histological analyses. 
Our results indicate that alterations in the βAR signaling pathway and in 
cardiomyocyte structure and function depend on underlying cause. These findings 
highlight the different alterations in ISHD and IDCM, which may modify heart failure 
risk, prognosis and response to treatment. 
 
Chapter 4. Fabry disease is an inherited X-linked inborn lysosomal storage disorder 
characterized by intracellular glycosphingolipid depositions resulting from deficient α-
galactosidase A activity. To reveal if alterations in myofilament function and protein 
composition contribute to left ventricule myocardial dysfunction in Fabry disease 
patients, both were determined in left ventricule endomyocardial biopsies of patients 
with the cardiac variant of Fabry disease. In addition cardiomyocyte cross sectional 
area, area of glycosphingolipid vacuoles, myofibrillolysis and extent of fibrosis were 
determined. Our data showed high cardiomyocyte passive stiffness and low active 
tension which may both contribute to left ventricule myocardial dysfunction observed 
in Fabry disease patients. The high resting tension relates to the observed diastolic 
LV dysfunction and may be partly explained by decreased phosphorylation of 
myofibrillar and/or cytoskeletal proteins, while the low active tension relates to 
reduced tissue Doppler systolic shortening velocity and may be due to proteolysis of 
troponin I and desmin. As cardiomyocyte stiffness is an important determinant of left 
ventricule stiffness in heart failure, the augmented passive stiffness in Fabry disease 
patients may be detrimental for left ventricule diastolic function.  
 
Chapter 5. The aims of β-blocker therapy are to improve survival and quality of life of 
patients. To investigate if β-blocker therapy induces disparate effects in heart failure 
with normal ejection fraction (HFNEF) and heart failure with reduced ejection fraction 
(HFREF), this chapter compared myocardial structure, function and protein 
composition in HFNEF and HFREF patients without or with β-blocker therapy.  
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Changes in active tension, calcium sensitivity and troponin I phosphorylation are 
shared by HFNEF and HFREF and are all beneficial for left ventricule contractility. 
Changes in collagen volume fraction, cardiomyocyte diameter and passive stiffness 
are unique to HFNEF and affect diastolic left ventricule function. Lower G-inhibitory is 
unique to HFREF and may improve left ventricule contractility. β-blocker therapy 
induces myocardial effects unique to HFNEF or HFREF. This may explain the 
dissimilar outcome of β-blocker therapy in HFNEF and HFREF phenotype. The 
clinical benefits obtained with β-blocker therapy are multi-factorial, involving 
improvement of calcium handling, reversal of cardiac remodeling, improved cardiac 
efficiency. Our data showed diverse effects of β-blocker therapy on myofilament 
function. Myofilament contractile reserve to β-adrenergic stimulation (i.e. exogenous 
PKA) was blunted in HFNEF+β and enhanced in HFREF+β. Our data indicate that β-
blocker therapy may improve systolic cardiac function in HFNEF patients by an 
increase in active cardiomyocyte force development and a reduction in 
cardiomyocyte hypertrophy. However, an increased passive stiffness was observed 
in cardiomyocytes from HFNEF patients receiving β-blocker therapy, which was no 
longer corrected to normal values upon PKA treatment. As it is generally believed 
that the dominant pathophysiological mechanism in HFNEF patients is abnormal 
diastolic function, our observations do not provide mechanistic evidence to support 
the use of β-blockers in HFNEF. 
 
Chapter 6. Raised diastolic left ventricule stiffness importantly contributes to heart 
failure in diabetes mellitus (DM) and results from myocardial deposition of advanced 
glycation endproducts (AGEs) and interstitial fibrosis. In diabetic patients with heart 
failure a contribution to this high diastolic left ventricule stiffness of an elevated 
passive stiffness has so far not been assessed. This study was designed to compare 
myocardial fibrosis, AGEs deposition and passive stiffness of isolated 
cardiomyocytes between diabetic and non-diabetic HFNEF patients and between 
diabetic and non-diabetic HFREF patients. Increased myocardial collagen volume 
fraction was found only in diabetic patients with HFREF, while elevated 
cardiomyocyte passive stiffness was present only in diabetic patients suffering from 
HFNEF. Diabetes increased myocardial AGEs deposition in patients with HFREF and 
less so in HFNEF patients. The question remains if β-blocker therapy reverses the 
changes observed in cardiomyocyte function and structure in heart failure patients 
with diabetes mellitus, especially the high passive stiffness observed in HFNEF 
patients. It is therefore very important to understand the cellular pathophysiology of 
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the β-blocker therapy in these patients, to improve the clinical outcome of patients 
with diabetic cardiomyopathy. 
Chapter 7.  In this chapter, we investigated whether the antibodies directed against 
β-adrenergic receptors can be used to determine expression of β-adrenergic 
receptors (βAR) in human myocardium. Using western blotting we investigated the 
specificity of commercially available antibodies directed against β1AR and β2AR in 
human left ventricular tissue.  The antibodies recognized several protein bands at 
different molecular weights in human myocardial samples and also multiple proteins 
in Chinese hamster ovary (CHO) cells expressing β1AR, β2AR and even β3AR, 
indicating that these antibodies are not specific and are not suited to study 
expression of β-adrenergic receptor in myocardium.  
 
Chapter 8. In this review an overview is given of the perturbed balance between 
receptor-mediated kinases and phosphatases coordinating phosphorylation of 
regulatory proteins involved in cardiomyocyte contractility during heart failure. The 
imbalance between kinases and phosphatases is related to increased neurohumoral 
stimulation to enhance cardiac pump function in heart failure. The data from different 
animal and human studies underline the importance of careful biopsy procurement, 
and the need to investigate localization of kinases and phosphatases within the 
cardiomyocyte. 
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Conclusion 
The research in this thesis was limited to the most important signal transduction 
pathway in the heart and the most frequent drug therapy in heart failure, in order to 
understand the alterations in the pathophysiology of heart failure patients. Despite 
the different studies performed, it is still unclear how we can improve the quality of life 
and prolong survival in patients with heart failure. Other options need to be taken in 
to consideration for a better therapy of patients with heart failure.  
Altered maximum force development, calcium sensitivity and increased passive 
stiffness largely originate from changed sarcomeric proteins in diseased myocardium, 
caused by neurohumoral-induced alterations in the kinase-phosphatase balance 
inside the cardiomyocytes. However alterations in β-adrenergic signaling pathway 
and cardiomyocyte function and structure depend on underlying cause of the 
cardiomyopathy. Therefore, these differences may explain in part the dissimilar 
outcome of β-blocker therapy in HFNEF and HFREF.  
Overall, the findings presented in this thesis indicate that cellular changes in heart 
failure depend on underlying cause and phenotype of the disease.  
 
Future perspectives  
In the chapter 2, 5 and 6 of this thesis it has been shown that Fpassive and pCa50 
remained higher after PKA treatment in β-blocker treated HFNEF patients. This 
increase may result from changes in the phosphorylation status of different 
myofilament proteins (e.g. titin, MyBP-C).  Apart from protein kinase A (PKA), other 
kinases are of interest. In particular preotein kinase G (PKG) since myocardial activity 
of PKG can be increased by nitric oxide (NO) and natriuretic peptides and improve in-
vivo diastolic LV stiffness in humans and in experimental rodent models. In pilot 
experiments (Hamdani et al. Circulation. 2007;116:S_708. Abstract), it has been 
shown that PKG treatment reduced Fpassive in HFNEF cells. Moreover the fall in Fpassive 
observed after PKG equals the fall in Fpassive observed after PKA, suggesting that 
PKG phosphorylates the same myofilament proteins as PKA. It would be of interest 
to find out whether PKG can be used as a target in drug therapy. Apart from 
phosphorylation, post-translational modifications resulting from oxidative stress might 
impair sarcomeric function and may explain part of the increased Fpassive and pCa50. 
Further research has to be done to investigate the involvement of such protein 
alterations in sarcomeric function in heart failure. 
Raised diastolic LV stiffness importantly contributes to heart failure in DM 
patients and results from myocardial deposition of advanced glycation endproducts 
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(AGEs), interstitial fibrosis, cardiomyocyte hypertrophy and elevated diastolic Fpassive 
of cardiomyocytes (chapter ). Pilot data (Hamdani et al. Circulation. 2008;116:S_953. 
Abstract) have shown that in HFNEF patients with diabetic cardiomyopathy, β-blocker 
therapy lowered CVF but increased Fpassive of cardiomyocytes. The role of 
glycosylation of sarcomeric proteins, in particular in patients with diabetic 
cardiomyopathy, warrants further research. 
Large-scale trials have shown that different β-blockers (bisoprolol, carvedilol, 
metoprolol) exert similar effects on clinical outcome. Based on their specific βAR 
blocking properties these drugs are divided into second generation β-blockers 
(bisoprolol, metoprolol), which selectively block β1ARs and aspecific, third generation, 
β-blockers (carvedilol), which also block  β2ARs and α1ARs. Despite their similar 
effects on clinical outcome, the cellular effects might be diverse in both heart failure 
phenotypes HFNEF and HFREF. Further research in this area would be important to 
clarify their effect on the heart. Moreover it would be of interest to assess whether 
there are gender differences of β-blockers on the structure and the function of 
cardiomyocytes. 
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In dit proefschrift zijn de veranderingen in cellulaire functie en structuur in hartfalen 
met verschillende onderliggende oorzaken en fenotype bestudeerd. Dit om inzicht te 
krijgen in de cellulaire pathomechanismen die bijdragen aan de progressieve afname 
in de pompfunctie van het hart in patiënten met hartfalen. De verkregen resultaten 
kunnen gebruikt worden om nieuwe therapeutische interventies te ontwikkelen voor 
toekomstige behandeling van hartfalen. 
 
Hoofdstuk 1 bevat een introductie met de achtergrond en de methoden van de 
studies beschreven in dit proefschrift.  
 
Hoofdstuk 2. In dit hoofdstuk is de functionele rol van de individuele sarcomeer eiwit 
isovormen en de post-translationele eiwit modificaties, zoals eiwit degradatie en 
fosforyleringsgraad, beschreven. Door een veranderde eiwitsamenstelling is de 
functie van de sarcomeren in hartspiercellen van patiënten met hartfalen veranderd. 
Deze sarcomeer disfunctie betreft een afname in maximale krachtsontwikkeling en 
een toename van de calcium gevoeligheid en passieve stijfheid. Deze veranderingen 
kunnen voor een groot deel verklaard worden door de veranderde 
fosforyleringsgraad van sarcomeer eiwitten zoals troponine I, titine, het myosine 
bindend eiwit C en myosine lichte keten 2. Veranderingen in fosforylatie kunnen 
mogelijk verklaard worden door wijzigingen in de kinase-fosfatase balans in de 
hartspiercellen. Kennis betreffende fosforylatie plaatsen van sarcomeer eiwitten en 
de kinasen en fosfatasen kan gebruikt worden om nieuwe therapeutische strategieën 
te ontwikkelen om de pompfunctie van het hart bij hartfalen te verbeteren. 
 
Hoofdstuk 3. afwijkingen in de β-adrenerge signaalroute zijn niet alleen betrokken bij 
verslechtering van de hartpompfunctie, maar spelen ook een rol bij de structurele 
veranderingen die geobserveerd zijn bij hartfalen. Een toename in catecholamines 
resulteert in afname in het aantal β-adrenerge receptoren aan de celmembraan. 
Tevens zijn de β-adrenerge receptoren minder gevoelig voor catecholamines.  
In hoofdstuk 3 is een vergelijking gemaakt tussen  hartweefsel van patiënten 
met een ischemische hartziekte (ISHD) en idiopathische hartspierziekte (IDCM) om 
te onderzoeken of de veranderingen in β-adrenerge receptor signaalroute een 
verklaring kunnen bieden voor de verschillen in functie en structuur van het 
hartspierweefsel. Donor harten zijn gebruikt als gezonde controles. In beide groepen 
is een duidelijke afname in het aantal β-adrenerge receptoren gevonden. 
Uiteenlopende veranderingen zijn gevonden in de expressieniveaus van onderdelen 
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van de β-adrenerge receptor signaalroute tussen ISHD en IDCM harten. Bovendien 
is er een verschil gevonden in de expressie van het eiwit betrokken bij de 
calciumhuishouding in de hartspiercel, het sarcoplasmatisch reticulum calcium 
ATPase (SERCA2a). Krachtmetingen in enkele hartspiercellen toonden aan dat het 
calcium gevoeligheid hoger was in IDCM dan in ISHD harten, wat verklaard kon 
worden door het verschil in troponine I fosforyleringsgraad. Histologische analyses 
toonden minder collageen aan in ISHD ten opzichte van IDCM. 
De resultaten laten zien dat componenten van de β-adrenerge receptor 
signaalroute en de structuur en functie van hartspiercellen verschillen tussen ISHD 
and IDCM patiënten. Deze verschillen kunnen een basis vormen voor een meer 
specifieke therapie in de verschillende patiëntgroepen.  
 
Hoofdstuk 4. Fabry ziekte is één van de lysosomale stapelingsziekten. Deze ziekte 
wordt gekenmerkt door een tekort aan het enzym α-galactosidase A. Om te weten te 
komen of veranderingen in myofilament functie en eiwitsamenstelling bijdragen aan 
disfunctie van het hart bij Fabry patiënten, is in dit hoofdstuk onderzoek gedaan naar 
structuur en functie van hartspierweefsel van patiënten met Fabry. Onze data 
toonden een hoge passieve stijfheid en een lage actieve kracht in hartspiercellen van 
Fabry patiënten, welke mogelijk kunnen bijdragen aan de verminderde pompfunctie 
van het hart. De hoge passieve stijfheid kan oorzaak zijn van de verminderde 
diastolische functie. Het hart kan zich minder goed ontspannen. Dit kon deels 
verklaard worden door een verlaagde fosforylatiegraad van contractiele eiwitten. De 
lage actieve kracht kan leiden tot een verminderde pompfunctie en zou mogelijk 
veroorzaakt kunnen zijn door degradatie van troponine I en desmine. 
 
Hoofdstuk 5. Het doel van bètablokker therapie is om de mortaliteit en kwaliteit van 
leven van patiënten te verbeteren. Eerder onderzoek heeft aangetoond dat 
bètablokkertherapie en gunstig effect heeft op het calcium huishouding in de 
harspiercel, de cardiale remodelering tegengaat en een verbetering geeft van de 
cardiale efficiëntie. 
Om te onderzoeken of bètablokker therapie overeenkomstige effecten induceert bij 
patiënten met hartfalen met normale ejectie fractie (HFNEF) en hartfalen met een 
verlaagde ejectie fractie (HFREF), zijn in dit hoofdstuk de effecten van de 
bètablokker therapie bestudeerd op structuur, functie en eiwit samenstelling van 
hartspierweefsel van HFNEF en HFREF patiënten.  
Onze metingen toonden uiteenlopende effecten van bètablokker therapie op 
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myofilament functie. Onze data gaven aan dat bètablokker therapie de systolische 
pompfunctie kan verbeteren bij patiënten met een normale ejectie fractie door een 
toename van de actieve krachtontwikkeling voor de hartspiercellen en een vertraging 
of omkering van hartspiercelhypertrofie. Echter, een verhoogde passieve stijfheid 
werd gevonden in hartspiercellen van HFNEF patiënten behandeld met bètablokkers, 
welke niet meer gecorrigeerd kon worden met proteïne kinase A behandeling. Onze 
observaties geven geen mechanistisch bewijs om het gebruik van bètablokkers in 
patiënten met een voornamelijk diastolische disfunctie te ondersteunen.  
 
Hoofdstuk 6. Toegenomen diastolische hartspierstijfheid draagt aanzienlijk bij aan 
het ontwikkelen van hartfalen in patiënten met diabetes mellitus (DM) en is het 
gevolg van myocardiale afzetting van zgn. “advanced glycation endproducts” (AGEs) 
en van interstitiële fibrose. In dit hoofdstuk is onderzocht of passieve stijfheid van 
geïsoleerde  hartspiercellen bijdraagt aan de diastolische disfunctie bij diabetes 
patiënten met hartfalen. Een vergelijking is gemaakt van myocardiale fibrose, 
afzetting van AGEs en de passieve stijfheid van hartspiercellen tussen diabetische 
en niet-diabetische patiënten met hartfalen. Alleen bij  diabetes patiënten met een 
lage ejectie fractie was de myocardiale collageen hoeveelheid verhoogd, terwijl de 
toegenomen passieve stijfheid van hartspiercellen alleen werd gevonden bij 
diabetische patiënten met een diastolische disfunctie. De vraag blijft of 
bètablokkertherapie de veranderingen die geconstateerd zijn in hartspiercel functie 
en structuur bij  hartfalen patiënten met diabetes mellitus, met name de hoge 
passieve stijfheid, verbetert. Het is daarom van belang om de veranderingen in 
eiwitsamenstelling, en mate name de post-translationele modificaties van eiwitten 
verder te onderzoeken in patiënten met diabetische cardiomyopathie voor het 
optimaliseren van de behandeling. 
 
Hoofdstuk 7. In dit hoofdstuk is onderzocht of de antilichamen gericht tegen β-
adrenerge receptoren gebruikt kunnen worden om de expressie van β-adrenerge 
receptoren in humaan hartspierweefsel te bepalen. Met western blot analyses werd 
de specificiteit van antilichamen, gericht tegen β1 en β2 adrenerge receptoren, in 
humaan hartspierweefsel onderzocht. De antilichamen herkenden meerdere eiwitten 
met verschillende moleculaire gewichten in het humane hartspierweefsel. Opvallend 
was dat deze antilichamen ook verschillende eiwitten herkenden in gekweekte 
ovarium cellen van de chinese hamster waarin de expressie van β1, β2 en zelfs β3 
adrenerge receptoren verhoogde was. De resultaten duiden aan dat deze 
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antilichamen niet specifiek zijn en niet  geschikt zijn om de expressie van β-
adrenerge receptoren in humaan hartspierweefsel te bestuderen.  
 
Hoofdstuk 8. In dit overzichtsartikel wordt de verstoorde balans beschreven tussen 
receptor-gemedieerde kinasen en fosfatasen die de fosforyleringsgraad van 
contractiele eiwitten tijdens hartfalen veranderen. De disbalans tussen kinasen en 
fosfatasen is gerelateerd aan de verhoogde neurohumorale stimulatie om de pomp 
functie van het hart bij hartfalen te verhogen. De resultaten  van diverse proefdier en  
humane studies verklaren het belang van het op zorgvuldige wijzen verwerven van 
bioptmateriaal en de noodzaak  om de lokalisatie van kinasen en fosfatasen in 
hartspiercellen te bestuderen. 
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Het lijkt nog als de dag van gisteren dat ik begonnen ben met mijn 
promotieonderzoek, maar inmiddels zijn er 4 jaar voorbij. Ik heb mijn werk altijd met 
veel plezier en genot gedaan. Het waren mooie jaren, waarin ik veel heb geleerd. 
Natuurlijk doe je een proefschrift niet alleen. Je hebt altijd mensen nodig, mensen die 
je kunnen helpen en steunen. Hierbij wil ik de vele mensen bedanken voor hun hulp 
en steun. 
 
Mijn co-promotor dr. Jolanda van der Velden, altijd met een brede glimlach. Bij jou wil 
ik even stil staan: je bent mijn co-promotor en mijn directe begeleidster. Ten eerste 
wil ik je bedanken voor de mogelijkheid die je mij hebt gegeven om onderzoek bij je 
te mogen doen, voor de vrijheid die je mij gaf en voor je vertrouwen. Ik heb veel van 
je geleerd, alles wat betreft onderzoek, nadenken over de experimenten, plannen, 
uitvoeren en schrijven. Samen hebben we het altijd leuk gehad en ook in de 
toekomst met het project van ESC en wie weet bij misschien nog meer projecten in 
de toekomst. Wat ik vooral enorm aan je waardeer, is je enthousiasme voor het vak 
en onderzoek, je positieve instelling, je goede ideeën, je creativiteit, je volledige 
toewijding aan de wetenschap en de goede balans die je hebt tussen werk en privé 
met 4 mannetjes thuis. Verder verraste je mij keer op keer door de enorme 
hoeveelheid energie die jij hebt en het warme persoonlijke contact dat je onderhoudt 
met mij en met andere mensen. Jouw deur stond letterlijk altijd open voor vragen. Je 
nam altijd de tijd om mijn manuscripten en proefschrift kritisch te lezen ondanks de 
drukte. Bedankt voor alles en voor wat je me geleerd hebt binnen dit vakgebied, 
maar ook voor de overige dingen die geen betrekking hebben op het werk, onder 
anderen je gastvrijheid. Natuurlijk wil ik jouw mannetjes niet vergeten. Bas bedankt 
voor alle gezelligheid en voor het feit dat ik altijd welkom bij jullie was. Tomas, Mike 
en Boris bedankt voor de kusjes, de knuffeltjes en de tekeningen.   
 
Mijn promotoren Prof. dr. Walter J. Paulus en Prof. dr. Ger J.M. Stienen, jullie 
enthousiasme, ideeën, enorm gedrevenheid, inzet en relativeringsvermogen waren 
zeer belangrijk voor het succes van dit onderzoek. Betere promotoren en co-
promotor zoals jullie kan een AIO zich niet wensen. 
Prof. dr. Walter J. Paulus, je hebt ervoor gezorgd dat ik naast mijn 
promotieonderzoek ook verschillende samenwerkingsprojecten deed zowel in het 
binnen als het buitenland. Je enthousiasme voor het vak en je grote ideeën heb ik 
veel van geleerd en hebben mij enorm geïnspireerd. Bedankt voor het meedenken 
en jouw kritische inbreng, bedankt voor alles wat ik van je heb geleerd en vooral het 
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schrijven. 
Prof. dr. Ger J.M. Stienen, hartelijk dank voor je kritische blik op zowel een 
manuscript, als een aanvraag. Jouw gehele overzicht van probleemstellingen heeft 
niet alleen tot aanzienlijk betere artikelen geleid, maar heeft mij ook een breder 
inzicht gegeven. Jouw deur stond en staat altijd voor mij en voor alle andere AIO’s 
open, voor zowel korte als lange vragen, je zegt nooit nee ondanks het feit dat je het 
erg druk hebt. Ik heb veel van jou geleerd, van kritisch naar dingen kijken tot 
schrijven. Bedankt voor alles en ook voor de snelle commentaren en correcties. Ik 
ben erg blij dat ik de komende tijd nog als post-doc in de groep blijf werken en nog 
meer van jullie kan leren.  
 
Mijn paranimfen Nicky en Pauline. Lieve Nicky, vanaf het eerste moment had ik het 
idee dat we elkaar altijd wel ‘begrepen’, al was het maar om de bepaalde cynische 
humor die jij en ik hebben. Met jou kan ik altijd veel lachen, dus niet gek dat je mijn 
paranimf bent. Ik heb van jou alle technieken geleerd, je stond altijd klaar voor mij. 
Bovendien, je bent mijn grootste sushi-, bioscoop-, lekker-eten- maatje en af en toe 
samen met de trein! reizen naar Londen, rarararara hoe komt dat? Een kaartje kopen 
voor de musical Chicago voor 25 pond en vervolgens slapen tijdens de show, dat 
doe je goed! Binnenkort ga je een grote reis maken met Thomas. Ik wens je veel 
plezier en succes, geniet en maak er wat van. Bedankt voor al je hulp en 
gezelligheid.  
Lieve Pauline, je bent mijn beste vriendin we kennen elkaar al jaren. Het is dus voor 
mij logisch dat je mijn paranimf bent. Het is voor mij een eer dat je 4 juni naast mij zal 
staan als ik mijn proefschrift moet verdedigen, we hebben het altijd leuk samen 
bedank voor je hulp, voor alle goede zorgen en luisterend oor. Ik ben erg blij met je 
vriendschap. Bedankt voor alles. 
 
Kamer B-156, een onvergetelijke kamer. De afgelopen jaren was dit mijn thuisbasis 
en het heeft vele verschillende bewoners gehad: Viola, Loek, Attila, Ines, Nadija, 
Sander, Koen en Daniel. Jullie allen ontzettend bedankt voor de gezelligheid. Beste 
Viola, of anders gezegd “snoepmonster” die niet zomaar snoepmonster wordt 
genoemd. Je bent mijn koffie- en theemaatje. Het is altijd leuk om jou als 
kamergenoot te hebben. Ik ben blij dat ik nog even mag blijven tot eind november en 
je gezelschap kan houden.  Bedankt voor je steun, gezelligheid, snoepjes en 
natuurlijk je luisterend oor. Jij en Nicky zorgden voor de nodige afleiding en 
gemeende belangstelling die ik nodig had tijdens de vele uren werk. Veel succes met 
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je verdere carrière en met je eigen promotie de komende anderhalf jaar! Loek, ik heb  
altijd een goede en fijne samenwerking met jou gehad. Ook was het super gezellig 
om met jou koffie te drinken. Veel succes met je opleiding als cardioloog en met je 
eigen promotie.  
 
Ik heb met verschillende collega’s in zowel binnen- als buitenland mogen 
samenwerken:  
Dr. C. Chemilti from Italy, I. Falcao-Pires from Portugal, dr. A. Borbely and D. 
Czurigad from Hungery, prof.dr. MC. Michel from Amsterdam, M. Swinnen and D. 
Vanhoutte from Maastricht.  
Dr. C. Chimenti, thank you for the collaboration. Attila, during your stay in Amsterdam 
we had lots of fun! Cleaning and taking care of the room was the major part that I 
missed of you when you left. Changing your habits to Dutch habits was my biggest 
challenge like eating dropjes as part of the Dutch course that I gave you. But also 
working together with you appears to turn into a great success (CircRes), thank you 
for everything. Daniel, thank you as well. Ines, we worked together and we had a 
great time with the myocytes, I am happy that you will come to my defense since you 
are also busy with finalizing your own thesis. I hope everything will go as fast as with 
your CircRes paper. Good luck! And see you the 4th of June. Prof.dr. MC. Michel van 
het AMC hartelijk dank voor de samenwerking en ben erg blij dat u deel uitmaakt van 
de promotiecommissie. Mellissa en Davy, het was erg gezellig met jullie in de AHA 
van 2008, dank voor de samenwerking. Thank you for the opportunity to collaborate 
with all of you which already resulted in a couple of articles and I hope to continue 
this collaboration. 
 
Regis, ik ben begonnen bij de afdeling als student. Als student heb ik aan jouw 
project gezeten, sindsdien werken we samen. Onze samenwerking heeft mooie 
publicaties opgeleverd en nu zit je ook in mijn promotiecommissie, daar ben erg blij 
mee. Ik hoop dat we nog meer gaan samenwerken in de komende tijd. Succes met je 
aanvraag. Coen, je hebt Viola ingehaald, je weet wel wat ik bedoel. Bedankt voor de 
goede tips voor de Rubicon en voor je gezelligheid. Ruud, bedankt voor de 
technische ondersteuning. Je bent erg gezellig, maar nog gezelliger als je een biertje 
op hebt. Sabine bedankt voor de fijne tijd en succes met je promotieonderzoek.  
 
Charissa, Frances, Kanita, Louis en Rob, inmiddels zijn jullie ook sushi-, The Basket- 
en pannenkoekmaatjes. Ik ben blij dat jullie mijn promotie zullen bijwonen. Rob, wel 
Dankwoord 
223
 
goed opletten op de ceremonie. Veel succes met jullie promotieonderzoek. Kanita, je 
bent weg gegaan, verhuisd naar Utrecht en straks ook nog naar Maastricht, maar 
toch lijkt het alsof je nog steeds bij ons rondloopt. Het is altijd lachen met je. Heel 
veel succes en plezier met je promotieonderzoek, je verdere carrière en met 
verhuizen.  
 
Foppo en Duncan, bedankt. Jullie hebben veel bijgedragen op het gebied van 
software en elektronica. Dirk de Jong, bedankt voor de posters en het afmaken van 
de omslag. Aimee en Hans, bedankt voor alle jullie klusjes en de administratieve 
ondersteuning. Daarnaast wil ik ook de medewerkers van de instrumentmakerij 
bedanken met name Peter voor de transducers. Chris Zwart, ooit gaan we samen 
lopen☺, beloofd en wie weet misschien lopen we samen de Dam tot Dam. 
 
Ook heb ik tijdens mijn promotieonderzoek verschillende stagiaires mogen 
begeleiden. Brain, Imad, Kai, Ashwyn, Sophie, Sebastian, Wellimijn en Wim, jullie 
hebben veel werk uit mijn handen genomen, maar het was vooral een genot om met 
jullie samen te werken. Ik hoop dat jullie net zo veel van mij hebben geleerd als ik 
van jullie.  
 
Alle andere collega’s van de afdeling wil ik hartelijk danken voor de stimulerende 
omgeving en de heerlijke tijd. 
 
Alle AIO’s: Everaldo, Yeung-Ying, Sabine, Wineke, Koen, Robert, Jacqueline, Nora, 
Melanie, Lonneke, Ester, Evi, Christine, Cora en Kakkhee, ik wens jullie veel succes 
met het afronden van jullie eigen promotie. Alle post-docs: Amanda, Lynda, Coen en 
Ed, succes met jullie projecten. Roland, veel succes in Utrecht. Het gaat je goed, je 
hebt het daar naar je zin en dat is erg belangrijk. Alle analisten: Caro-Lynn, Ingrid, 
Dorine, Sylvia, Michiel en Jan bedankt voor de leuke tijd en de gezelligheid.  
 
Sjoukje Bonekamp, ik ben je zeer dankbaar voor al je hulp en steun, hoewel ik nog 
steeds denk dat ik niet eigenwijs ben☺. 
 
De leden van de lees- en promotiecommissie, prof.dr. DJ. Duncker, prof.dr. HW. 
Niessen, dr. JG. Bronzwaer, dr. RG. Schoemaker, prof.dr. MC. Michel, dr. RR. 
Lamberts, dr. AJ. Ijsselmuiden en prof.dr. GJ. Tangelder, hartelijk dank voor de 
goedkeuring en voor de bereidheid om zitting te nemen in de 
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beoordelingscommissie. 
 
Mijn vrienden Pauline, Nadia, Santi, Mieke, Amber, Kamar, Farnoush, Soumia, 
Nasreen, Davi en Mary, ik wil jullie bedanken voor al jullie steun en begrip.  
Nadia, Pauline, Santi en Far, jullie zijn mijn beste en gouden vriendinnen, hoewel we 
vaak hebben afgesproken en ik op het laatste moment afzegde, wist 100% zeker dat 
jullie het begrepen. Jullie antwoord was altijd “ik weet dat jij het druk hebt”. Bedankt 
voor jullie begrip. 
 
Nu iets speciaals voor mijn prachtige familie: mijn zussen, broers, neefje en nichtjes, 
bedankt voor al jullie steun, liefde en jullie begrip. 
Lieve mama en papa, ik wil jullie bedanken voor alle steun en zorg die ik altijd van 
jullie gekregen heb. Mama, bedankt voor je lekkere koffie en papa bedankt voor je 
lekkere soep. Jammer dat er geen gelegenheid is om jullie in het openbaar te 
bedanken, dus wil ik van deze gelegenheid gebruik maken. Ik weet zeker dat jullie 
zullen genieten van de hele ceremonie en vooral niet klappen tijdens de ceremonie 
papa! 
 
Natuurlijk kan ik nu een hele lijst mensen opnoemen die de afgelopen jaren 
belangrijk zijn geweest, zowel binnen als buiten mijn promotieproject. Hier noemde ik 
slechts enkele speciaal bij naam, hoewel misschien diegene die niet expliciet werden 
genoemd nog belangrijker waren, op welke wijze dan ook. 
 
Nazha Hamdani,  
Amsterdam, 8 april 2009  
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universiteit van Amsterdam met studie de Farmaceutische wetenschappen met 
specialisatie Farmacologie als eerste afstudeeropdracht en Toxicologie als tweede 
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In 2005 behaalde zij haar doctoraalexamen. Tijdens haar afstudeeropdrachten kwam 
zij voor het eerste in aanraking met het wetenschappelijk onderzoek. In  februari 
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